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Measurements of exhaled nitric oxide (eNO) are non-invasive and easily 
measured. Levels have been postulated as providing an indication of underlying 
airway inflammation. This series of studies was conducted to investigate the role 
of eNO in measuring airway inflammation in patients with asthma and COPD 
(chronic obstructive pulmonary disease) . 
78 asthma patients controlled on maintenance inhaled corticosteroid were assessed 
for 2-4 weeks. Measurements of eNO demonstrated good repeatability both 
within-sitting (coefficient of variation (c.v.) 4.1 %) and between weekly visits (c.v. 
10.5%; 95% reference range of -38 to +61% of individual patient means). Patients 
then underwent cessation of inhaled corticosteroid therapy until loss of control 
occurred or for a maximum of six weeks. Comparisons were made between eNO, 
symptoms, lung function, sputum eosinophils and airway hyperresponsiveness to 
hypertonic saline (4.5%) in predicting and diagnosing loss of control. Sixty 
patients (77.9%) developed loss of control. Exhaled NO increased to a greater 
degree in patients who developed loss of control (2.16 versus 1.44-fold increase, 
p=0.004). Both single measurements and changes in eNO (lOppb, 15ppb or an 
increase of >60% over baseline) had positive predictive values that ranged from 
80-90% for predicting and diagnosing loss of control. This compared well with 
other more invasive markers. In a further extension of this design but with a total 
of 87 patients participating, 65 developed loss of control and were entered into a 
randomised placebo-controlled, double-blind dose-response study of 50, 100, 200 
and 500!-!g of beclomethasone/day for eight weeks. Linear dose-response 
relationships between dose and changes in eNO and FEV 1 existed at one-week 
(p=0.002 and p=0.043 respectively) and at the end of treatment (p=0.015 and 
p=0.006 respectively). A similar linear dose-response relationship was seen with 
sputum eosinophils (p=0.037) but not with airway hyperresponsiveness. In 
differentiating between treatment groups eNO was superior to both FEV 1 and 
eosinophils. Throughout all of these study phases eNO was shown to correlate 





particularly strong with sputum eosinophils, where significant correlations were 
seen whether assessed as point-in-time measurements (range of r=0.46 to 0.62, 
p<0.002) or as changes-over-time during both deteriorating (r=0.44, p<0.001) and 
improving asthma control (r=0.40, p=0.002). Finally, the effect of a course of oral 
prednisone on eNO, lung function and 6-minute walk in 30 COPD patients was 
assessed. A significant decrease in eNO (-3.31ppb; 95%C.I.: -1.45 to -5.16) was 
seen in association with an improvement in 6-minute walk (34.36m; 95%C.I.: 
22.64 to 46. 08). An eNO of s 1 Oppb at baseline was associated with a negative 
predictive value of 82.2% in predicting a significant improvement in 6-minute 
walk, but the positive predictive value was only 43.7%. No improvement was 
seen in lung function. 
These results indicate that eNO measurements are reliable and provide important 
clinical information in the control of asthma, correlating to the degree of sputum 
eosinophilia. Levels can be used to predict and diagnose poor asthma control as 
well as demonstrating a dose-response to inhaled corticosteroid therapy. However 
its usefulness is limited in assessing steroid responsiveness in COPD, perhaps a 
reflection of the different inflammatory processes occurring. Further longitudinal 
studies are required to investigate whether adding serial eNO measurements into 
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INTRODUCTION: ASTHMA, INFLAMMATION & 
ASSESSMENT 
1.1. Asthma and airway inflammation 
Asthma is a complex disease of the airways characterised clinically by reversible 
airway obstruction and airway hyperresponsiveness (AHR). Histologically asthma 
consists of airway wall hypertrophy and oedema, excess mucous secretion, 
epithelial cell damage and the presence of inflammatory cells (Djukanovic et al. 
1990). It is this inflammation which is thought to play the pivotal role in the 
whole disease process in asthma, and when left untreated can lead to potentially 
irreversible airway obstruction via a process of airway remodelling (Fabbri et al. 
1998b). 
The inflammatory process in asthma involves inflammatory cells such as 
eosinophils, neutrophils, macrophages, T-lymphocytes and mast cells (Djukanovic 
et al. 1990; Dirnberger et al. 1998). These cells produce their effect through the 
release of a vast number of inflammatory mediators, such as inter-leukin-4, inter-
leukin-5, tumour necrosis factor-a, histamine and nitric oxide (NO), as well other 
substances causing oxidative damage to the airways. Such inflammatory infiltrates 
are present in the airways of patients with clinically mild disease (F oresi et al. 
1990; Haley and Drazen 1998) as well as those with fatal asthma (Houston et al. 
1953; Saetta et al. 1991). 
For over a century the eosinophil has been documented as having an important 
role in the inflammatory process of asthma ( Gollasch 1889; Ellis 1908), and 
despite there being an assortment of inflammatory cells involved, the eosinophil 
still appears to be central in its role (Bousquet et al. 1990). The level of 
eosinophilic inflammation as assessed both by bronchoalveolar lavage (BAL) 
fluid and bronchial biopsies correlate directly with the severity of asthma 










control, increasing following allergen challenge (Metzger et al. 1986) and 
decreasing following treatment with corticosteroids (Bentley et al. 1996). 
For example, Djukanovic et al (1992) obtained bronchial biopsies in 10 asthma 
patients prior to and following a 6-week course of anti-inflammatory treatment 
with inhaled beclomethasone dipropionate. Following treatment there was a 
significant reduction in median eosinophil numbers in both epithelial basement 
membrane (from 1.7 to 0 cells/mm, p=0.04) and submucosal tissues (from 34.5 to 
3.5 cell/mm2, p=0.005). This was seen in conjunction with marked improvements 
in forced expiratory volume in one second (FEV I) (FEV 1 % predicted increased 
from a mean (SD) 99.8 (13.2)% to 107.5 (15.0)%, p=0.02), morning peak 
expiratory flow rates (p<0.05), use of reliever medications (p<0.05) and a 
decrease in asthma symptoms (such as wheeze, cough, chest tightness and 
exercise limitation) (p<0.01). There was also a sevenfold decrease in airway 
hyperresponsiveness to methacholine inhalation (p=0.001), indicating reduced 
levels of airway inflammation and emphasising the important role that controlling 
eosinophilic inflammation plays in the clinical control of asthma. 
1.2. Treatment with corticosteroids 
Glucocorticoids are the most effective therapy currently available for the 
treatment of airway inflammation in asthma (Barnes 1998c; Barnes 1998b ). They 
produce their effect at the molecular level where they have been shown to alter the 
transcription of various cell genes, as well as having a direct effect on recruitment 
and activation of inflammatory cells (Barnes 1998b; Barnes et al. 1998). For 
example corticosteroids cause an increase in the expression of anti-inflammatory 
proteins, such as interleukin-1 receptor antagonist, interleukin-1 0, and neutral 
endopeptidase. They also cause repression of the genes producing the pro-
inflammatory cytokines interleukin-4 and interleukin-5, and chemokines involved 
in eosinophil recruitment and activation. 
Since 1972 (Morrowbrown et al. 1972), when inhaled corticosteroid therapy was 







treated. Several biopsy studies in asthma have confirmed that inhaled steroids 
reduce the number and activation of inflammatory cells, leading to a reversal of 
the inflammatory changes in the airways (Djukanovic et al. 1992; Jeffery et al. 
1992; Trigg et al. 1994). As a result, in the hope of preventing both short-tenn and 
long-term complications of asthma, inhaled corticosteroid therapy is now 
indicated in all but the mildest form of asthma (Sheffer 1992; NHLBIIWHO 1995; 
BTS 1997b). 
Inhaled steroid treatment is effective in helping to control asthma in patients of all 
ages (Barnes 1998b ). Their use results in improvements in symptoms, quality of 
life, lung function and exacerbation rates (Barnes 1998b). For example, a double-
blind four-week crossover study comparing the effects of regular budesonide (an 
inhaled corticosteroid) versus regular turbutaline (a beta-agonist, 'reliever' 
medication) in mild-moderate asthma demonstrated that treatment with 
budesonide resulted in a marked improvement in lung function (Kraan et al. 
1985). Budesonide was given at a dose of 400~-tg/d and resulted in an 
improvement in FEV 1 %predicted from 85.3 to 96.2% occurring in a step-wise 
fashion over time. Additionally budesonide treatment resulted in a substantial 
increase in the dose of histamine required to induce a 20% fall in FEV 1 (PD20 
histamine); PDzo rose from 4.0 to 9.5mg/ml. Over this same time period regular 
terbutaline was associated with no change in FEV 1 % predicted, and if anything a 
worsening in airway hyperresponsiveness. Similar results have been seen in 
children with asthma who were randomised to receive the inhaled steroid 
beclomethasone or salmeterol (a long-acting beta-agonist) for a year (Verberne et 
al. 1997). 
Once maximal improvement in asthma is obtained in response to corticosteroid 
therapy, current guidelines suggest back titration of inhaled steroid dose to the 
minimum dose required for maintenance of asthma control (NHLBIIWHO 1995; 
BTS 1997b ). The dose of inhaled therapy should be titrated using a combination 
of symptoms and lung function to indirectly gauge the level of control of 









management has recently been questioned. Part of the difficulty lies in the fact 
that the dose-response curve for changes in lung function is relatively flat 
(Kamada et al. 1996; Lipworth 1996; Pederson and O'Byrne 1997). A marked 
effect is seen at low doses and only minor and insignificant differences are 
obtained using further adjacent doses, suggesting that lung function may be 
insensitive to changes occurring in airway inflammation. This insensitivity is 
demonstrated in a recent study by van Rensen et al (1999). They studied the effect 
of fluticasone propionate at a dose of 1000~-tg/d, on steroid naive asthma over a 
four-week period. At baseline patients had a mean FEV1 of 96.2% predicted and 
there was no significant improvement in this following treatment. However at 
baseline these patients had a high level of sputum eosinophils, which decreased 
significantly following treatment (mean (SD) of 2.85 ,(2.46)% to 0.44 (0.56)%, 
p<0.01). This change in eosinophils was seen in association with a decrease in 
airway hyperresponsiveness to methacholine (mean PD20 (SD) 0.91 (1.62) mg/ml 
to 3.67 (1.05)mg/ml, p<0.01 respectively) and thus demonstrates a significant 
improvement in airway inflammation, an improvement undetected by 
measurements of lung function. 
Further incongruities have been found in the relationship between both symptoms 
and lung function and the more direct markers of airway inflammation such as 
airway hyperresponsiveness and sputum eosinophils (Sont et al. 1996; Haley and 
Drazen 1998; Jatakanon et al. 1998a). A number of studies have yielded evidence 
of ongoing airway inflammation in patients who were clinically thought to be in 
remission (Foresi et al. 1990; Boulet et al. 1994; Sont et al. 1996; van der Thoorn 
et al. 2000). In contrast ongoing symptoms may occur despite adequate control of 
airway inflammation (Sont et al. 1996). These findings are consistent with a poor 
correlation between clinical judgement of asthma control and the actual degree of 
airway inflammation present (Parameswaran et al. 1998). Sont et al (1999) have 
recently demonstrated that by adding airway hyperresponsiveness into the normal 
treatment logarithm both clinical and histopathological outcomes are improved. 
These results again raise the question as to whether the optimal dose titration of 

















airway inflammation, rather than the traditionally used symptoms and lung 
function. 
1.3. Assessment of inflammation 
1.3.1. Induced sputum 
Since the last half of the 19th century clinicians have been interested in the 
macroscopic and microscopic characteristics of sputum in asthma (Pavord et al. 
1997). In particular, interest has centred on the presence of sputum eosinophilia 
(Marrow-Brown 1958; Gibson et al. 1989; Hargreave 1998). Historically analysis 
has been limited to samples obtained from either spontaneously expectorated 
sputum or from fluid obtained at bronchoscopy. However both of these 
approaches are limited in their clinical applicability. Not every patient with 
asthma can spontaneously produce sputum, and bronchoscopy is a relatively 
invasive procedure - which limits its use both in poorly controlled asthma and for 
obtaining serial specimens. 
Over the last decade the use of hypertonic saline nebulisation to induce sputum 
for cell analysis has been developed (Pin et al. 1992b; Hansel 1994; Pavord et al. 
1997). Inhalation of hypertonic saline has been shown to increase mucociliary 
clearance in .both asthmatic and healthy subjects therefore aiding the process of 
sputum production and expectoration (Daviskas et al. 1996). This method has 
resulted in sputum samples which show the same cell differential as spontaneous 
sputum but with the advantages of an increased yield, better cell viability, less 
squamous cell contamination, and a better quality of cytospin (Pizzichini et al. 
1996b; Bhowmik et al. 1998). Furthermore induced sputum analyses have been 
shown to be valid (Keatings and Barnes 1997), reliable (Pizzichini et al. 1996a ), 













The concentration of nebulised saline used to induce sputum has been shown not 
to affect the cell count in the sputum sample (Popov et al. 1995). However cell 
counts have been shown to change with increasing length of induction, samples 
collected later demonstrating a higher percentage of neutrophils (Holz et al. 
1998a). Therefore in order to reduce any bias from the length of time of induction, 
it has been suggested that the first adequate sample produced by the patient should 
be used for analysis (or induction time standardised) (Magnussen and Holz 1999). 
The rise in neutrophils seen during sputum induction suggests that the procedure 
itself may be pro-inflammatory. Consistent with this is the finding of a relative 
neutrophilia persisting for at least twenty-four-hours following sputum induction 
(Holz et al. 1998b; Nightingale et al. 1998). However any pro-inflammatory 
consequence is short lived, as repeated samples obtained within a six-day period 
demonstrate good reproducibility, with a high intraclass correlation coefficient 
and no evidence of ongoing neutrophilia (Pizzichini et al. 1996a). This therefore 
permits the use of serial measurements of induced sputum cell counts in analysing 
changes in airway inflammation providing a period of one week separates the 
procedures. 
Processing of sputum samples 
There are two methods of processing induced sputum for cell counts: analysis of 
the whole expectorate and plug selection (Kips et al. 1998a; Kips et al. 1998b; 
Spanevello et al. 1998). The former involves processing sputum plus saliva, 
whereas the latter requires the use of an inverted microscope to select sputum 
plugs. Initially it was thought that plug selection would provide a more reliable 
result, as it would decrease the level of contamination by other cells present in 
saliva. However 99.8% of cells in saliva are squamous cells and therefore do not 
affect the non-squamous cell differential (Fahy et al. 1993). As a consequence 
both methods have been shown to produce viable results (Kips et al. 1998a; Kips 
et al. 1998b; Spanevello et al. 1998). Furthermore minimising saliva 








expectoration, has been shown to decrease squamous cell content and improve 
slide quality of the 'whole expectorate' (Gershman et al. 1996). 
But is the analysis of induced sputum a valid marker of airway inflammation? Are 
the cell counts obtained of clinical importance? These questions may be addressed 
first by comparing induced sputum to the established 'gold standard' (i.e. samples 
obtained from bronchoscopy) (criterion validity), then by demonstrating that it 
responds as expected to different states of asthma control (content validity). 
Criterion Validity 
Several studies have compared induced sputum cell counts with samples of 
bronchoalveolar lavage fluid obtained at bronchoscopy. Lensmar et al (1998) 
compared leucocyte counts obtained from induced sputum and lavage fluid in 
sixteen healthy volunteers (nine smokers, seven non-smokers) and found that the 
eosinophil count was consistent using both sampling methods. However sputum 
samples did have a lower proportion of macrophages (median ( interquartile range) 
52.0 (41.2-76.0)% versus 95.4 (89.6-97.2)%, p<O.OOl) and a higher proportion of 
neutrophils (47.0 (18.2-53.6) % versus 1.4 (0.4-2.4) %, p<O.OOl). These 
differences may have occurred because the sputum sample analysed was the 
second sample produced, and as discussed previously, sputum induction may in 
itself cause an increase in the number of neutrophils (Holz et al. 199 8a). However 
this is unlikely to solely explain the large differences seen. Indeed similar 
differences have also been found in other studies of both healthy controls (Fahy et 
al. 1995) and asthmatic subjects (Fahy et al. 1995; Maestrelli et al. 1995; 
Grootendorst et al. 1997; Keatings et al. 1997a). Induced sputum cell counts 
consistently demonstrate the same proportion of eosinophils, increased levels of 
neutrophils, and lower levels of macrophages compared to counts obtained from 
lavage fluid. However do these differences mean that induced sputum is invalid as 
a marker of airway inflammation, or do they simply reflect different sampling 




















The distribution of cell types has been shown to vary throughout the different lung 
compartments; in the alveoli the macrophage is the predominant cell type, 
whereas the neutrophil becomes more predominant in the proximal airways 
(Rankin et al. 1992). It could therefore be postulated that induced sputum 
comprises a sample from the airways whereas bronchoalveolar lavage may be 
more representative of the alveolar spaces. Consistent with this hypothesis is the 
finding that induced sputum cell differentials correlate to a greater degree with 
those obtained from bronchial washings (Keatings et al. 1997a). Bronchial 
washings are thought to sample the airways, whereas bronchoalveolar lavage 
samples more distal sites (A albers et al. 1993 ). Therefore, because asthma is 
primarily an inflammatory disease of the airways and this is where induced 
sputum samples are thought originate, the use of sputum may be more valid than 
the previous 'gold standard' ofbronchoalveolar lavage. 
Content Validity 
There is a large body of evidence to confirm the content validity of induced 
sputum techniques. Induced sputum from patients with asthma has been shown to 
have a significantly higher percentage of eosinophils when compared to the 
normal population (Gibson et al. 1989; Pin et al. 1992b; Fahy et al. 1993; 
Maestrelli et al. 1995; Pizzichini et al. 1996a; Keatings and Barnes 1997; Pavord 
et al. 1997), the degree of eosinophilia correlating well with parameters of airway 
obstruction (Pin et al. 1992b). Furthermore sputum obtained from asthmatics has 
higher concentrations of eosinophil degranulation products, namely eosinophilic 
cationic protein (Fahy et al. 1993; Pizzichini et al. 1996a; Keatings and Barnes 
1997; Pavord et al. 1997), eosinophil granule peroxidase (Keatings and Barnes 
1997) and major base protein (Pizzichini et al. 1996a), indicating that induced 
sputum provides samples that reflect the eosinophil inflammation present in 
asthmatic airways. 
a. Sputum Following Allergen Challenge 
Fahy et al (1994) and Pin et al (1992a) have both demonstrated an increase in 
sputum eosinophil numbers in patients with asthma following allergen challenge, 
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consistent with the increase in inflammation occurring in this setting (Metzger et 
al. 1986). The increase in sputum eosinophil numbers occurred within four hours 
of the challenge (Fahy et al. 1994) and was still present at thirty-six hours post-
challenge (Pin et al. 1992a). Furthermore, the increase in eosinophils correlated 
directly with the change in airway hyperresponsiveness occurring as a result of the 
allergen exposure (Pin et al. 1992a). 
The link between sputum eosinophils and allergen exposure in asthma is further 
supported by the results of studies in occupational asthma (Lemiere et al. 1999; 
Obata et al. 1999). Patients with occupational asthma re-exposed to the 
occupational setting have been shown to increase the number of eosinophils and 
their degradation products in induced sputum samples. Median eosinophil 
differential increasing from 0.8 to 10.0% (p=0.007), and eosinophil cationic 
protein increasing from 166 to 3,840f.tg/l (p=0.01) on re-exposure (Lemiere et al. 
1999). Likewise Obata et al (1999) demonstrated a significant increase in sputum 
eosinophils six and twenty-four hours following an allergen challenge in patients 
with suspected western red cedar induced asthma. The increase in eosinophils 
reflecting both impairment of lung function (Chan-Yeung et al. 1999; Obata et al. 
1999) and the severity of symptoms (Chan-Yeung et al. 1999). Thus greater 
eosinophil numbers in induced sputum is associated with more severe disease. 
b. Sputum During Exacerbations of Airway Inflammation 
Induced sputum samples obtained during an acute exacerbation of asthma is 
characterised by marked eosinophilia, with median levels reaching 20% of the 
total cell differential (Pizzichini et al. 1997). Likewise during exacerbations 
resulting from the withdrawal of both oral and inhaled steroids sputum eosinophil 
numbers have been shown to increase greatly (Pizzichini et al. 1997; in't Veen et 
al. 1999; Jatakanon et al. 2000). For example in't Veen et al (1999) demonstrated 
an increase in sputum eosinophils from (mean± SEM) 3.2 ± 1.1% to 12.5 ± 4.4% 
following a period of inhaled steroid tapering. Over the same time those who 
remained on a stable dose showed no change (3.1 ± 1.6% to 2.1 ± 0.7%) (p<0.05 













Perhaps more importantly, increases in sputum eosinophils have been shown to 
occur prior to the onset of a symptomatic asthma exacerbation. For example, 
following tapering of oral prednisone increases in sputum eosinophils were seen 
four weeks prior to increases in blood eosinophils, and six weeks prior to 
worsening of symptoms and FEV 1 (Pizzichini et al. 1999). Similarly during step-
wise withdrawal of inhaled corticosteroid therapy increasing sputum eosinophilia 
has been shown to be useful in predicting an up-coming exacerbation (Jatakanon 
et al. 2000). Again emphasising the importance of inflammation in asthma 
exacerbations, and highlighting the fact that airway inflammation may be present 
for some time before the development of symptoms. 
c. Sputum in asymptomatic patients 
As mentioned previously asthma symptoms are often an insensitive measure of 
ongoing airway inflammation. The role of induced sputum in detecting airway 
inflammation in asymptomatic patients is well demonstrated in a study of patients 
with allergic rhinitis by Gutierrez et al (Gutierrez et al. 1998). In this study all 
patients were asymptomatic as far as lower respiratory tract disease was 
concerned and yet these patients were found to have a significantly higher 
proportion of eosinophils than healthy controls. Moreover this increase in 
eosinophils was directly related to airway hyperresponsiveness to methacholine. 
Patients with allergic rhinitis and methacholine hyperresponsiveness (PC2o 
<8mg/ml) had a higher eosinophil count than patients without 
hyperresponsiveness and the healthy controls (median eosinophil differentials of 
7.3% versus 2.5% and 1.0% respectively, p=0.03 and p=0.02 respectively). This 
group with higher numbers of eosinophils and hyperresponsiveness also 
demonstrated significantly higher peak flow variability, suggesting underlying 
mild asthma despite being asymptomatic on study entry . 
Similarly children with symptomatically controlled asthma receiving maintenance 
inhaled steroid treatment have also been shown to have elevated levels of 





that sputum eosinophilia may be able to identifY mild airway inflammation even 
in the absence of clinical asthma, further supporting the use of induced sputum 
analysis in evaluating asthma control. 
c. Sputum and Response to Steroids 
Glucocorticoids provide the mainstay of treatment in asthmatic inflammation. 
Consistent with this, decreases in sputum eosinophil numbers occur during oral 
corticosteroid therapy in both previously steroid-naive asthma (Claman et al. 
1994; Keatings et al. 1997b) and following an acute exacerbation of asthma 
(Pizzichini et al. 1997). This decrease occurs with corresponding improvements in 
lung function and symptom score, and decreases in the concentration of 
eosinophil degradation products ( Claman et al. 1994; Pizzichini et al. 1997). 
I 
Likewise sputum eosinophil counts have also been shown to be response to 
treatment with inhaled corticosteroid. Eosinophil numbers decrease within three 
hours of inhaled corticosteroid administration (Oh et al. 1999) and result in 
markedly reduced levels when compared to placebo (Jatakanon et al. 1998a) 
(mean ±SEM, 1.4 ±0.8% and 4.0 ±1.1% respectively, p<0.005). These changes 
were accompanied by improvements in lung function and airway 
hyperresponsiveness, again demonstrating the responsiveness of induced sputum 
cell analysis in assessing treatment of asthma. 
Summary 
Induced sputum analyses results in reproducible cell differentials that appear to be 
indicative of cell counts in the airways. Asthma is associated with an increase in 
sputum eosinophils that correlates with disease severity. The eosinophil 
differential is high during exacerbations and in untreated asthma, and levels 
decrease following treatment with corticosteroids. Thus analysis of induced 
sputum provides a valid assessment of airway inflammation, and therefore 















1.3.2. Hypertonic saline challenge 
Measurement of airway hyperresponsiveness by means of a bronchial challenge 
has been widely used in the assessment of asthma for many years (Sterk et al. 
1993 ). Methods include the inhalation of both direct and indirect stimulants of 
smooth muscle contraction, resulting in airway narrowing. Quantification of the 
degree of airway hyperresponsiveness is based on obtaining a dose-response curve 
from which the provocative dose/concentration of the agent causing a fall in FEV 1 
of either 15 or 20% is calculated. i.e. PCzo/PDzo are the provocative 
concentration/ dose of the inhaled agent producing a fall in FEV 1 of 20%. 
Methacholine and histamine are two commonly used direct bronchial challenges, 
both of which cause bronchial smooth muscle contraction and thus airway 
narrowing via binding to specific receptors. These challenges are very sensitive 
for detecting airway hyperresponsiveness in asthma (Cockcroft 1997), the degree 
of responsiveness being related to the level of airway inflammation (Chetta et al. 
1996) as well as to the severity of asthma (Juniper et al. 1981; Ryan et al. 1982). 
Following allergen exposure airway hyperresponsiveness increases (Cockcroft et 
al. 1977), and in contrast treatment with inhaled steroid decreases responsiveness 
(van Grunsven et al. 1999) - reflecting the changes in airway inflammation 
occurring in these settings. However the usefulness of both methacholine and 
histamine challenges in the population setting is limited because the airway 
hyperresponsiveness is normally rather than bimodally distributed (Salome et al. 
1987), thus making the differentiation between asthma and non-asthma difficult. 
For example, Enarson et al (1987) found that a positive methacholine challenge 
(PC20 s 8 mg/ml) in the general population had a positive predictive value of only 
12% in identifYing symptomatic asthma. Likewise a similar population study of 
876 adults in Western Australia has shown that approximately 30% of subjects 
with a positive histamine challenge had no history of any asthma symptoms 
(Woolcock et al. 1987). 
Recently the use of the indirect bronchial challenges, adenosine-5-
monophosphate, hypertonic saline, and exercise have been developed as more 












specific markers of asthma inflammation. These challenges do not act directly on 
the airway smooth muscle cells themselves, but rather have their effect via the 
release of mediators from the inflammatory cells present in the airway. 
Responsiveness to these indirect challenges has been found to be a better indicator 
of changes in airway inflammation occurring with inhaled corticosteroid therapy 
than both methacholine and histamine (O'Connor et al. 1992; Sterk et al. 1993; 
duToit et al. 1997; Hofstra et al. 2000). Furthermore, in a number of population 
studies it has been found that a positive hypertonic saline challenge has greater 
specificity in diagnosing current asthma than previously found with methacholine 
and histamine (Riedler et al. 1994a; Rabone et al. 1996; Riedler et al. 1998). A 
positive hypertonic saline challenge has a specificity of between 92-97% and a 
positive predictive value of between 71-81% in diagnosing patients with 'current 
wheeze'. 
The use of nebulised hypertonic saline to induce bronchoconstriction in asthma 
(Smith and Anderson 1989; Sterk et al. 1993; Anderson et al. 1995; Anderson 
1996) is thought to occur indirectly via a variety of mechanisms (Smith and 
Anderson 1989), one of which is thought to be a change in airway osmolality. The 
volume of fluid lining the airways is very small (Anderson 1984), and so 
inhalation of hypertonic saline can easily change the osmolality of this airway 
lining fluid (Smith and Anderson 1989). In tum this provokes the release of 
endogenous mediators from cells (e.g. mast cells) located in the airway epithelium 
and submucosa (Eschenbacher and Gravelyn 1988; Gravelyn et al. 1988; Maxwell 
et al. 1990), causing airway narrowing through a combination of bronchial smooth 
muscle contraction and airway oedema. Thus airway hyperresponsiveness to 
hypertonic saline is greatly dependent on the presence of inflammatory cells in the 
airways, making it a potentially better indicator of underlying airway 
inflammation than the previously mentioned direct stimulants. Moreover 
hypertonic saline challenges have the advantages of requiring readily accessible 
equipment, are relatively cheap to perform and are easier to conduct than previous 













Results obtained from repeated hypertonic saline challenges have shown the test 
to be reproducible in both adults (Smith and Anderson 1990) and children 
(Riedler et al. 1994b ). In eight patients undergoing repeated challenges within 
thirty-seven days, Smith et al (1990) were able to calculate a coefficient of 
variation of 14%, with a correlation coefficient of 0.92 between the results. 
Similarly Riedler et al (1994b), in a study of seventeen children with asthma to 
whom hypertonic saline challenges were performed twice within ten days, have 
demonstrated good repeatability in the results to within 0.85 doubling doses. 
Hypertonic Saline Challenges and Asthma Inflammation 
The relationship between responsiveness to hypertonic saline and the presence of 
inflammatory cells within the airway makes it a useful tool in the assessment of 
the airway inflammation in asthma. Hypertonic saline challenges are less sensitive 
than direct stimulants at detecting airway hyperresponsiveness (Smith and 
Anderson 1990), however a positive challenge has a high predictive value for 
diagnosing patients with moderate to severe asthma (Smith and Anderson 1989; 
Smith and Anderson 1990). Indeed, subjects without asthma demonstrate very 
little change in lung function in response to hypertonic saline (Anderson 1985), 
with no false-positive results reported in healthy volunteers (Anderson 1996; 
duToit et al. 1997). Using nebulised potassium chloride (10% KCl) Magyar et al 
(1984) compared the increases in airway resistance occurring in asthma (n=97), 
chronic bronchitis (n=56), and normal healthy subjects (n=32). They found a 
significant increase in airway resistance in all patients with asthma following 
inhalation of hypertonic saline, but no increase was seen in either patients with 
chronic bronchitis or the healthy controls. 
Responsiveness to hypertonic saline has also been shown to relate to the degree of 
airway inflammation in asthma. In an epidemiological study of 170 children, 
airway hyperresponsiveness to a hypertonic saline challenge was strongly 
associated with higher levels of sputum eosinophils ( eosinophils of> 2. 5% of the 

















Likewise a statistically significant but weak correlation has been found between 
sputum eosinophils and airway hyperresponsiveness to hypertonic saline in 
patients with either occupational (n=24) or non-occupational asthma (n=24) (r=-
0.4, p= 0.03) (DiFranco et al. 1998). 
Hypertonic Saline Challenge and Corticosteroid Treatment 
Airway hyperresponsiveness to hypertonic saline decreases following the 
administration of corticosteroids (Rodwell et al. 1992b; duToit et al. 1997), 
nedocromil sodium (Rodwell et al. 1992a) and sodium cromoglycate (Anderson et 
al. 1994). For example, Rodwell et al (1992b) demonstrated an increase in saline 
PD20 of 5.6 fold following eight weeks of treatment with inhaled beclomethasone 
600-1,500~-tg/day. Similarly, du Toit et al (1997) demonstrated progressive 
increases in hypertonic saline PD20 after 1, 4-5, and 6-10 weeks oftreatment with 
budesonide 1000~-tg/day, culminating in an increase of 9.7 fold (95% C. I.: 4.2 to 
22) at two months. Conversely steroid withdrawal results in an increase in 
hypertonic saline responsiveness, seen in association with a decline in lung 
function and an increase in airway inflammation (in't Veen et al. 1999). 
However the relationship between responsiveness to hypertonic saline and the 
degree of underlying airway inflammation is less definite in the presence of 
corticosteroid use. In contrast to the above study by DiFranco et al (1998), 
Iredale et al (1994) found no correlation between hypertonic saline responsiveness 
and sputum eosinophils in mild to moderate asthma (range of% predicted FEV 1 
43.3-111.5%). The reason for this apparent discrepancy is most likely a result of 
the difference in the use of steroid therapy within the study populations. In the Di 
Fanco study patients had been off their inhaled steroid therapy for a period of four 
weeks prior to investigation, whereas in the Iredale study 75% of the patients were 
currently on either inhaled or oral corticosteroids. This finding raises the 
possibility that induced sputum analyses and hypertonic saline challenges may 
measure different aspects of airway inflammation in steroid treated asthma. 














Hypertonic saline inhalation is thought to cause airway narrowing indirectly via a 
change in airway osmolality and mediator release. Resultant bronchoconstriction 
appears to be specific to those patients with moderate to severe asthma, and may 
be directly related to the level of underlying airway inflammation. Response to 
hypertonic saline has been shown to decrease with treatment, suggesting a 







EXHALED NITRIC OXIDE 
2.1 Background 
The discovery in 1987 (Palmer et al. 1987) that endothelium derived nitric oxide 
(NO) has an important role as a mediator of vascular smooth muscle relaxation 
was an important advance in our knowledge about the actions and interactions of 
cells. Since then, there has been an explosion in the roles identified for NO. Nitric 
oxides now appear to be involved in diverse physiological actions including 
neurotransmission, platelet function, smooth muscle function, cytotoxicity and as 
a mediator of immune responses (Barnes and Belvisi 1993; Gaston et al. 1994; 
Barnes and Liew 1995; Lundberg et al. 1996). 
Recently both Gaston et al (1994) and Zapol et al (1994) have reviewed the 
physiology of NO in humans. NO is produced endogenously from a variety 
sources, the most important of which is L-arginine. Arginine is oxidised by the 
enzyme NO synthase to produce citrulline and NO. NO synthase (NOS) exist in at 
least three isoforms, two of which are constitutive isoforms and the other one is an 
inducible isoform. The constitutive NO synthase are found mainly in vascular 
endothelium and the nervous system, and are calcium and calmodulin dependent 
enzymes. When activated they produce a small amount of NO which has its effect 
locally, to produce endothelium-dependent vasodilatation, or in peripheral 
neurones to produce non-adrenergic non-cholinergic neural responses, such as 
bronchodilatation. The inducible NO synthase isoform is induced by pro-
inflammatory cytokines such as interleukin-1~, tumour necrosis factor-a, and 
interferon-"(, as well as various endotoxins. Activation of inducible NO synthase 
results in the production of large amounts of NO and is postulated to be involved 
in several inflammatory processes. In the airway these high levels of NO can 
cause increased microvascular blood flow and oedema which may potentially 












2.2 Source of eNO 
NO was first discovered in the expired air of humans in 1991 by Gustaffson et al 
(1991). Soon after this it was reported that expired NO (eNO) was elevated in 
asthma (Alving et al. 1993~ Kharitonov et al. 1994b~ Persson et al. 1994), and the 
plausible link between eNO and inflammation in asthma was made (Barnes and 
Liew 1995~ Barnes and Kharitonov 1996). Studies have demonstrated numerous 
cells potentially capable of generating NO in the lung. These include 
macrophages, neutrophils, mast cells, nonadrenergic noncholinergic inhibitory 
neurones, fibroblasts, vascular smooth muscle cells, pulmonary arterial and 
venous endothelial cells, and pulmonary epithelial cells (Gaston et al. 1994). 
Immunohistochemical studies from bronchial biopsie~ indicate that there is an 
enhancement of inducible NO synthase expression in asthma, and that this 
expression is further stimulated by the cytokine tumour necrosis factor a (Hamid 
et al. 1993). This is thought to result in large amounts of NO being produced, 
which then plays a central role in the mediation of the inflammatory process 
(Barnes and Belvisi 1993; Barnes and Liew 1995; Lundberg et al. 1996). 
Furthermore inhalation of a relatively selective inhibitor of inducible NO 
synthase, aminoguanide, decreases eNO in patients with asthma but not in normal 
subjects (Yates et al. 1996b), implying that the high eNO levels seen in asthma are 
largely derived from the inducible NO synthase isoform. 
2.3 eNO and Asthma Inflammation 
NO concentration in exhaled breath is elevated in steroid-naive asthma 
(Kharitonov et al. 1994b; Persson et al. 1994; Rutgers et al. 1998; Sapienza et al. 
1998) where levels correlate well with other markers of airway inflammation such 
as sputum eosinophils and airway hyperresponsiveness (Jatakanon et al. 1998). 
Exhaled NO has further been shown to be raised during both asthma 
exacerbations (Massaro et al. 1995; Crater et al. 1999) and following an allergen 
challenge (Kharitonov et al. 1995a). Importantly, the increase following allergen 
exposure does not occur during acute phase bronchoconstriction but rather during 



















latter response (Pin et al. 1992a; Fahy et al. 1994). Moreover, this rise in eNO 
correlates with the fall in FEV 1 over the same time period. 
Response to Steroids 
Exhaled NO concentrations are not only elevated in asthma but they respond to 
treatment with corticosteroids. Concentrations decrease following anti-
inflammatory treatment with both oral prednisone (Massaro et al. 1995; Yates et 
al. 1995) and inhaled corticosteroid (Kharitonov et al. 1996b; Jatakanon et al. 
1998a; Lim et al. 1999; van Rensen et al. 1999), consistent with the decrease in 
inflammation observed in the airways as a result of steroid treatment (Djukanovic 
et al. 1992; Bentley et al. 1996). Furthermore, stable asthma treated with 
maintenance inhaled steroid is associated with eNO levels equivalent to healthy 
controls (Kharitonov et al. 1994b ), again consistent with the relative absence of 
inflammation in these individuals. Conversely, following a reduction in inhaled 
steroid dose, levels of eNO increase, reflecting the recurrence of airway 
inflammation (Kharitonov et al. 1996c ). 
The response of eNO to corticosteroid therapy is rapid, reflecting the fast decline 
in sputum eosinophils seen following treatment initiation (Claman et al. 1994; Oh 
et al. 1999). For example, during an exacerbation of asthma, eNO levels decrease 
within forty-eight hours of prednisone administration (mean ±SEM eNO 
decreasing from 20.0 ±3.1ppb to 11.6 ±3.0ppb, p = 0.002) (Massaro et al. 1995). 
Similarly, eNO has been shown to fall within seventy-two hours of prednisone 
treatment in steroid-naive asthma (Yates et al. 1995). In addition, the decrease in 
eNO with steroid therapy occurs in a step-wise fashion over time, seen in 
association with a decrease in airway hyperresponsiveness during this same period 
(Kharitonov et al. 1996b). 
At the molecular level corticosteroid therapy results in a reduction in the 
expression of inducible NO synthase (Springall et al. 1995). It is this reduction in 
the inducible isoform expression that is thought to be largely responsible for the 








constitutive NO synthase function. In healthy controls, in which constitutive NO 
synthase is present in the airways but with little of the inducible isoform, there is 
no demonstrable decrease in eNO following corticosteroid treatment (Yates et al. 
1995), suggesting that the main cause of the decreasing eNO in corticosteroid 
treated asthma is via changes in inducible NO synthase activity. 
A potential role for eNO in assessing the dose-response to inhaled steroid therapy 
is suggested in a small study by Alving et al ( 1995). These authors reported a 
dose-response relationship between inhaled steroid dose and eNO in children with 
asthma. Children taking 200~-tg/day beclomethasone had a mean eNO level of 
30ppb, whereas patients taking 400 and 800~--tg/day had eNO levels of 12 and 
7ppb respectively. The groups were small (n = 11, 8, and 5 subjects respectively), 
but the results point to the possibility that eNO may be useful tool for monitoring 
responses to inhaled steroid therapy. This question will be addressed in Chapter 7. 
Summary 
Patients with asthma and active airway inflammation have been shown to exhale a 
higher concentration of NO. This level of eNO has been shown to decrease 
following anti-inflammatory treatment with both oral and inhaled steroids. These 
findings suggest that eNO may be a useful non-invasive indicator of airway 
inflammation, something that would be clinically very useful in the long-term 
treatment and control of asthma. This is the basis upon which the studies 
described in this thesis were developed. 
2.4 Measuring eNO 
The levels of NO in exhaled breath are very small and are measured in parts per 
billion (ppb ). Such small quantities can only be accurately measured by means of 
a chemiluminescence analyser. The process of chemiluminescence is based on a 
reaction between NO and ozone in a cooled reaction chamber, during which NO is 
converted to nitrogen dioxide (N02). This reaction is a photochemical reaction 
that releases infrared light. A photomultiplier tube subsequently measures this 
emission of light, whose amount is linearly proportional to the concentration of 
21 
NO (Fontijin et al. 1970). Measurements of eNO can be made using samples of 
mixed expired air collected in a balloon, or by on-line measurement of single or 
tidal breaths (Robbins et al. 1996). In the subsequent investigations repeated in 
this thesis on-line measurements of single breaths were used and therefore further 
description of technique will be limited to this method. 
The process of chemiluminescence analysis has been developed to enable online 
breath analysis using rapid response analysers (response time< 2 sec) linked to a 
computer module and a biofeedback monitor (fig. 2.1 ). The patient exhales at a 
constant flow rate through the mouthpiece tubing against a known flow restrictor. 
Patients observe a biofeedback monitor indicating exhalation flow/pressure; thus 
enabling them to exhale at a constant rate. The reason for the flow restrictor is to 
provide a small amount of resistance, thus increasing the mouth pressure and 
closing off the nasopharynx to ensure that no nasal contamination occurs (as will 
be discussed later). The mouth-piece and all tubing is made of the inert material 
Teflon/polytetrafluoroethylene (PTFE) to avoid reaction with the very reactive 
NO molecules. 
Exhaled breath passing through the mouthpiece is then sampled via side arms for 
measurement of NO, carbon dioxide (C02) and pressure/flow. Recordings of NO, 
C02, pressure and lung volume are then displayed on the computer monitor (fig. 
2.2) from where recordings can be either read instantly or alternatively saved for 
reading at a later date. 
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Figure 2.1. A schematic diagram of single breath exhaled nitric oxide ( eNO) 
measurements. Patients exhaled through the mouthpiece against a flow restrictor 
creating in-built resistance (A). Nitric oxide measurements were made using a 
chemiluminscence analyser, sampling the breath via a side arm (B). Patients 
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Figure 2.2. A schematic illustration of the various recordings as displayed 
on the computer monitor. For any time point values for eNO, C02, mouth 
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Nitric oxide measurements (fig. 2.2) typically consist of an initial flat portion 
prior to the patient exhaling, during which ambient NO concentrations can be 
recorded. There is initially a peak in the exhaled NO seen during the early stages 
of exhalation, this is then followed by a plateau corresponding with the end of 
expiration. The reason for the peak followed by plateau is the difference between 
measuring air initially present in the dead space of the airways (peak) and air 
originating from the alveolar spaces (plateau). Recordings of eNO must always be 
made at the same stage of exhalation and can be read at either the peak or plateau 
values. However the plateau level is now the value most widely read and 
accepted, this is in order to reduce the risk of interference from nasal and ambient 
NO contamination which affects the peak levels. 
2.5 Factors affecting eNO levels 
Many factors are known to effect the measurement of eNO, so recently attempts 
have been made recently to standardise the procedure (Kharitonov et al. 1997a; 
Silkoff and Zamel 1998; ATS 1999). The following section is a summary the 
different factors causing variation in eNO levels, factors that need to be taken into 
account when using eNO in both the clinical and research settings. 
Exhalation flow rate 
One of the greatest influences on measuring eNO levels is the breath flow rate via 
the airways. Slower rates are associated with higher eNO recordings (Hogman et 
al. 1997; Silkoff et al. 1997; Corradi et al. 1998). NO rapidly binds to 
haemoglobin (Sharma et al. 1987; Cremona et al. 1995). As a result NO is 
quickly taken up by haemoglobin in the capillaries adjoining the alveolar space, 
creating alveolar air in which the NO concentration is relatively low. It is 
postulated that as the 'NO low' air is exhaled through the airways it takes up NO 
which has diffused into the lumen, driven by the gradient between airway wall 
mucosal concentration and the concentration in the lumen (Silkoff and Zamel 
1998). A slower flow will increase the transit time of the breath through the 



















concentration. This is highlighted in a paper by Silkoff et al (1997) who, by 
measuring eNO during 9 separate exhalation flow rates (ranging from 1550 to 4.2 
mVsec), observed a rise in eNO of almost 35-fold over the range of decreasing 
flow rates. 
The hypothesis of eNO measurements being flow rate dependent is also indirectly 
supported by studies demonstrating that eNO levels decrease during increasing 
degrees of bronchoconstriction (de Gouw et al. 1998b; Ho et al. 2000). During 
these studies different degrees of bronchoconstriction were induced and eNO 
measurements were performed at a constant exhalation flow rate. At greater 
bronchoconstriction there is an increase in velocity of air through the airways, 
resulting in a relative decrease in transit time, and a fall in measured eNO. This 
I 
hypothesis is further supported by the finding that breath-holding results in an 
increase in the initial peak eNO, but no change in end-expiration values 
(Kharitonov et al. 1996a; Tunnicliffe et al. 1996). Stasis of breath in the airway 
results in increased diffusion and therefore increased concentration of NO in the 
initial portion of exhaled air, but not during end-exhalation. 
Nasal contamination 
High NO concentrations are found in the nasal passages of humans (Kharitonov et 
al. 1996a; Robbins et al. 1996; Silkoff et al. 1997) and initially there were 
concerns that these high levels might contaminate exhaled air measured at the 
mouth (Lundberg et al. 1994; Kimberly et al. 1996). Indeed studies have shown 
that contamination by nasal NO does occur with breath-holding (Kimberly et al. 
1996) and tidal breathing (Kharitonov and Barnes 1997). For this reason the use 
of nose-clips was introduced. However, their use has since been shown to 
potentially increase the level of nasal contamination because intranasal airway 
pressures are raised when they are worn (Silkoff et al. 1997), thus the vellum does 
not close to separate oropharynx from nasopharynx and air from the nasal 
passages can contaminate the sample. Instead it has been found that exhaling 


















nasopharynx is effectively closed off preventing nasal contamination (Kharitonov 
et al. 1996a; Kharitonov and Barnes 1997; Silkoff et al. 1997). 
In order to examine the validity of exhalation against resistance, eNO levels at the 
mouth have been compared with those measured in the lower airways (Kharitonov 
et al. 1996a; Silkoff et al. 1997; Gabbay et al. 1998). These studies have shown 
that eNO measured at the mouth correlates well with levels obtained from the 
bronchi, trachea and glottis, and demonstrate a lack of nasal contamination . 
Ambient NO levels 
There has been conflicting reports about the effect of ambient NO concentrations 
on eNO recordings, although much of this variation can be explained by 
differences in techniques used. As mentioned previously (see fig 2.2) the first part 
of exhalation consists of air originating from the dead-space, a mixture of ambient 
NO and nasal NO contamination. Because of this, single breath recordings read at 
the peak level and NO concentrations taking from bags of mixed expiratory air 
will be greatly affected by ambient NO concentration. However, the use of a 
standardised single-breath on-line measurement of eNO, read during the end-
expiration plateau (corresponding to air from the alveolar spaces), has been shown 
to be unaffected by ambient NO levels (Kharitonov et al. 1994b; Robbins et al. 
1996; Piacentini et al. 1998; Sippel et al. 2000). This may be explained by the fact 
that NO is quickly bound to haemoglobin (Sharma et al. 1987; Cremona et al. 
1995) therefore creating alveolar air that is relatively low in NO, independent of 
ambient levels. For example, Piacentini et al (1998) measured single-breath on-
line eNO following inhalation of ambient levels ranging from 0 -150ppb. Values 
were read at the eNO plateau and no relationship was found between ambient and 
eNO. Furthermore, inhaling artificially high concentrations ofNO (up to JOOOppb 
- much higher than those found in ambient levels) has been shown to have no 
effect on end-expiratory eNO values, although increases in the initial peak eNO 


















Nocturnal asthma is characterised by a circadian rhythm, with the greatest airway 
obstruction occurring at 0400 hours, the least at 1600 hours (Hetzel and Clark 
1980). It has been postulated that eNO levels may follow a similar circadian 
rhythm, particularly in patients experiencing nocturnal symptoms. In a study by 
ten Hacken et al (1998), eNO was measured four-hourly from mid-day for a 
period of twenty-four hours. The mean eNO concentration was significantly 
higher in those patients with nocturnal asthma when compared to both healthy 
controls (p<O.Ol) and patients with asthma but no nocturnal symptoms (p<0.05) 
(mean ±SD of 46.0 ±18.7ppb, 9.9 ±2.1ppb, and 26.6 ±12.6ppb respectively). 
There was a circadian rhythm found for FEV 1 in asthma patients with and without 
nocturnal symptoms, but eNO levels did not vary with this circadian rhythm. 
However patients with nocturnal asthma did have significantly higher eNO 
recordings at 0400 hours compared to 1600 hours (mean ±SD of 50 ±20ppb and 
42 ±15ppb respectively, p<0.05). There was no significant difference in eNO 
values at any other time point. In contrast to these findings, Georges et al ( 1999) 
found a decrease in eNO at 0400 hours in patients with nocturnal asthma as 
compared to values taken at 1600 hours and 2200 hours (mean ±SEM of 66.0 
±8.5ppb, 77.2 ±8.2ppb and 68.4 ±8.7ppb respectively). In this study no 
differences were found in the values of eNO recorded at these times in asthmatics 
with no nocturnal symptoms. The reason for the apparent discrepancy between 
these two studies is unclear. Both studies used similar methods for the analysis of 
eNO and followed a similar study design. Unfortunately both studies used small 
numbers of patients with nocturnal symptoms (n=8 and n=5 respectively), and so 
their results may have been skewed by data from just one or two individuals. The 
conclusion from these studies is that while there may be a change in eNO during 
night-time in patients with nocturnal asthma, the direction of change is 
inconsistent and the cause for it is unknown. However, in order to avoid any 
possible variation in eNO with time of day it is suggested that recordings be 







Cigarette smoke is known to contain a high amount of NO (Norman and Keith 
1965). Many studies have shown that current chronic cigarette smoking is 
associated with a decrease in eNO (Persson et al. 1994; Schilling et al. 1994; 
Kharitonov et al. 1995b; Robbins et al. 1996; Robbins et al. 1997; Rutgers et al. 
1998; Verleden et al. 1999), the degree of reduction correlating with the number 
of cigarettes smoked per day (Kharitonov et al. 1995b ). The mechanism for this 
reduction is as yet unknown, but may be related to the negative feedback 
inhibition exerted by high concentrations of airway NO on NO synthase (Assreuy 
et aL 1993 ). This is consistent with the observation of Robbins et al (1997) that 
within one week of cessation of smoking eNO levels increase, with further 
increases in eNO seen over the subsequent eight weeks. 
Changes occurring in eNO following acute exposure to cigarette smoke are not so 
clear-cut. Initially, Kharitonov et al (1995b) demonstrated a decrease in peak eNO 
concentrations five minutes after smoking a single cigarette. This decrease 
returned to baseline levels within fifteen minutes. In contrast to this, Chambers et 
al (1998) observed an increase in plateau phase eNO following a single cigarette. 
This increase was greatest at one minute, but also present ten minutes later. The 
differences in these results may be a reflection of differences in the reading of 
eNO between the studies; the Kharitonov study measuring peak levels while the 
Chambers study measured plateau. Chambers et al (1998) have postulated that the 
increases they observed may be the result of NO being retained in the airway 
epithelial lining fluid. In tum this would result in high local NO concentrations 
causing an initial increase in eNO, this could also lead to the chronic down-
regulation of NO synthase in the airways of smokers. 
Alcohol 
Ingestion of alcohol has been shown to decrease the level of eNO in both humans 
(Yates et al. 1996a) and in rabbits (Persson and Gustafsson 1992). Interestingly, 
this decrease in eNO was not reversed by the addition of the NO substrate L-
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arginine, suggesting that alcohol may affect NO production via interaction with 
one of the NO synthase in the lung. As yet the precise mechanism is not known. 
Menstrual cycle 
Initially it was thought that eNO levels fluctuated with the female menstrual 
cycle. This was first reported by Kharitonov et al (1994a) who found that during 
midcycle female subjects exhaled almost three times the level of eNO measured 
during menses (mean (SD) 150 (39) v 59 (25)ppb). It was proposed that the 
increase in eNO might be due to the increases in oestradiol, oestrone, luteinising 
hormone and follicle stimulating hormone occurring at the luteal phase of the 
menstrual cycle. However, eNO levels in the study were read at peak rather at the 
plateau phase of exhalation, and patients were inhaling ambient air - which is 
known to affect the peak eNO, and the exhalation flow rate was not standardised. 
In contrast to these findings, others have found no difference in eNO between 
male and female subjects (Massaro et al. 1995; Morris et al. 1996). Furthermore, 
Morris et al (1996) investigated the relationship between eNO and menstruation in 
5 healthy premenopausal women who had eNO measured daily throughout the 
entire menstrual cycle. Levels were obtained on each occasion after inhaling both 
ambient and NO free air, exhaling at a constant rate. They found no relationship 
between female sex hormone production and eNO levels. Likewise the hormonal 
changes associated with pregnancy have been shown to have no effect on eNO 
levels (Morris et al. 1995), suggesting that eNO is unrelated to female hormone 
levels and that the results of the previous study may have been spurious. 
Exercise 
Exercise results in a decrease in the concentration of eNO, largely as a result of an 
increased flow rate of air through the airways (Iwamoto et al. 1994; Trolin et al. 
1994; Phillips et al. 1996). Exercise also results in an increase in total NO 
excretion by means of an increased per minute ventilation rate (Iwamoto et al. 
1994; Trolin et al. 1994). Similar findings affecting both eNO concentration and 




Phillips et al. 1996), although there is some suggestion that hyperventilation only 
explains part of the changes seen, and that other factors such as pulmonary blood 
flow may also be involved (Phillips et al. 1996). 
Other Medication 
Apart from medications designed to treat inflammation in asthma there are a 
number of other medications that could possibly interfere with eNO readings. 
a) NOdonors 
NO donors are commonly used in the treatment of cardiovascular disorders. A 
study investigating the effect of intravenous infusions of the NO donors 
glycerin trinitrate (GTN) and sodium nitroprusside on eNO has been 
performed. (Dirnberger et al. 1998). The rates of the infusions used were great 
enough to result in a significantly reduced diastolic blood pressure and 
increased heart rate, but they were found to have no effect on eNO levels. 
Interestingly, both GTN and sodium nitroprusside were found to increase 
FEV1, suggesting smooth muscle relaxation in the airways as a result of the 
infusions. 
In contrast to this Marczin et al (1997), in a study of anaesthetised patients, 
was able to demonstrate an increase in eNO during both an infusion of GTN 
and following GTN boluses. The increase was small during the infusion, 12.6 
(0.2)ppb to 14.1 (0.1)ppb, and the dose of GTN used was extremely high (45 
mg/hr) (20-40 fold that ofDimberger et al). This dose is far above what would 
be tolerated by a non-anaesthetised patient and much greater than would be 
used clinically. Likewise the boluses of 125, 250 and 500!-tg of GTN resulted 
in increases in eNO of 3.1, 6.0, and 8.1ppb respectively. However no 
statistical analysis was performed and small patient numbers (n = 7) would 




Both short-acting and long-acting beta-agonists are widely used in the 
treatment of asthma. Their use results in increased levels of eNO (Yates et al. 
1997; Fuglsang et al. 1998; Silkoff et al. 1999), although the increase is mild 
and often fails to reach statistical significance (Yates et al. 1997; Fuglsang et 
al. 1998). The cause of this mild increase is uncertain, but may be explained 
by changes in airway calibre. Beta-agonists bind to beta-receptors on smooth 
muscle causing relaxation and hence bronchodilation. As a result their use 
leads to increased airway calibre and improvements in FEV 1. This increase in 
airway calibre will result in a relative slowing of air through the airways when 
exhalation at the mouth is kept at a constant rate. Thus these drugs may result 
in a relative increase in the concentration of eNO as measured at the mouth. 
c) Prostaglandins 
Cyclo-oxygenase products are known to play a part in the pathophysiology of 
asthma. In particular prostaglandin-E2 has been shown to inhibit exercise-
induced bronchoconstriction and allergen-induced early- and late-phase 
responses, as well as modulate the expression of NO synthase in certain cell 
types. Recently a study by Kharitonov et al (1998) has demonstrated a 
decrease in eNO in asthma and healthy subjects following inhalation of the 
prostaglandins E2 and F 2a.· Study participants were given increasing doses of 
both prostaglandins, both of which caused a decrease in eNO, however the 
greatest response was seen following prostaglandin E2 in the asthma patients. 
This decrease in eNO was independent of change in airway calibre, suggesting 
an effect at the molecular leveL 
Other medical conditions 
A number of medical conditions other than asthma have been postulated to affect 
the concentration of eNO. Although some of these do alter eNO levels, generally 





a) Systemic sclerosis 
This systemic connective tissue disorder is associated with various lung 
complications. Exhaled NO levels are increased in patients with systemic 
sclerosis regardless of known lung pathology when compared to healthy 
controls (Kharitonov et al. 1997b ). Interestingly, given the vasodilatory effect 
of NO on vascular smooth muscle, the presence of pulmonary hypertension in 
systemic sclerosis is associated with lower eNO values. 
b) COPD (Chronic Obstructive Pulmonary Disease) 
Studies investigating eNO in COPD have demonstrated varying results; some 
finding increased eNO (Kanazawa et al. 1998; Maziak et al. 1998; Corradi et 
al. 1999), while others finding normal or even lo'-"; levels (Clini et al. 1998; 
Rutgers et al. 1999; Delen et al. 2000). Despite this, eNO has been found to be 
elevated in COPD patients with active inflammation (Maziak et al. 1998; 
Agusti et al. 1999) and levels have been shown to correlate with other markers 
of airway inflammation (Kanazawa et al. 1998; Rutgers et al. 1999; Silkoff et 
al. 2000). Furthermore, COPD patients demonstrating partial reversibility to 
bronchodilator also have increased levels of eNO (Papi et al. 2000), 
suggesting that eNO may be a good marker for inflammation and reversibility 
in COPD. The relationship between eNO and COPD will be discussed more 
fully in Chapters three and eight. 
c) Cystic Fibrosis and Bronchiectasis 
In the only study to date in which eNO was measured using a standardised 
technique, no differences were observed in eNO levels obtained from patients 
with cystic fibrosis or bronchiectasis compared to healthy controls (Ho et al. 
1998). Moreover during an infective exacerbation of cystic fibrosis no 
increase in eNO was observed. The cause of this lack of increase in eNO with 
these inflammatory diseases is unknown. It may be the result of a lack of 
expression of inducible NO synthase in the airways, or alternatively NO 










excretions that characterise these conditions (although given the small size of 
NO molecules and its rapid diffusion this would seem unlikely). 
d) Upper respiratory tract infections 
Upper respiratory tract infections are associated with an increase in peak eNO 
in normally healthy subjects (Kharitonov et al. 1995c). Levels then return to 
normal within 3 weeks. The cause for this increase is thought to be due to the 
induction of NO synthase expression. Induction of NO synthase is regulated 
by transcription factors of which the most important is nuclear factor-KB. 
Viral infections are thought to induce nuclear factor-KB thus increasing the 
expression of NO synthase and the production of NO. 
De Gouw et al (1998a) have further studied the effect of viral infection in 
asthma. In a blinded study asthmatic patients underwent inoculation with 
either rhinovirus 16 or placebo. Following rhinovirus 16 infection there was a 
significant increase in eNO at days two and three compared to baseline 
(median 7.7 and 6.2ppb compared with 1.9ppb respectively), whereas there 
was no change seen in the placebo treated group. There was no change in 
FEV1 in either group throughout the study, so this change in eNO appears to 
occur irrespective of any change in airway calibre that may be associated with 
a viral infection in asthma. An increase in airway hyperresponsiveness to 
histamine was also seen in the virus-inoculated group, the decrease in PC20 
histamine correlating inversely to the increase in eNO. Suggesting that the 
changes in eNO are a reflection of changes in underlying airway 
inflammation. 
e) Allergic rhinitis 
Allergic rhinitis is associated with inflammation of the nasal mucosa. Non-
asthmatic patients with seasonal rhinitis have been shown to exhale a higher 
concentration of NO compared to nonatopic volunteers (Martinet al. 1996; 
Henriksen et al. 1999), even outside ofthe pollen season (Baraldi et al. 1999; 
Henriksen et al. 1999). These levels are higher both with nasal (Martin et al. 
,. 
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1996) and oral exhalation (Martinet al. 1996; Hemiksen et al. 1999), and are 
associated with an increase in airway hyperresponsiveness (Hemiksen et al. 
1999). These findings suggest that patients with allergic rhinitis may also have 








Chronic obstructive pulmonary disease (COPD) is defined as a disorder 
characterised by abnormal tests of expiratory flow that do not change markedly 
over periods of several months observation (ATS 1987). It occurs in 
approximately 10-15 % of smokers and the obstruction is thought to result from 
airway remodelling (Saetta et al. 1994b; Lambert and Pare 1997). The exact 
mechanism leading to airway remodelling is uncertain, however there is an 
increasing body of evidence to suggest inflammation may play an important role 
in this process. 
3.2. COPD and airway inflammation 
Cigarette smoking in itself causes both acute and chronic inflammatory processes 
affecting the central airways, peripheral airways and lung parenchyma - even in 
smokers with normal lung function (Saetta 1999). The inflammatory cells in the 
lungs consist mainly of macrophages, T lymphocytes and neutrophils, the 
presence of which is related to the degree of parenchymal destruction (Saetta 
1999). In those patients who go on to develop COPD this inflammatory response 
is thought to be pivotal to disease progression. 
During acute exacerbations of COPD there is a marked increase in the number of 
inflammatory cells and cytokines in the airways (Saetta et al. 1994a; Bhowmik et 
al. 2000 ). However even during stable COPD those patients who have more 
frequent exacerbations have greater amounts of inflammatory markers in their 
sputum (Bhowmik et al. 2000). Bronchial biopsies obtained from stable, 
corticosteroid free, patients with COPD have been shown to have increased 
numbers of inflammatory cells, the degree of which correlates directly with 
severity of lung function impairment (Di Stefano et al. 1998). Likewise, sputum 




to have increased numbers of neutrophils and to lesser degree eosinophils in 
COPD, regardless of curredt smoking status (Stanescu et al. 1996; Balzano et al. 
1999; Peleman et al. 1999; Rutgers et al. 2000). Furthermore, the degree of 
inflammation present in induced sputum correlates not only with the severity of 
airway obstruction (Balzano et al. 1999; Peleman et al. 1999; Rutgers et al. 2000) 
but also with a clinical history of a more rapid decline in lung function over time 
(Stanescu et al. 1996). Again emphasising the importance of inflammation in 
COPD progression. 
3.3. Response to corticosteroids 
Inhaled corticosteroid therapy is widely used in the treatment of airway 
inflammation associated with asthma and results in improvements in both 
symptoms and lung function (Barnes 1998b). Inhaled steroids have also been 
widely used in the treatment of COPD, although their role in long-term COPD 
management has often been debated (van Schayck et al. 1996; Barnes 1998a; 
Anthonisen 1999). It has been postulated that there may only be a subset ofCOPD 
patients ( 10-15%) who respond to corticosteroid therapy (Callahan et al. 1991; 
Nishimura et al. 1999). This view is reflected in current guidelines (BTS 1997a) 
which suggest that ongoing inhaled steroid therapy is recommended for those 
patients who show a clear objective response to a formal trial of either oral or high 
dose inhaled corticosteroid. A positive trial defined as a 15% increase in baseline 
FEV1, with an absolute increase of greater than 200ml. 
It has been suggested that COPD patients who respond to steroids may actually 
belong a pathologically distinct subgroup with inflammatory features similar to 
asthma (Hargreave and Leigh 1999). Both the presence of increased amounts of 
eosinophils and their degradation product eosinophil cationic protein in 
bronchoalveolar lavage, and a thickened reticular basement membrane have been 
found to characterise COPD patients whose lung function improves following a 
course of prednisone (Chanez et al. 1997). Similarly, sputum eosinophilia has also 
been shown to correlate with the degree of reversibility of airway obstruction 




Interestingly these studies have demonstrated significant reductions in both 
eosinophil count and levels of eosinophil cationic protein following treatment, 
whereas neutrophil count and the various measures of neutrophil activity 
remained unchanged (Pizzichini et al. 1998; Fujimoto et al. 1999). In fact those 
patients who did not have sputum eosinophilia at study entry showed no change in 
lung function, symptoms or inflammatory markers following treatment. 
Suggesting that the reversible component of airway inflammation in COPD may 
be eosinophilic in nature (Hargreave and Leigh 1999). 
3.4. Nitric oxide and COPD 
Exhaled NO has recently been developed as a marker of airway inflammation in 
asthma (see Chapter 2.3). If those patients with COPD responsive to 
corticosteroids have underlying pathology similar to asthma then it follows that 
these patients may also have elevated levels of eNO. In turn eNO could then be 
used to identify those patients in whom corticosteroid therapy would be 
appropriate. 
Recent studies analysing eNO in COPD have demonstrated varying results; some 
finding increased eNO (Kanazawa et al. 1998; Maziak et al. 1998; Corradi et al. 
1999), while others finding normal or even low levels (Clini et al. 1998; Rutgers 
et al. 1999; Delen et al. 2000). These differences may be explained partly by 
differences in methodology used, such as single breath versus tidal breathing, 
concentrations versus excretion rates, and variability in exhalation flow rates 
(Sterk et al. 1999). Also differences may partly be explained because COPD is not 
a homogeneous disease, and that both the degree and type of inflammation present 
may vary widely. For example,' in the study by Del en et al. (2000), in which low 
levels of eNO in COPD were reported, chronic bronchitis (COPD with a history 
of a productive cough) was associated with elevated levels of eNO when 
compared to other forms of COPD (non-productive) and to normal controls. 
Furthermore, the levels seen in chronic bronchitis were comparable to those 




During times of increased inflammation, such as with unstable COPD or during 
an acute exacerbation (Saetta et al. 1994a), it has been shown that eNO levels are 
elevated (Maziak et al. 1998; Agusti et al. 1999). Following treatment of an 
exacerbation and the return to clinical stability eNO levels then return to normal 
(Agusti et al. 1999). Exhaled NO levels have also been shown to correlate with 
other markers of airway inflammation (Kanazawa et al. 1998; Rutgers et al. 1999; 
Silkoff et al. 2000), suggesting that eNO may be a useful indicator of airway 
inflammation in COPD patients. 
Another common characteristic of asthma is the presence of reversible airway 
obstruction, and just as asthma-like inflammation is associated with elevated 
levels of eNO in COPD, so elevated eNO has also been found in COPD patients 
demonstrating partial reversibility to bronchodilators (Papi et al. 2000). Papi et al 
divided COPD patients into two groups based on their response to inhalation of 
200!lg of salbutamol. Partial reversibility was defined as those who had in 
increase in FEV1 of <12% of predicted but ?;200ml and non-responders as those 
with a response of <12% and <200ml. Partial reversibility was associated with a 
significantly higher· eNO (24ppb) when compared to both non-responders 
(8.9ppb) and control subjects (9.9ppb)(p<O.Ol). Alternatively, when divided on 
the basis of baseline eNO, those with a level of?; 15ppb had a significantly larger 
increase in FEV1 post-salbutamol (median (interquartile range) 220 (200-230)mls 
versus 65 (10-180)mls respectively; p<0.01). 
In conclusion, inflammation plays an important role in COPD, both in dictating 
disease progression and also in providing the basis for a reversible component 
against which the use of corticosteroids may be effective. Exhaled NO appears to 
be elevated in COPD characterised by increased inflammation and the presence of 
some reversibility, however the role of eNO in predicting those patients in whom 
corticosteroids will result in significant improvements in lung function has yet to 
be investigated. This will be discussed in Chapter eight, in which a study to 
investigate the usefulness of eNO as a predictor for the response to oral 






In this chapter, the methods used in each of the subsequent studies are outlined in 
detail. Only minor variations in methodology will be repeated elsewhere. 
4.1 Daily diary data 
All participating patients completed a daily record card (fig 4.1) of morning and 
evening peak expiratory flow rates, bronchodilator use, and asthma symptoms. In 
addition during the dose-response study (Chapter Seven) diaries also included a 
section to record medication compliance. 
PEFRs were measured prior to medication use using a mini-Wright peak flow 
meter (Clement Clarke Int Ltd, Harlow, UK). The highest of three measurements 
was recorded. 
Daily peak flow variability was calculated by: 
I Evening PEFR- Morning PEFR (1/sec) I xlOO% 
(Morning PEFR + Evening PEFR) I 2 
For assessment of symptoms patients were asked to score their symptoms based 
on a scale of 0-3, 0 being no symptoms and 3 being severe. Scores were obtained 
for: 
Nocturnal: cough and wheeze 
Daytime: cough, wheeze, shortness ofbreath and sputum. 
The daily total symptom score was the sum of the individual scores (maximum 
score of 18). 
40 
\ Fig 4.1 A sample page from the daily record card. 
I Mon I Tues I Wed Thurs Fri 
1 I 2 I 3 4 5 
Date 
c - ~---.-- lete th· -- --- tion in th - -----------





No. of puffs of 
reliever 
Reliever in the last 
6 hours? Y/N 
c -----.-- lete th· -- --- tion in th - --------o.~ 
Best Peak Flow 
Wheeze 0-3 
Cough 0-3 
Activity 0 - 3 
Sputum 0-3 
No. of puffs of 
:' reliever 
Reliever in the last 
6 hours? YIN 
Stuffy/runny nose? 
Y/N 











Spirometry was performed at each clinic visit in all of the studies. Spirometry was 
performed according to A TS standards and using the 'Morris Normal Set' for 
calculation of normal predictive values. Forced expiratory volume in one second 
(FEV1) and forced vital capacity (FVC) were measured using a rolling seal 
spirometer (Spirotech, Graseby, Georgia, USA). The highest of three reproducible 
measurements was recorded. The highest FEV1 and FVC from technically 
acceptable "blows" were used, even if not from the same "blow'. 
4.3 Exhaled nitric oxide 
Exhaled NO measurements were obtained using a chemiluminescence analyser 
designed for on-line measurement of eNO concentration (LR2000, Logan 
Research, Rochester, Kent, UK) (see fig. 2.1 ). The analyser had a response time 
of <2 seconds and was calibrated using a gas mixture containing 103ppb NO, thus 
permitting a signal within the range 0-200ppb to be accurately measured. 
Measurements were obtained using a standardised protocol (Kharitonov et al. 
1997a; ATS 1999) with the exception of flow rate. The flow rate used was 
250mls/sec, much higher than the now recommended 50mls/sec. This was in 
keeping with the manufacturer's instructions, and was adopted prior to the 
publication of international guidelines (Kharitonov et al. 1997a; ATS 1999). At 
lower flow rates it has been shown that the spread of eNO measurements between 
individual patients is greater (Silkoff et al. 1997). Thus allowing for better 
differentiation between individual patients and improving both the sensitivity and 
specificity of eNO in distinguishing between asthma and non-asthma subjects 
(Silkoff et al. 1997; Pedroletti et al. 2000). This has implications for the following 
studies because using the higher flow rate may bias against finding significant 
differences between the patient groups. 
When possible each visit was conducted at the same time of day. Patients were 
asked to refrain from doing strenuous exercise or having any alcohol for four 




were non-smokers or who had stopped smoking for at least one year, with a total 
smoking history of <5 pack years (one pack year equals twenty cigarettes/day for 
a period of one year). In the COPD study, patients were asked to refrain from 
smoking on the day of the clinic visit. At each visit patients were asked regarding 
recent symptoms associated with either allergic rhinitis or an upper respiratory 
tract infection. 
Nitric oxide measurements were made prior to any other study procedures. 
Patients sat quietly for five minutes before measurements were made. No nose 
clips were used. Measurements of eNO were made by expiring from total lung 
capacity without breath holding. Patients exhaled their whole vital capacity slowly 
through a mouthpiece against a known resistance (see Figure 2.1). Throughout 
exhalation the patient viewed a biofeedback monitor that enabled them to keep 
their exhalation constant at a flow rate of 250ml/sec and a mouth pressure of 50 
mmH20. Tests in which a steady flow was not achieved were discarded. Exhaled 
NO was sampled at a rate of 250mls/sec via a side arm in the mouthpiece. A total 
of at least three measurements were made at each visit and stored for later 
analysis. 
Nitric oxide measurements were read at a later date by an independent observer 
who was blinded to the patient's current clinical status. The eNO plateau level at 
70-80% of the exhaled volume was recorded (Chambers et al. 1996) (see Figure 
2.2). 
4.4 Hypertonic saline challenge 
Hypertonic saline challenges were performed using a modification of a 
standardised protocol (Sterk et al. 1993~ Iredale et al. 1994). Hypertonic (4.5%) 
saline solution was nebulised via an ultrasonic nebuliser, (De Vilbiss Ultraneb 
2000~ DeVilbiss, Somerset, PA., USA.), connected to 90 em of corrugated aerosol 
tubing (smooth interior surface) and a large Hans-Rudolf two-way nonrebreathing 
valve (No. 2700 Hans Rudolph, Inc., Kansas City, Mo., USA.). During the 





by increasing the inhalation time. The initial inhalation of saline was for a period 
of30 seconds, followed by a repeat of 30 sec, then 1-min, 2-min, and repeated 4-
min nebulisations. Spirometry was performed at one minute following each 
nebulisation and the better of two measurements was recorded. 
The hypertonic saline challenge was completed when there had been a 20% drop 
in FEY1, or a cumulative time of twenty minutes had been achieved. The 
nebuliser canister plus tubing was weighed prior to the challenge, and again after 
completion of the challenge, on a top pan Sartorius balance (Sartorius, 
Goettingen, Germany). From this the total amount of saline nebulised was 
measured and the nebuliser output per minute calculated. There is no need to 
weigh the amount of nebulised saline used after each inhalation because results 
obtained from calculating the saline delivered at each time point do not differ 
from those obtained by calculating the difference between initial and final weight 
(Riedler et al. 1994b ). From these data both the cumulative dose of saline causing 
a 15% fall in FEY 1 (PD1s) and the dose-response slope(% drop in FEY 1 following 
the final dose divided by the total dose of saline administered) were calculated 
(Peat et al. 1992). 
Foil owing completion of the hypertonic saline challenge patients were then 
administered two puffs of lOO~g of salbutamol (Yentolin, Glaxo-Welcome) via a 
spacer, these puffs were repeated every five minutes until lung function returned 
to at least 90% of baseline. 
4.5 Sputum induction and cell counts 
During the saline challenge patients were encouraged to produce sputum in the 
intervals between: saline inhalation. At the end of each dose of saline, patients 
rinsed out their mouth with water, discarding the water and saliva in order to 
produce better quality sputum samples (Gershman et al. 1996). Patients were then 
asked to expectorate any sputum into a sterile container. A forced expiration 
'huff technique was employed to aid the movement of airway secretions 






If insufficient sputum had been produced at the end of the hypertonic saline 
challenge then sputum induction was continued. As long as the patient's FEV I 
had returned to at least 90% of baseline following two puffs of salbutamol, they 
then inhaled further doses of saline as required to obtain a sufficient sample of 
sputum, up to a maximum cumulative dose of twenty minutes. This further 
nebulisation occurred after the hypertonic saline challenge had finished and the 
saline weighed, and therefore had no bearing on the challenge results. If the FEV I 
again dropped to <80% of baseline during these further periods of nebulisation 
then the patient was given further salbutamol and sputum induction discontinued. 
Patients remained under observation until such time that their FEV I had returned 
to at least 90% of their baseline value. 
The first adequate sample of sputum produced was used for analysis, reducing the 
bias that may occur due to changes in sputum during the induction process (Holz 
et al. 1998a). Sputum was analysed using a standardised method (Fahy et al. 
1993). Sputum was weighed and processed within two hours of the sample being 
obtained, during this time it was stored at 4 °C: The whole specimen (sputum plus 
saliva) was combined with a solution of 10% dithiothreitol (Sputolysin, 
Calbiochem, La Jolla, California, USA) at a ratio of 1:2, gently mixed, and 
incubated in a shaking waterbath at 37°C for thirty minutes in order to ensure a 
homogenised solution. This was then filtered through a 48~m nylon mesh (B&SH 
Thompson, Mississauga, Ontario, Canada). Cell viability was assessed by the 
trypan blue exclusion test, and total cell count performed using a 
haemocytometer. Cytospin slides were prepared and stained with May-Grunwald-
Giemsa stain. Each slide was coded and a total of 400 nonsquamous cells were 
counted on two separate occasions. The mean differential of these two counts was 
then recorded. If the difference between the two counts was greater than 10% for 
any cell type then the counts were repeated on a further two occasions and the 
mean differential of the four counts was recorded. The remaining sputum mixture 
was centrifuged at 1500rpm (lOOOG) for five minutes, the supernatant decanted 






4.6 Six-minute walk tests 
Due to limitations in respiratory function, COPD patients may have markedly 
reduced functional capacity. "Functional exercise capacity" is defined as a 
patient's ability to undertake physically taxing activities encountered in everyday 
life. These are not always reflected by conventional methods of assessing disease 
activity. Over the last two of decades walking tests have been developed as a 
measure of "functional exercise capacity" and have been found to be particularly 
useful in patients suffering from moderate to severe exercise limitation due to 
pulmonary causes (Steele 1996). In particular the '6-minute walk' test has been 
developed as a test of functional capacity which can easily be repeated on the 
same day (Steele 1996) and results correlate well with those of longer walks 
(Butland et al. 1982). 
Reproducibility 
Walking tests have been shown to have good reproducibility, with an intra-subject 
coefficient of variation of9.0% when measured at weekly intervals (Noseda et aL 
1989). Learning effect appears to play an important role when measuring multiple 
tests, particularly so in the first 1-3 walks (Knox et al. 1988; Noseda et aL 1989). 
Thus the establishment of a stable baseiine walking distance is of critical 
importance. The effects of coaching and encouragement have also been shown to 
significantly improve the distance covered during a walking test. Performance 
during a 6-minute walk has been shown to improve by as much as 30.5 metres 
when compared to distances covered while receiving no encouragement (Guyatt et 
al. 1984). As a result it is recommended that the level of coaching/encouragement 
should be recorded and standardised to reduce any variance from this. 
Response to treatment 
The 6-minute walking test has been used to assess the response to both 
pharmacological treatment (O'Reilly et al. 1980; Leitch et al. 1981) and 
pulmonary rehabilitation (Lacasse et al. 1996; Troosters et al. 2000). It has been 





difference perceived by the average patient, for the 6-minute walk is 54m (95% 
CI: 37 to 71m) (Redelmeier et al. 1997). As a result, when assessing response to 
treatment in the COPD study "reversibility" was defined not only using 
spirometric criteria but also on the basis of improvement in 6-minute walk of 
greater than 50m. 
Method 
At each visit during the "eNO in COPD" study (Chapter Eight) patients were 
asked to perform a 6-minute walk using a standardised procedure (Steele 1996). 
Prior to the first walk, dyspnoea was assessed using the 1 0-point Borg Scale. 
Pulse and pulse oximetry was recorded. In addition, the patient took their 
medications they normally require prior to exercise (e.g. ipratropium, fh-agonist 
l 
orGTN). 
Patients were asked to walk from end to end of a marked walking track (of thirty 
metres in length), covering as much ground as possible in six minutes. 
Each assessment of '6-minute walk' consisted of two repeated walks with a rest 
period of at least fifteen minutes in between. 
The following instructions were given to the patient: 
"The purpose of this test is to find out how far you can walk in six minutes. You 
will start from this point (indicate marker at one end of the course) and follow the 
hallway to the marker at the other end, then turn around and walk back. When you 
arrive at the starting point, you will turn around and go back again. You will go 
back and forth as many times as possible in six minutes. If you need to, you may 
stop and rest. Just remain where you are until you can go again. However, the 
most important thing about this test is that you cover as much ground as you 
possibly can during the six minutes. I will let you know the time along the way, 








During the test patients were told when two, four, and six minutes had elapsed. 
The following words of encouragement were also given: 







"keep going you're doing well" 
"halfway - keep going as far as possible" 
"keep going you're doing well" 
"one minute to go - go as far as you can" 
"30 seconds to go" 
"STOP" 
A staff member walked behind the patient so as not to influence the patient's 
pace, and faced the patient only when giving encouragement. 
During the walks, staff members completed a standardised 6-minute walk 
observation sheet recording pulse and 02 saturation every minute throughout the 
walk and for three minutes post-walk. The longer distance walked during two 
identical tests was recorded, although both distances were noted. Duration of time 
spent resting was also recorded. 
Immediately following completion of each walking test, patients were asked to 






EXHALED NITRIC OXIDE- NORMAL VARIATION AND 
CORRELATION WITH OTHER MARKERS OF AIRWAY 
INFLAMMATION DURING STABLE ASTHMA 
5.1. Abstract 
Aim: To assess within-patient variation in exhaled nitric oxide (eNO) 
concentration, and to correlate eNO with other markers of inflammation in stable 
asthma. 
Methods: 78 patients (69 atopic) on inhaled steroids were studied. On-line single 
breath eNO measurements at 70-80% of total lung capacity were obtained weekly 
for 2-4 weeks. Patients completed a twice-daily record of symptoms and peak 
flows. Following this patients underwent a hypertonic saline challenge with 
sputum induction. 
Results: Geometric mean eNO was 10.28 and 9.38ppb at the first and last visits. 
The within-visit and between-visit coefficients of variation were 4.1 and 10.5% 
respectively. The week-to-week 95% reference range was -38% to +61% of 
individual patient means. Higher eNO was associated with nocturnal waking and 
increased bronchodilator use (p=0.008 and p=0.026, respectively). Exhaled NO 
increased by 11% for each doubling of sputum eosinophils (p=0.002). There was 
no significant correlation between eNO and hypertonic saline challenge PD15 or 
slope of hypertonic saline challenge dose-response curve. 
Conclusion: Exhaled NO demonstrates good repeatability within a sitting but 
shows greater variability week-to-week. Measurements are elevated in patients 
with recent breakthrough of asthma symptoms (nocturnal waking and reliever use) 
and in the presence of eosinophil airway inflammation. 
5.2. Introduction 
Asthma is an obstructive airways disease consisting of an interaction between 
inflammation and airway remodelling and hyperresponsiveness (Brusasco et al. 







been based on the control of inflammation using medications such as inhaled 
corticosteroids (Djukanovic et al. 1992; Barnes 1998c). Until now monitoring 
asthma has largely depended on symptom control and measurements of lung 
function (ATS 1987; NHLBIIWHO 1995; BTS 1997b). Yet these measurements 
provide an incomplete picture of asthma control. Ongoing inflammation has been 
found in asthma patients thought to be clinically controlled (Foresi et al. 1990; 
Laitinen et al. 1993; Cai et al. 1998; Haley and Drazen 1998; Parameswaran et al. 
1998). As a result over the last decade attempts have been made to develop a 
repeatable marker of airway inflammation that may be of use in longitudinal 
asthma control. 
The gold standard for measuring airway inflammation is by bronchial biopsy 
obtained during bronchoscopy, but this procedure is not amenable to day-to-day 
use due to its invasive nature. Recently less invasive techniques of induced 
sputum (Pin et al. 1992b) and hypertonic saline challenges (Smith and Anderson 
1989) have been developed to assess airway inflammation. However, these 
procedures are both time consuming and labour intensive limiting their clinical 
usefulness. 
Exhaled NO has·been developed as a marker of airway inflammation in asthma. 
Exhaled NO is higher in asthma (Alving et al. 1993; Kharitonov et al. 1994b; 
Persson et al. 1994) and in atopic individuals (Martinet al. 1996; Henriksen et al. 
1999) when compared to normal controls. In steroid-naive asthma elevated levels 
of eNO correlate strongly with eosinophils in sputum (Jatakanon et al. 1998), but 
in corticosteroid treated asthma this relationship is less certain (Mattes et al. 1999; 
Piacentini et al. 1999; Berlyne et al. 2000; Lim et al. 2000). 
If eNO is to be of use longitudinally in assessing asthma control then it needs to 
be a reproducible test that correlates well with the degree of underlying airway 
inflammation. It is also necessary to assess variation with time in stable asthma. 
This will then permit a valid assessment of what is "abnormal". This study was 





week-to-week variability of eNO in a population of stable asthma patients taking 
regular inhaled steroids, and secondly to correlate eNO with other markers of 
disease control in this setting. 
5.3. Methods 
Subjects 
Patients aged between eighteen and sixty-eight years with a diagnosis of mild to 
moderate stable asthma (ATS 1987) requiring maintenance inhaled corticosteroid 
therapy were invited to take part. Patients were required to have been on inhaled 
steroid therapy for at least six months with no change in dose over the preceding 
six weeks. Recruitment was made through a combination of newspaper 
advertisements, flyers in public places, and patients whose names were in the 
Respiratory Research database. 
Exclusion criteria 
1. Patients with a history of acute severe asthma requiring hospital admission 
within the previous twelve months or with asthma characterised by sudden, 
catastrophic changes in symptoms and peak flow rates. 
2. Pre-bronchodilator FEV 1 at screening less than 50% predicted. 
3. ~Patients whose asthma was seasonal or who experienced symptoms only after 
a viral respiratory tract infection. 
4. Current or ex-smokers of greater than five pack years (one pack year equal to 
20 cigarette/day for one year) who had smoked within the last year. 
5. Unstable asthma requiring the use of oral prednisone during the previous 
three months. 
6. Respiratory infection in last four weeks 
7. Co-existing lung disease- for example bronchiectasis I cystic fibrosis 
Design 
Patients were maintained on a fixed dose of inhaled corticosteroid for a period of 
two (n=22) or four (n=56) weeks. Two times each day patients completed a record 








Patients attended weekly clinic visits at which eNO measurements and spirometry 
were performed. Exhaled NO measurements were obtained prior to any other 
study procedure. At the last of the series of visits patients also underwent a 
hypertonic saline challenge with associated sputum induction and cell counts. 
For a further description of methods used please refer to Chapter Four (Methods). 
Ethics 
Written informed consent was obtained from all study participants before entry 
into the study. Ethical approval was obtained from the Otago Ethics Committee. 
Statistical analysis 
Sources of variability in eNO measurements were estimated using random effects 
regression models and variance components methods (Searle 1992). Associations 
between eNO and other measurements were analysed using the rank correlation 
coefficient since it does not depend on the measurement scale. Exhaled nitric 
oxide and PD1s saline measurements were analysed using logarithmic 
transformations to remove the skew in these data; other measurements were 
analysed without transformation. The results of these analyses did not change 
following the transformations. 
5.4. Results 
Seventy-eight patients entered the study, one withdrew following the baseline 
visit due to personal reasons. Demographic data are given in table 5 .1. Twelve 
patients were ex-smokers and the remainder were life-long non-smokers. All 
patients remained on a fixed dose of inhaled corticosteroid (mean 630.8!-lg/day, 








Table 5.1. Demographic data of the study participants. 
Unless stated results are given as mean (95% C.I. ). 
Number of patients, n 78 
Male : Female 30:48 
Age, yrs (range) 42.9 (19-64) 
Height, m (range) 1.69 (1.49-1.85) 
Duration of asthma, yrs 25.9 (22.4-28.4) 
Skin test positive, n (%) 69 (88%) 
History of rhinitis, n (%) 56 (72%) 
History of eczema, n (%) 38 (49%) 
FEV I, litres 2.88 (2.70-3.06) 
FEVI,% predicted 92.0 (87.9-96.1) 
FEVI /FVC,% 71.0 (68.3-73. 7) 
FEV I = forced expiratory volume in one second. 
PVC= forced vital capacity . 
Variation in eND 
The mean eNO concentrations at each of the study visits are given in Table 5.2. 
The within-patient, within-sitting coefficient of variation for eNO was 4.1 %, 
whereas the within-patient between-sitting coefficient of variation was 10.5 %. 
The 95% reference range for variation in eNO between weekly visits was -38% to 
+61% of the individual patients mean eNO. The coefficient of variation for eNO 










Table 5.2. Geometric mean eNO values at each of the study visits. No 
significant differences were found between the study visits. 
Visit n MeaneNO ±2xSD 
R1 78 10.28 (2.75, 38.45) 
R2 56 10.21 (2.82, 36.93) 
R3 56 10.62 (2.91, 38.68) 
R4 56 10.58 (2.70, 41.43) 
Vl 78 9.38 (2.72, 32.35) 
R =run-in visit, V =visit at study completion. 
Ambient NO recordings throughout the study ranged from 0 to 234.7ppb. The 
median ambient NO was 5.25ppb. By using random effects regression models no 
correlation was found between ambient NO and eNO (p=0.23). 
There was no significant correlation between eNO and baseline patient 
characteristics except for height (Table 5.3.). For every increase in height of 10 
em, eNO was found to increase by 19% (p<0.03). The range of heights in the 
study population was 1.49m to 1.85m. None of the baseline patient characteristics 
were associated with significant differences in variability of eNO between visits 









Table 5.3. The proportional change (ratio) in eNO associated with the 




change in eNO 
Sex (male:female)a 1.020 0.771, 1.350 0.89 
Skin test positive (Y:N) a 1.363 0.895, 2.074 0.15 
Ex-smoker (Y:N) a 1.305 0.900, 1.894 0.16 
Height (each increase of lOcm) b 1.191 1.017' 1.394 0.03 
Weight (each increase of 10kg) b 1.041 0.959, 1.131 0.34 
Steroid dose (each increase of 100 
f.tg/day) b 0.965 0.925, 1.006 0.10 
FEV1 % predicted (each increase 
of10%)b 0.948 0.889, 1.010 0.102 
FEV1/FVC (each increase of 
10%)b 0.939 0.843, 1.046 0.257 
FEV 1 = forced expiratory volume in one second. 
FVC = forced vital capacity. 
a = categorical variable. Proportional change is expressed as a ratio of the 
difference between the two groups. 











ExhaledNO and clinical control 
Changes in eNO associated with data from the daily record cards as assessed over 
the one, three and five days prior to the clinic visits are given in Table 5.4. 
Exhaled NO was significantly higher in patients who had been woken from sleep 
by asthma symptoms and those who had used greater amounts of reliever in the 
one to three days/nights before the study visit. Those who had been woken by 
their asthma the night immediately prior to the clinic visit had an eNO that was 
28.6% higher than those who had not woken, and those who had woken sometime 
during the three nights prior to the visit had an eNO that was 19.8% higher than 
those who had not woken. No association was found between eNO and PEFR 
variation assessed either as diurnal differences or changes in morning PEFR over 
the preceding 5 days before the visit (p=0.053 and p=0.60, respectively). 
Exhaled NO and sputum eosinophiL'! 
Adequate sputum samples were obtained from 72 of the 76 patients (94. 7% 
success rate). Exhaled NO was directly correlated with the percentage of sputum 
eosinophils (r=0.46, p<0.002) and inversely correlated with neutrophils (r= -0.24, 
p<O.Ol6) (Figures 5.1 and 5.2). There was no relationship between eNO and any 
of the other cell types. Changes in eNO associated with the respective increases in 
the proportion of sputum eosinophils and neutrophils are shown in Table 5.5. For 
each doubling in the percentage of sputum eosinophils there was an associated 
increase in eNO of 10.9%. 
Exhaled NO and hypertonic saline challenge 
A hypertonic saline challenge was performed in 68 of the 76 patients. Ofthese, 49 
(72.1%) demonstrated a fall in FEV1 of 15% or greater. No significant 
relationships between eNO and either PD15 saline or the slope of the dose-







Table 5.4. The proportional change (ratio) of eNO associated with 
measurements of asthma control recorded during the 1, 3 and 5 days prior to clinic 
visits. 
Variable 
Number of days Proportional 
95% C.I. p-value 
prior to visit change in eNO 
1 1.001 (1.000, 1.002) 0.275 
Morning PEFR 
(1/min) a 
3 1.001 (1.000, 1.002) 0.264 
5 1.000 (0.999, 1.002) 0.414 
1 1.286 (1.070, 1.545) 0.008 
Awake any 
nights (Y:N) b 
3 1.198 (1.032, 1.392) 0.019 
5 1.090 (0.948, 1.253) 0.226 
Average daily 1 1.045 (1.006, 1.085) 0.026 
reliever use 3 1.049 (1.001, 1.099) 0.048 
(puffs/ day) c 
5 1.052 (1.003, 1.1 03) 0.039 
1 1.014 (0.987, 1.042) 0.305 
Average daily 
3 1.009 (0.978, 1.042) 0.583 
symptom scored 
5 1.004 (0.971, 1.037) 0.820 
Significant results are highlighted in bold. 
PEFR = peak expiratory flow rate. 
a = change in eNO for each increase in I/ min 
b = change in eNO between those who had awoken during any of the nights versus 
those who had not. 
c = change for each increase in puffs/ day. 









Figure 5.1. Scatter plot demonstrating the correlation between eNO and 
percentage of eosinophils in sputum at the end of the run-in phase, r=0.46, 
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Figure 5.2. Scatter plot demonstrating the correlation between eNO and 
percentage ofneutrophils in sputum, r= -0.24, p<O.Ol6. Both eNO and percentage 
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Table 5.5. The proportional change (ratio) in eNO associated with every 
doubling in sputum cell count and airway hyperresponsiveness. 
Variable 
Proportional 
95% CI p-value 
change 
% eosinophils a 1.109 1.042-1.181 0.002 
% neutrophils a 0.846 0. 742-0.966 0.016 
PD1s saline 0.955 0.819-1.113 0.319 
Slope of the hypertonic 
1.106 0.957-1.278 0.242 
saline dose-response curve 
a = eosinophils and neutrophils are expressed as a percentage of the total sputum 
cell count. 










Variation in eNO 
The results of this present study confirm that measurements of eNO are 
reproducible (Kharitonov et al. 1997a; Gabbay et al. 1998) and that these 
measurements provide a good marker of airway inflammation despite the use of 
maintenance inhaled steroid therapy. There was very little variation in eNO 
recordings within a sitting (a coefficient of variation of only 4.1 %) and no 
difference between weekly mean eNO levels obtained (range 9.38- 10.32ppb). 
However, there was greater variation between the weekly measurements in 
individual patients (coefficient of variation 10.5%). The 95% reference range of 
weekly variation was -38% to +61% of the mean eNO.' This larger variation may 
be a reflection of weekly changes in airway inflammation occurring in patients 
with less well-controlled asthma. 
The pattern of variation in eNO recordings also provides evidence for the 
reliability of eNO measurements. The coefficient of variation was lowest within a 
sitting (the coefficient of variation of 4.1% accounting for only 2.2% of the total 
variation in eNO seen), was greater between visits, and was even greater still 
between patients (with the between-patient variation accounting for 83.7% of the 
total variation in eNO recordings). This makes biological sense as the degree of 
airway inflammation is unlikely to differ within the time frame of a single visit 
(consistent with the low coefficient of variation within a sitting), but may occur 
between weekly visits, and is most likely to occur when comparing patients with 
one another. 
A possible problem with the study design when attempting to assess normal 
variation in eNO recordings lies in the definition of stable asthma. The entry 
criteria into the study were 'asthma patients controlled on a stable dose of inhaled 
corticosteroid therapy'. This criterion was designed to exclude unstable asthma, in 
which the dose of inhaled therapy may have been altered during recent weeks. 









management plan' is satisfactory. It has been reported previously that patients 
with severe asthma may have poor insight into disease control (in't Veen et al. 
1998; Jatakanon et al. 1998; Sont et al. 1999). This poor insight may mean that 
some of the patients entered into the study with unstable asthma. There is some 
evidence that this may have been the case. For example, on twenty -one occasions 
(out of a total of 249 visits) patients reported nocturnal waking during the night 
prior to the clinic visit, and on thirty-seven occasions patients had used more than 
three puffs of reliever during the preceding twenty-four hours. Likewise 25% 
(18/72) of patients had greater than 3.5% eosinophils in their sputum, indicating 
the presence of significant ongoing inflammation. Demonstrating that some of our 
patients may have had poorly controlled asthma at study entry. This does not 
invalidate the results of the study, but rather suggests that the weekly variation in 
eNO in fully controlled asthma may in fact be less than the variation recorded 
here. However, for the purposes of the subsequent study, in which eNO was 
evaluated as a predictor of poorly controlled asthma, the 95% reference range of 
-38% to +61% has been used. 
Exhaled NO and baseline characteristics 
On the whole, baseline patient characteristics did not affect eNO levels. No 
difference was seen when comparing male and female patients in either absolute 
eNO or in variation in eNO over several weeks. This is consistent with the 
findings of Morris et al (1994) who found no change in eNO throughout the 
menstrual cycle but is in contrast to the earlier findings of Kharitonov et al 
(1994a) who suggested that menstrual cycle may lead to changes in eNO. Some 
technical issues may have influenced the results of the Kharitonov study adversely 
including an unstandardised exhalation flow rate and the use of peak rather than 
plateau eNO recordings . 
Previous studies have found that eNO levels are elevated with atopy (Martin et al. 
1996; Moody et al. 2000). By contrast, no significant difference was seen between 











(interquartile range) of eNO in atopic compared with non-atopic patients in the 
current study was ll.Oppb (6-16) and 5.1ppb (4-8) respectively (Fig. 5.3). 
















Non Atopic Atopic 
There are two possible explanations for the lack of significance in this 
comparison. Firstly all of our patients were on maintenance inhaled corticosteroid 
therapy, therefore suppressing underlying airway inflammation. Whereas the 
earlier studies had examined the relationship between atopy and eNO in patients 








eNO. Further assessment of the effects of atopy on eNO in our asthma patients 
will be made in Chapter Six following cessation of inhaled corticosteroid therapy. 
The second reason for a lack of significance is that there were only a small 
number of non-atopic individuals in our study population (9/78), making a valid 
comparison between these groups difficult. 
Higher levels of eNO were seen with increasing patient height in the current study 
population. A 19% increase in eNO was seen for every 1 Ocm increase in height 
(p=0.03) (fig. 5.4). 
Figure 5.4. Mean eNO levels from patients grouped into height quartiles. 
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Biologically the finding is plausible given that eNO concentration is dependent on 
the transit time of the breath through the airways; the greater the transit time 
through the airways and the greater the recorded eNO (Silkoff et al. 1997). 
Consistent with this, previous studies have demonstrated that acute 
bronchoconstriction decreases eNO (Ho et al. 2000), whereas bronchodilatation 
increases eNO (Yates et al. 1997; Silkoff et al. 1999; Ho et al. 2000). In a similar 











would increase the overall transit time of air through the airways and in 
association with increased surface area would allow a greater concentration of 
eNO to diffuse into the breath. However, previously two studies have found no 
correlation between eNO and height (Ho et al. 2000; Sippel et al. 2000). The Ho 
et al study (2000) was limited by small numbers (n=12 asthmatics, n=17 normal 
controls), and in both studies neither the range of heights nor the eNO levels 
obtained were reported. 
Exhaled NO and ambient NO 
An important finding of the current study was the absence of any relationship 
between eNO and ambient NO concentrations (over a range of ambient levels of 0 
to 234 ppb, p=0.23). This is important because it indicates that patients do not 
require to inhale 'NO-free' air in order to obtain valid measurements of eNO, thus 
improving the ease with which eNO can be measured in the clinical setting. It 
confirms previous reports that eNO levels, when read at erld-expiration, are not 
affected by the concentration of NO in inhaled air (Silkoff et al. 1997; Corradi et 
al. 1998; Ho et al. 1998; Piacentini et al. 1998; Sippel et al. 2000) even when 
patients inhale NO concentrations up to 1 OOOppb (Silkoff et al. 1997). This is 
thought to be due to the high binding affinity that NO has with haemoglobin 
(Sharma et al. 1987; Cremona et al. 1995). This high binding affinity creates 'NO-
free' air in the alveoli, and therefore allows the use of end-expiratory eNO 
(corresponding to air originating from the alveoli) as a measurement of the airway 
NO independent of ambient concentrations. 
Exhaled NO and asthma control 
An indication that eNO reflects the extent of underlying airway inflammation is 
gained from assessing its relationship with patient symptoms over the preceding 
twenty-four hours. Exhaled NO was elevated in patients with nocturnal waking; 
13.4 7ppb for those who had woken during the night with asthma symptoms in the 
preceding twenty-four hours, compared to 9.92ppb for those who had not 











Figure 5.5. Mean eNO of patients who had woken with asthma symptoms 











Awoke Did not awake 
Exhaled NO was also elevated in those requiring greater use of ~-agonist in the 
preceding twenty-four hours; 0 puff/day: 9.50ppb; 1 puff/day: 10.99ppb; 2 
puffs/day: 9.68ppb; and greater than 3 puffs/day: 12.97ppb (p=0.026 for 
difference across these values) (Fig. 5.6). Thus patients with increasing severity of 










Figure 5.6. Mean eNO measured in patients grouped by the number of puffs of 
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Furthermore, the occurrence of either nocturnal waking or increased 
bronchodilator use in the twenty-four hours prior to the clinic visit was associated 
with a higher eNO than if they had occurred during the three to five days earlier. 
Suggesting that eNO may be sensitive to acute changes in the amount of 
underlying inflammation. For example, patients who had woken due to asthma 
symptoms in the 24-hours prior to the clinic visit had eNO levels that were 
increased by 28.6% (95% CI: 7.0 to 54.5%) when compared to those who had not 
woken. Likewise, waking during the preceding three days was associated with an 
increase in eNO of 19.8% (95% CI: 3.2 to 39.2%). Whereas patients waking 
sometime during the preceding five days demonstrated no significant increase in 
eNO when compared to those who had not woken (mean difference of9.0%, 95% 
CI: -5.4 to25.3%). 
Previously, elevated levels of eNO have been found in asthma characterised by 
nocturnal symptoms (ten Hacken et al. 1998). Similarly, elevated eNO has been 









(Stirling et al. 1998~ Sippel et al. 2000). In a cross-sectional study of 100 asthma 
patients, Sippel et al (2000) found elevated levels of eNO in patients who had 
been troubled by recent symptoms (within the last two weeks) despite the use of 
maintenance inhaled steroid therapy. They found that patients who had symptoms 
during the two weeks had an eNO of 74.1 ±8ppb, whereas those who had no 
symptoms had levels of 49.2 ±7ppb (p=0.02 for the comparison). However, these 
authors found no increase in eNO levels in the patients reporting symptoms 
occurring in the proceeding one and six months (p=0.99 and p=0.22 respectively). 
Furthermore, they found no difference in eNO levels when patients were divided 
solely in terms of previous history. of asthma severity further indicating that eNO 
provides a good assessment of acute airway inflammation rather than chronic 
airway changes . 
Exhaled NO and airway inflammation 
It has been suggested that eNO may not a good indicator of airway inflammation 
in patients taking regular inhaled corticosteroid therapy, as previous studies have 
found no correlation between eNO levels and the amount of underlying airway 
eosinophilia in such circumstances (Berlyne et al. 2000~ Lim et al. 2000). 
Interpretation of these previous studies is limited as they have involved patients 
with very low levels of ongoing airway inflammation. For example, in the study 
by Berlyne et al (2000) inhaled steroid treated patients had a median (interquartile 
range) sputum eosinophil count of only 0.6% (0-3.8%). In contrast, in our current 
study nearly one quarter of the patients had greater than 3.5% eosinophils in their 
sputum, and the group mean was 4.0% (95% C.I.: ±2.1%) indicating the presence 
of significant ongoing airway inflammation in our current study. In this setting of 
increased levels of airway inflammation eNO was shown to correlate directly with 
the degree of sputum eosinophilia despite inhaled corticosteroid use (r=0.46, 
p<0.002) (see Fig 5.1). Moreover, eNO was shown to increase by 10.9% (95% CI: 
4.2 to 18.1%) for every doubling of sputum eosinophils observed, supporting the 
use of eNO as a marker of airway inflammation even when patients are taking 











There was no relationship between eNO and the degree of airway 
hyperresponsiveness to hypertonic saline in our current study. Previously other 
investigators have found a relationship between eNO and airway 
hyperresponsiveness in steroid-naive asthma (Dupont et al. 1998~ Jatakanon et al. 
1998; Verleden et aL 1999~ van der Thoorn et al. 2000) however this relationship 
appears to be lost in the presence of inhaled corticosteroid therapy (Verleden et al. 
1999; Ichinose et aL 2000). The cause for this lack of consistent relationship is 
unknown but suggests that these two assessments of asthma severity are 
measuring different aspects of asthma pathophysiology. 
A more in-depth look at the usefulness of eNO in assessing airway inflammation 
during inhaled corticosteroid therapy will be undertaken in Chapter Seven. 
Summary 
Measurements of eNO are easily performed and demonstrate good intra-patient 
reproducibility. Elevated levels of eNO are seen in patients with symptoms of 
unstable asthma and correlate directly with the degree of sputum eosinophilia 
despite maintenance inhaled corticosteroid therapy. These findings imply that 
serial eNO may be a useful tool in the clinical assessment of asthma control, both 
in identifying poorly controlled asthma and monitoring response to treatment. 










THE PREDICTIVE VALUE OF EXHALED NITRIC OXIDE 
MEASUREMENTS IN ASSESSING CHANGES IN ASTHMA 
CONTROL 
6.1 Abstract 
Exhaled NO levels are increased in untreated or unstable asthma and 
measurements can be made easily. 
Aim: To assess the usefulness of eNO for diagnosing and predicting loss of 
control in asthma following steroid withdrawal. 
Method: Seventy-eight patients with mild/moderate asthma had their inhaled 
steroid therapy withdrawn until loss of control occurred or for a maximum of six 
weeks. Comparisons were made between eNO, symptoms, lung function, sputum 
eosinophils and airway hyperresponsiveness to hypertonic saline (4.5%) in both 
predicting and diagnosing loss of control. 
Results: Sixty patients (77.9%) developed loss of control. There were highly 
significant correlations between the changes in eNO and symptoms (p<O.OOOI), 
FEV1 (p<0.002), sputum eosinophils (p<0.0002) and PD1s saline (p<0.0002), and 
there were significant differences between loss of control and no loss of control 
groups. Both single measurements and changes of eNO ( 1 Oppb, 15ppb or an 
increase of >60% over baseline) had positive predictive values that ranged from 
80-90% for predicting and diagnosing loss of control. These values were similar 
to those obtained using sputum eosinophils and PD1s saline measurements. 
Conclusion: Exhaled NO measurements can be used to predict and diagnose 
poorly controlled asthma, and are as useful as induced sputum analysis and airway 
hyperresponsiveness in assessing airway inflammation, with the advantage that 













Nitric oxide is a key messenger for cell to cell signalling, and has an important 
role in the biochemistry of inflammation (Gaston et al. 1994~ Barnes and Liew 
1995). Exhaled NO has been confirmed as a marker of airway inflammation and is 
present in higher concentrations in steroid-naive asthma compared to normal 
controls (Alving et al. 1993). Higher levels of eNO are seen during asthma 
exacerbations (Crater et al. 1999), and decreases occur following treatment with 
both inhaled (Kharitonov et al. 1996b) and systemic corticosteroids (Massaro et 
al. 1995). Furthermore, eNO appears to be sensitive to changes in anti-
inflammatory treatment, even in the absence of changes in lung function 
(Kharitonov et al. 1996c). These findings suggest that eNO may be a useful 
indicator in the longitudinal assessment of asthma control. 
Both induced sputum cell counts (Pin et al. 1992b) and responsiveness to 
hypertonic saline (Smith and Anderson 1989) have also been investigated as 
markers of airway inflammation in asthma. Sputum eosinophil numbers increase 
during asthma exacerbations (Pizzichini et al. 1999) and decrease following both 
oral prednisone ( Claman et al. 1994) and inhaled corticosteroid therapy 
(Jatakanon et al. 1998a). Likewise, Du Toit and co-workers (1997) have 
demonstrated a progressive reduction in airway responsiveness to hypertonic 
saline following initiation of inhaled corticosteroid treatment. However, the scope 
for using these techniques to monitor asthma control in clinical practice is limited 
by the resources required for repeated measurements. In contrast, measuring eNO 
is quick and easy to perform and lends itself to repeated measurements over time. 
Although single measurements of eNO have been used to assess airway 
inflammation in asthma (Jatakanon et al. 1998; Stirling et al. 1998; Piacentini et 
al. 1999; Lim et al. 2000), the usefulness of eNO in the longitudinal assessment of 
asthma control has not been extensively investigated. To be clinically useful eNO 
would need to correlate with known markers of asthma control as well as airway 
inflammation, and be responsive to changes in these parameters over time. If this 
were the case, then eNO measurements could be used to confirm poorly 












role for eNO in optimising anti-inflammatory therapy such as has been done using 
measurements of airway hyperresponsiveness (Sont et al. 1999). 
The aim of this study was to evaluate the predictive and diagnostic value of eNO 
in unstable asthma and to correlate this with sputum eosinophils and airway 
hyperresponsiveness to hypertonic saline. A model of steroid withdrawal 
described by Gibson et al (1992) was used in order to induce a deterioration in 
asthma control in the majority of patients thus enabling the assessment of these 
parameters in the context of increasing degrees of airway inflammation. 
6.3 Methods 
Subjects 
Patients with mild to moderate asthma, confirmed at our research screening clinic 
using ATS criteria (A TS 1987), and who had been taking inhaled corticosteroid 
therapy for at least six months were recruited. Their dose of inhaled steroid was 
unchanged for at least six weeks prior to study entry. 
Exclusion criteria were made to exclude severe asthma (as the study involved the 
withdrawal of inhaled corticosteroid therapy) and also to exclude factors that may 
have interfered with eNO recordings. The exclusion criteria are as given in 
Chapter Five. 
Study Design 
Patients initially had a two to four week run-in period during which the 
maintenance dose of inhaled corticosteroid therapy remained unchanged. This 
run-in period provided the basis on which individual baseline data were derived. 
Following this run-in inhaled corticosteroid therapy was withdrawn. Patients were 
then reviewed weekly, or sooner if required, until loss of control developed OR 
for a maximum of six weeks. When loss of control occurred, patients were seen 
within twenty-four hours. The visit at which the inhaled steroids were stopped 
was designated visit 1; the final visit of the study, visit F; and the visit 














Criteria for loss of control were: 




greater than 10% from baseline~ OR a fall in either morning or evening peak 
expiratory flow rate on two consecutive days to 80% of baseline or less; OR 
Mean daily bronchodilator use (over the last 7 days) of greater than 3 puffs 
more than during run-in; OR 
Nocturnal wakening with asthma symptoms on three nights or more per week 
greater than during the run-in; OR 
Asthma symptoms which were disagreeable or distressing. 
Study procedures 
Diurnal peak expiratory flow rates, bronchodilator use, and symptom scores were 
recorded by the patient on a daily record card. Measurements obtained at each 
study visit are shown in Table 6.1. Exhaled NO was measured prior to all other 
study procedures using a calibrated chemiluminescence analyser with on-line 
measurement of single exhalations according to a standard protocol (Kharitonov 
et al. 1997a~ ATS 1999), with the exception of flow rate (250 mls/sec). Exhaled 
NO levels were read at the plateau corresponding to 70-80% of the COz curve. 
Full descriptions of the methods used for the various study procedures are given 















Table 6.1. Study protocol for measurements at each visit. 
Visit No. Vl V2 V3 V4 V5 VP VF 
eNO X X X X X X X 
Spirometry X X X X X X X 
HSC X X 
Sputum analysis X X 
i I I 
Stop inhaled LOCor 
steroids end of6 
weeks 
Visits at which measurements of exhaled nitric oxide (eNO), spirometry, 
hypertonic saline challenge (HSC), and sputum analysis were made are indicated 
by (x). The number of visits between Vl and VF was variable. 
LOC= loss of control. 
V= visit; P= penultimate; F= final. 
Ethical considerations and safety 
Each patient's asthma control was monitored closely throughout the study. All 
patients were provided with an individualised self-management plan, an 
emergency card, and a supply of prednisone tablets. Patients had 24-hour access 
to one of the study investigators via the hospital paging system. For ethical 
reasons, loss of control criteria included symptoms that were disagreeable or 
distressing irrespective of peak expiratory flow rate changes. Ethical approval was 
obtained from the Otago Ethics Committee and written informed consent was 












Associations between eNO and other measurements were analysed using the rank 
correlation coefficient since it does not depend on the measurement scale. 
Regression methods were used to compare airway inflammation parameters in 
patients who lost control with those who did not, and to adjust the comparisons 
for baseline differences. The prognostic and diagnostic utility of eNO was 
evaluated and compared to other measures using methods for constructing 
receiver-operator characteristic (ROC) curves (Swets and Picket 1982). Exhaled 
nitric oxide and PD15 saline measurements were analysed using logarithmic 
transformations to remove the skew in these data; other measurements were 
analysed without transformation. The results of these analyses did not change 
following the transformations. 
6.4 Results 
Seventy-eight patients entered the study. Demographic data are given in Table 
6.2. The mean eNO during run-in was 9.38ppb (95% reference range: 2.72-32.35). 
Over the run-in period eNO was not related to ambient NO (range 0-234ppb, 
p=0.23) and so no corrections were made for ambient NO measurements. Patients 
with atopy had a significantly higher eNO at visit F than those non-atopic patients, 
regardless of asthma control status. Atopic patients had a mean (95% CI) eNO of 
24.53ppb (20.3 to 28.77ppb) compared to 12.49ppb (3.97 to 2l.Olppb) in non-
atopic patients (p=0.009). 
Loss of control 
Sixty patients (77.9%) developed loss of control according to the pre-determined 
study criteria (the 'loss of control' (LOC) group) and seventeen did not (the no-
LOC group). Figure 6.1 is a Kaplan-Meier survival plot demonstrating the 
proportion of patients at each time point remaining with controlled asthma. The 
median time to loss of control was seventeen days (95% C.I: 14 to 28). Twenty-















withdrawal. The frequencies with which 'loss of control' criteria were met were: 
fall in PEFR, 40; increased bronchodilator use, 15; increased nocturnal waking, 
10; distressing symptoms, 39. Nine patients had 'loss of control' on the basis of 
distressing symptoms alone, 2 on the basis of increased reliever use alone. Thirty-
two patients fulfilled two or more criteria at the time of 'loss of control'. 
Table 6.2. Demographic data for study population. 
Number of patients (n) 78 




Duration of asthma (yrs) 
25.9 
(range 3-60) 
Skin test positive (n) 69 (88%) 
Ex-smokers: non-smokers 12:66 
ICS dose (~-tg/day) 630 
(beclomethasone equivalent) (range 100-1600) 
FEV 1 (litres) 2.88 (2.70, 3.06) 
FEV 1 (% predicted) 92.0 (87.9, 96.1) 
FEVI/FVC (%) 71.0 (68.3, 73.7) 
Unless stated otherwise, figures are means with 95% C.I. in parenthesis. 
Ex-smokers had not smoked for more than one year and had a smoking history of 
<5 pack years (one pack year= 20 cigarette/day for one year) . 
ICS = inhaled corticosteroid . 
FEV1 = forced expiratory volume in one second. 
















Figure 6.1. Kaplan-Meier survival plot demonstrating the proportion of 
patients with controlled asthma at each time point. 
Dashed lines represent the 95% C. I. 















































Sputum induction was performed in all patients at visits 1 and F. Adequate 
sputum samples were obtained in 71177 patients at visit 1 (92%), and in 54 (90%) 
and 15 (88%) of the LOC and no-LOC groups at visit F respectively. 
Comparisons between the LOC and no-LOC groups at visit 1 and F and change 
between these visits are given in Table 6.3. The LOC group experienced a 2.16-
fold increase in eNO between visits 1 and F, which was significantly greater than 
the 1.44-fold increase for the no-LOC group (p=0.004). There were also 
significant differences between LOC and no-LOC groups for: the fall in mean 
morning peak expiratory flow rate (13% versus 1%, p<0.0001); the decrease in 
FEV1 (mean fall of 11.9% predicted compared to 2.6% predicted, p=0.001); the 
increase in sputum eosinophils (4.73-fold increase compared to 2.05-fold, 
p=0.044); and the decrease in PD1s saline (0.8 doubling doses compared to 0.03 
doubling doses, p=0.001). 
Correlations between study end-points 
There were highly significant correlations between the changes in eNO that 
occurred between visits 1 and F and the changes in symptoms, lung function, 
sputum eosinophils and airway hyperresponsiveness to hypertonic saline 
challenge that occurred over the same period (Table 6.4). In general, the 
correlations between single measurements of eNO and these same parameters 
were lower than those seen with changes over time and were not consistently 
significant (Table 6.4). Figure 6.2 shows a scatter-plot representation of the 
correlation between eNO and sputum eosinophils . 
78 
Table 6.3. Comparisons between loss of control and no loss of control 




.I 89.6 102.1 ' Visit 1 0.015 
FEV1 (84. 7, 94.5) (94.4, 109.8) 
(% predicted) a 77.7 101.0 
Visit F 
(72.5, 82.9) (92.2, 109.9) 
<0.0001 
d Change -11.9 -1.1 0.0003 









(17.15, 25.34) (8.48, 16.91) 
Change 2.16 1.44 
0.004 
(VF/V1) ( 1. 88, 2.48) (1.13, 1.82) 
Visit 1 
4.6 3.9 
0.83 Sputum (1.8, 7.3) (0.2, 7.7) 
"' eosinophils 
(%)a Visit F 
18.9 6.8 
0.050 
(12.6, 25.1) (1.6, 12.1) 
Change 14.3 3.3 
0.067 
(VF-V1) (8.0, 20.6) (-1.5, 8.0) 
,., 





( 4.53, 8.47) (9.12, 21.56) 
·"' Change -0.80 -0.03 
0.010 
"' (d.d.)* ( -1.18, -0.42) (-0.33, 0.28) 
a= arithmetic mean. 
b . = geometnc mean. 
I -,-
LOC = loss of control. 
.l 
FEV 1 = forced expiratory volume in one second. 
PD15 saline= the cumulative dose of hypertonic saline required to induce a 15% 
·~- fall in FEV I· 
















Table 6.4 Rank correlations between eNO and other measures of asthma 
control and airway inflammation measured at visit F (left hand column) and (right 
hand column) between the changes in eNO and the changes in each of the other 



































FEV 1 = forced expiratory volume in one second. 
I 
I 























PD 15 saline= the cumulative dose of hypertonic saline required to induce a 15% 
















Figure 6.2. Scatter plot of correlation between eNO and % sputum 
eosinophils at visit F, r = 0. 62, p<O. 000 1. 
Both eNO and % eosinophils are expressed on a logarithmic scale. 
x =patients who had loss of control. 
• = patients who did not have loss of control. 
0 
0 
I ,.... R = 0.62 
gl X 
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Predictive and diagnostic values 
The ability of eNO measurements to predict up-coming 'loss of control' was 
assessed in three ways. Firstly by using the baseline eNO measurement (visit 1 ). 
Secondly by using the measurement of eNO at the visit immediately prior to loss 
of control (the penultimate visit, visit P). And thirdly by using the change in eNO 
which occurred between visit 1 and visit P. Analysis of receiver-operator curves 
demonstrated parity between these different approaches (Figure 6.3). The curves 
were similar whether absolute or proportional changes in eNO were used. The 
prognostic utility of changes in eNO between visit 1 and visit P is demonstrated 
by a receiver-operator curve in Figure 6.4 (top panel). In figure 6.4 (bottom panel) 
the receiver-operator curve for changes in eNO is then compared to changes in 
FEV 1% predicted, daily peak expiratory flow rate variation, symptom scores and 
I 
bronchodilator use between visit 1 and visit P. None of these clinical parameters 
was found to be superior to eNO in predicting loss of control despite being a part 
of the definition of loss of control. The sensitivities, specificities, positive and 
negative predictive values at relevant cut points also showed that no one 
prognostic indicator was clearly superior (Table 6.5). Specific eNO cut points 
evaluated included lOppb, 15ppb and a 60% increase over the baseline mean (the 
upper limit of the 95% reference range for weekly variation in eNO over the run-
in period). 
The prognostic value of eNO was also compared with other indices of airway 
inflammation, specifically single measurements of responsiveness to hypertonic 
saline (PD15 less than 12mls) and sputum eosinophils (greater than 4%) obtained 
at visit 1 (Figure 6.5, Table 6.5). Again compared to eNO, no measurement was 
clearly superior. 
The ability of eNO to diagnose 'loss of control' was also assessed using eNO 
measurements at visit F (Table 6.6). Both the single measurements of eNO at visit 
F and the change between visit 1 and visit F were evaluated. As for the assessment 
















performance of eNO was comparable to that based on sputum eosinophil counts 
and PD15 saline measurements . 
Figure 6.3. Receiver-operator curves assessing the various methods of 
monitoring eNO in predicting up-coming loss of control. Point-in-time 
measurements at visits 1 and P and change in eNO assessed both as absolute 
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Figure 6.4. Receiver-operator curve for changes in eNO (proportional 
change between visit 1 and visit P) in predicting up-coming loss of control (Top 
panel). The lower panel shows this same receiver-operator curve for changes in 
eNO superimposed on the receiver-operator curves of lung function and daily 
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Table 6.5. Predicting loss of control. The predictive values of measurements of eNO, % eosinophils and PD 15saline measured at 
visit 1, and for eNO at the visit immediately prior to loss of control (visit P) in distinguishing those who went on to develop loss of control 
from those who did not. Figures in parenthesis are 95% confidence intervals. 
Sensitivity Specificity 
Positive Predictive Negative 
Value Predictive Value 
>10ppb. 
0.50 0.53 0.79 0.23 
(0.37, 0.63) (0.28, 0.77) (0.63, 0.90) (0.11, 0.39) 
eNO at visit 1 
> 15 ppb. 
0.25 0.88 0.88 0.25 
(0.15, 0.38) (0.64, 0.99) (0.64, 0.99) (0.15, 0.38) 
0.65 0.41 0.80 0.25 
>10 ppb. 
(0.52, 0.77) (0.18, 0.67) (0.66, 0.90) (0.11, 0.45) 
eNO at visit P 
>15 ppb. 
0.50 0.65 0.83 0.27 00 
(0.37, 0.63) (0.38, 0.86) (0.67, 0.94) (0.14, 0.43) 
.j:>. 
~>10ppb. 
0.27 0.76 0.80 0.23 
Change in eNO from visit 1 (0.16, 0.40) (0.50, 0.93) (0.56, 0.94) (0.13, 0.36) 
to visit P 0.50 0.65 0.83 0.27 
~>60% 
(0.37, 0.63) (0.38, 0.86) (0.67, 0.94) (0.14, 0.43) 
% eosinophils at visit 1 >4% 
0.21 0.80 0.80 0.21 
(0.12, 0.34) (0.52, 0.96) (0.52, 0.96) (0.12, 0.34) 
PD1s saline at visit 1 <12ml 
0.53 0.50 0.77 0.25 
(0.38, 0.67) (0.25, 0.75) (0.60, 0.90) (0.11' 0.43) 
PD 15 saline = the cumulative dose of hypertonic saline required to induce a 15% fall in FEVJ. % esoinophils = the percentage of 





















Figure 6.5. Receiver-operator curves for eNO (proportional change between 
visit 1 and P), percentage sputum eosinophils at visit 1, and PD 15 saline at visit 1, 
for predicting up-corning loss of control. 
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Table 6.6. Diagnosing loss of control. The predictive values of eNO, sputum eosinophils, and PD 15 saline measured at visit F for 
diagnosing loss of control. Figures in parenthesis are 95% confidence intervals. 
Sensitivity Specificity 
Positive Predictive Negative 
Value Predictive Value 
>10 ppb. 
0.83 0.29 0.81 0.33 
(0.71' 0.93) (0.1 0, 0.56) (0.69, 0.90) (0.12, 0.62) 
eNO at visit F 
>15 ppb. 
0.60 0.65 0.86 0.31 
(0.47, 0.72) (0.38, 0.86) (0.71, 0.95) (0.17, 0.49) 
~ >10 ppb. 
0.48 0.82 0.91 0.31 
Change in eNO from visit 1 to (0.35, 0.62) (0.57, 0.96) (0.75, 0.98) (0.18, 0.47) 
visit F 0.68 0.65 0.87 0.37 
~>60% 00 
(0.55, 0.80) (0.38, 0.86) (0.74, 0.95) (0.20, 0.56) 0\ 
Sputum eosinophils at visit F >4% 
0.59 0.60 0.84 0.29 
(0.45, 0.72) (0.32, 0.84) (0.69, 0.94) (0.14, 0.48) 
Change in sputum eosinophils 
~>4% 
0.51 0.64 0.84 0.26 
from visit 1 to visit F (0.37, 0.65) (0.35, 0.87) (0.67, 0.95) (0.12, 0.43) 
PD 15 saline at visit F <12 mls. 
0.43 0.82 0.87 0.35 
(0.29, 0.61) (0.57, 0.96) (0.66, 0.97) (0.21' 0.52) 
Change in PD15 saline from visit 1 ~ >1 d.d. 0.41 0.94 0.95 0.36 
to visit F mcrease (0.27' 0.57) (0.70, 1.00) (0.75, 1.00) (0.22, 0.52) 
PD 15 saline = the cumulative dose of hypertonic saline required to induce a 15% fall in FEV 1. % esoinophils = the percentage of 
















The results of the current study indicate that eNO is not only easily measured but 
can provide valuable information regarding the longitudinal control of asthma. In 
particular, both absolute values of eNO as well as changes over time provide 
useful clinical information in predicting and diagnosing poorly controlled asthma. 
Loss of Control 
Approximately 80% of the patients developed loss of control following cessation 
of their maintenance inhaled corticosteroid therapy, the median (95% CI) time to 
loss of control being seventeen (14 to 28) days (fig. 6.1 ). Gibson et al (1992) have 
previously demonstrated that withdrawal of inhaled corticosteroids results in an 
exacerbation of asthma in the majority of patients, which occurs on average 
sixteen days (range 7 to 26 days) following steroid reduction. Likewise, Leuppi et 
al (200 1) found that exacerbations of asthma occurred in 85% of patients 
following a step-wise withdrawal of inhaled corticosteroid, and that a minority of 
patients remained well despite removal of inhaled corticosteroid therapy during a 
two month follow-up. These results confirm the importance of inhaled 
corticosteroid therapy in maintaining asthma control, but also suggest that there 
may be a few asthma patients in whom the need for continued inhaled 
corticosteroid therapy appears unnecessary, at least in the short-term. 
The current study was designed to assess the usefulness of eNO in a clinical 
context. For this reason, loss of control criteria were prospectively based on a 
combination of peak flow and symptom changes as used in clinical practice. 
Evidence that these criteria were relevant and appropriate is provided by the 
significantly greater changes in FEV1, sputum eosinophils and PD15 saline seen in 
the LOC group (table 6.3 and fig. 6.6). However, it should also be noted that even 
in those patients in whom loss of control did not occur there was a significant 
increase in the levels of eNO. In this group there was a mean (95% CI) increase in 













Figure 6.6. Changes in FEV1, airway hyperresponsiveness and sputum 
eosinophils occurring between visits 1 and F in the LOC and no-LOC groups: 
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non-significant increase in sputum eosinophils of 3.3% (95% CI: -1.5 to 8.0%). 
These results suggest that even in the no-LOC group there may have been a small 
increase in airway inflammation that was undetected by the clinical parameters 
used in our diagnosis of loss of control but detected by changes in eNO. Such 
airway inflammation may play a role in the development of long-term irreversible 
damage to the airway via remodelling (Fabbri et al. 1998b). 
Exhaled NO and atopy 
At visit F atopic asthma was associated with eNO levels that were twice that of 
non-atopic asthma, eNO was 24.53ppb (20.3 to 28.77ppb) compared to 12.49ppb 
(3.97 to 21.01ppb) respectively (p=0.009). This is in contrast to the findings of 
Chapter Five where atopic status was not associated with increased levels of eNO. 
This discrepancy is most likely due to differences in inhaled corticosteroid use 
and the degree of airway inflammation. The finding of elevated levels of eNO in 
association with atopy in patients not receiving corticosteroid therapy is consistent 
with previous reports (Martinet al. 1996; Moody et al. 2000) and may reflect two 
different phenotypes of airway inflammation in these subsets of asthma. 
Moreover, it suggests that eNO may be of more clinical value in atopic asthma, in 
whom higher levels of eNO are seen during uncontrolled asthma. However, the 
current study was not designed to differentiate the relative merits of measuring 
eNO in atopic and non-atopic asthma, and because only nine patients were non-
atopic no formal comparison of the usefulness of eNO in this subgroup was 
possible. 
Correlations between inflammatory markers 
The results of our current study confirm earlier findings that eNO levels are 
elevated in unstable asthma (Massaro et al. 1995; Crater et al. 1999), and point to 
eNO being a useful marker of airway inflammation. Previous studies have yielded 
inconsistent data regarding the correlation between eNO and sputum eosinophils 
because of the confounding effect of inhaled steroid use (Mattes et al. 1999; 
Piacentini et al. 1999; Lim et al. 2000). This was not the case in our present study 










therapy had been temporarily withdrawn. Highly significant correlations were 
obtained at Visit F between eNO and the direct markers of airway inflammation, 
namely sputum eosinophils (rank correlation 0.62, p<O.OOOl) and PD1s saline 
(rank correlation -0.41, p<0.0008). However, apart from symptom score (r=0.33, 
p=0.004) the point-in-time correlations at Visit F between eNO and both FEV1 
and the clinical markers of control were non-significant (Table 6.4). More 
importantly, when measured longitudinally, the changes in eNO correlated 
significantly with changes in the direct markers of airway inflammation as well as 
with the changes occurring in FEV1 and the clinical markers (see Table 6.4). 
These findings provide additional support for the use of eNO measurements as a 
tool in the assessment of airway inflammation and long-term asthma control. 
Prognostic and diagnostic utility 
The results of the current study document the usefulness of eNO for predicting 
and diagnosing poorly controlled asthma compared to other currently used 
markers of airway inflammation and clinical parameters. Regardless of the way in 
which eNO measurements were analysed (absolute values, absolute changes, or 
proportional changes from baseline) the results were similar. Exhaled NO was 
associated with a positive predictive value of between 80 and 90% for predicting 
and diagnosing poor asthma control. On the whole, changes in eNO over time had 
higher positive predictive values, sensitivities and specificities both for predicting 
and diagnosing loss of control than did single measurements. For example, an 
increase in eNO between visit 1 and the penultimate visit of more than 60% over 
baseline had a positive predictive value for predicting up-coming loss of control 
of 83% (sensitivity 50%, specificity 65%). A similar increase between visit 1 and 
visit F had a positive predictive value for diagnosing poor asthma control of 87% 
(sensitivity 68%, specificity 65%). In comparison, a single measurement of 
greater than 15ppb obtained at visit 1, when patients were still taking inhaled 
steroids, had a positive predictive value of 88% (sensitivity 25%, specificity 88%) 




Overall, using the cut points selected, these outcomes reflect poor sensitivity but 
good specificity for eNO measurements. Nevertheless, they compare favourably 
with the usefulness of the other, more elaborate techniques of sputum induction 
and hypertonic saline challenge used in this study to assess deteriorating asthma. 
For example, we found that a doubling dose increase in PD1s saline was 
marginally better than the other measurements for diagnosing loss of control, with 
a positive predictive value of 95% (sensitivity 41%, specificity 94%). This 
compared to a positive predictive value of 84% for a 4% change in eosinophils 
(sensitivity 51%, specificity 64%) and with a positive predictive value of91% for 
an increase in eNO of lOppb (sensitivity 48%, specificity 82%). However, 
measuring eNO has the advantage of being quick and easy to perform, making it a 
more suitable test for use in the clinical rather than the research setting. This 
becomes all the more important given the finding that changes in eNO have 
higher sensitivity and specificity for changes in clinical status than do single 
measurements, implying the need for repeated tests. Interestingly, eNO proved to 
be comparable to other more conventional measurements such as FEV1, peak 
flows, symptom score and daily reliever use in predicting up-coming loss of 
control (see Fig. 6.4) despite the fact that many of these parameters were used in 
the definition of loss of control. 
A number of investigators have sought to evaluate the role of eNO in assessing 
long-term asthma control (Kharitonov et al. 1996c; Baraldi et al. 1999; Jatakanon 
et al. 2000; Leuppi et al. 2001 ). In the present study, withdrawal of inhaled 
corticosteroid therapy was performed in an attempt to induce deterioration in 
asthma control and mimic an exacerbation. This implies that the findings of the 
current study may not strictly apply to patients receiving maintenance inhaled 
corticosteroid. However, the usefulness of eNO in the presence of inhaled steroid 
use is supported by Stirling et al (1998) who found higher levels ofeNO in 
patients with greater asthma severity irrespective of steroid use. Further, 
Kharitonov et al (1996c) have demonstrated that a simple reduction in the dose of 
inhaled corticosteroid increases eNO even in the absence of significant change in 











It has been previously reported that eNO is not as reliable as either responsiveness 
to hypertonic saline or sputum eosinophils in predicting up-coming poor asthma 
control (Leuppi et al. 2001 ). In that study Leuppi et al halved the dose of inhaled 
corticosteroid therapy every eight weeks until patients developed an exacerbation 
of asthma or had been off inhaled corticosteroid therapy for at least two months. 
Measurements of eNO, FEV r, hypertonic saline challenge and sputum eosinophils 
were made on a monthly basis. Exhaled NO was reported to have no predictive 
value at any of the time points in predicting poor asthma control. Part of the 
reason for this negative finding may have been due to technical factors involving 
the measurement of eNO. Measurements were performed on samples of mixed 
expiratory air collected in a polyethylene bag following inhalation of ambient air, 
therefore making these measurements affected by ambient NO. Also the authors 
found no significant increase in eNO during asthma exacerbations which is in 
contrast with both our present study and previous studies which have found raised 
eNO levels during exacerbations (Crater et al. 1999; Jatakanon et al. 2000). This 
finding highlights the limitations in comparing results involving eNO when 
different measurement techniques are used (Silkoff and Zamel 1998; ATS 1999). 
Using a similar study design to our own, but with incomplete withdrawal of 
inhaled corticosteroid, Jatakanon et al (2000) reduced the dose of inhaled 
budesonide to 200~-tg/day (less than one quarter of the patients usual maintenance 
dose) in fifteen asthmatics. Patients were followed for a maximum of eight weeks. 
Just under half developed an exacerbation. There was a parallel increase in eNO 
and sputum eosinophils, which correlated over time with changes in FEV 1 and P-
agonist use. The authors suggested that changes in sputum eosinophil numbers 
were superior to eNO in predicting loss of asthma control. However, owing to the 
small study numbers a quantitative assessment of the predictive values of the 
changes in eNO and sputum eosinophils was not possible. 
In another longitudinal study, Baraldi et al (1999) measured eNO in asthmatic 





the pollen season consistent with the presumed increase in airway inflammation 
that occurred with allergen exposure, although no measurements of sputum 
eosinophils were made to confirm the presence of this inflammation. This rise in 
eNO occurred despite the fact that over one third of the children were taking 
inhaled steroids, and it occurred in the absence of any changes in FEV1. The 
authors concluded that eNO may be useful in the longitudinal assessment of 
asthma. 
During our current study measurements of eNO were made online using single 
exhalations at an exhalation flow rate of 250mls/sec. This flow rate is 
significantly more than current guidelines suggest (ATS 1999), however the study 
was commenced before these guidelines were published. Exhaled NO has been 
shown to be flow dependent (Silkoff et al. 1997), and at lower flow rates the 
differences between healthy and asthmatic individuals are increased (Pedroletti et 
al. 2000). Thus it is possible that at a lower expiratory flow rate (e.g. 50mls/sec) 
differences between patients who did and did not experience 'loss of control' 
might have been greater. If this were the case, then the sensitivities, specificities 
and predictive values of eNO as a diagnostic test may be better than what is 
reported in the current study. 
Summary 
Following cessation of corticosteroid therapy an exacerbation occurred in the 
majority of asthma patients. Deterioration of asthma control was associated with 
significant worsening of lung function, increase in sputum eosinophils and 
increase airway hyperresponsiveness. Steroid cessation also lead to a significant 
increase in the levels of eNO. This increase in eNO occurred to a greater degree in 
patients who developed clinical 'loss of control' and in those with atopic asthma. 
Serial measurements of eNO proved useful in both the diagnosis of 'loss of 
control' and the prediction of up-coming 'loss of control' when used both as a 
point-in-time and as a change-over-time measurement. The data indicate that an 




60% over baseline, are useful thresholds for the detection of ongoing airway 
inflammation, and they also positively predict the occurrence of breakthrough 
symptoms (positive predictive values of 80-90%). However, although specific for 
poorly controlled asthma, eNO often lacked good sensitivity and thus the absence 
of these changes does not preclude the possibility of deteriorating asthma. It is 
possible that this may have been improved by the use of lower exhalation flow 
rates, however further investigations will need to be done to confirm this. Also 
further long-term studies are required to confirm that the clinical application of 
serial eNO measurements is worthwhile in optimising asthma management. In 
particular, the usefulness of eNO in detecting airway inflammation in the presence 
of inhaled corticosteroid therapy has not been fully investigated; this is the subject 









ASSESSING THE ANTI-INFLAMMATORY EFFECTS OF 
INHALED CORTICOSTEROIDS. 
7.1. 
Dose-response relationships for exhaled nitric oxide, sputum 
eosinophils, hypertonic saline challenge and lung function. 
Abstract 
Background: Dose-response relationships for the anti-inflammatory effects of 
inhaled corticosteroid have not been extensively investigated. This study was 
undertaken to evaluate the usefulness of serial measurements of exhaled nitric 
oxide ( eNO) for this, and to compare eNO with other markers of airway 
inflammation. 
Methods: Following deterioration in asthma control, 65 patients entered a double-
blind, parallel-group, placebo-controlled trial of 50, 100, 200, or 500~-tg/day 
beclomethasone for eight weeks. Exhaled NO and spirometry were performed 
weekly and a hypertonic saline challenge with sputum induction was performed at 
the beginning and end of treatment. 
Results: Linear relationships between the dose of inhaled corticosteroid and 
changes in eNO and FEV1 existed at one-week (p=0.022 and p=0.043, 
respectively) and at end of treatment (p=O.Ol5 and p=0.006, respectively). A 
linear dose-response relationship was also seen for sputum eosinophils (p=0.037). 
Changes in eNO were able to differentiate between treatment groups to a greater 
degree than FEV1 or eosinophils. Changes in eNO correlated significantly with 
changes in sputum eosinophils (r=0.403; p=0.002). Changes in PD15 did not differ 
across the treatment groups nor correlate with changes in other measurements. 
Conclusions: Over the range 0-500~-tg/day beclomethasone there was a linear 
dose-response relationship for its anti-inflammatory effects. Exhaled NO provides 
useful information regarding this relationship and corresponds significantly to the 










Inhaled corticosteroids are the most effective treatment for airway inflammation 
in asthma (Barnes 1998b; Barnes et al. 1998). Their use results in improvement in 
symptoms and lung function, as well as reductions in inflammatory cells in 
bronchial biopsies (Djukanovic et al. 1992) and induced sputum (Jatakanon et al. 
1998a; van Rensen et al. 1999). As a result airway hyperresponsiveness is also 
reduced (Rodwell et al. 1992b; duToit et al. 1997; van Grunsven et al. 1999). 
Current guidelines recommend the use of inhaled corticosteroid therapy in all but 
the mildest asthma (NHLBI/WHO 1995; BTS 1997b). The guidelines are based 
on the assumption that treating airway inflammation leads to improvement in 
asthma control. However, several studies have demonstrated incongruities in the 
relationship between both symptoms and lung function and airway inflammation 
(Sont et al. 1996; Haley and Drazen 1998; Jatakanon et al. 1998a). Evidence for 
ongoing airway inflammation has been found in asthmatic patients during clinical 
remission (Foresi et al. 1990; Boulet et al. 1994; Sont et al. 1996; van der Thoorn 
et al. 2000). Conversely ongoing symptoms may occur despite the fact that airway 
inflammation is adequately controlled (Sont et al. 1996). This raises questions as 
to whether the primary goal when using inhaled corticosteroid is to achieve 
symptom control, optimise lung function, minimise airway inflammation or 
reduce airway hyperresponsiveness. 
Dose-response relationships for inhaled corticosteroid have been described in the 
past using symptoms and lung function as the main outcome variables. Although a 
dose-response relationship exists for these endpoints, it may plateau at a relatively 
low dose (Lipworth 1996; Pederson and O'Byrne 1997; Barnes 1998b; Barnes et 
al. 1998). Thus, there may be difficulty in differentiating between the effects of 
adjacent doses. Other studies have shown that dose-response relationships vary 
when other end-points are used (Toogood et al. 1977). For example, much higher 
doses of inhaled corticosteroid are required to control airway hyperresponsiveness 










clarify these relationships for airway inflammation. Such information might be 
clinically helpful in assessing the relative efficacy of different inhaled 
corticosteroid doses and as a guide to optimising long-term therapy. 
Exhaled nitric oxide (eNO) is a repeatable easily measured marker of airway 
inflammation (Kharitonov et al. 1997a; Silkoff and Zamel 1998; ATS 1999). High 
levels are seen in both steroid-naive asthma (Alving et al. 1993) and during acute 
exacerbations (Crater et al. 1999). Furthermore, levels decrease following 
treatment with both inhaled (Kharitonov et al. 1996b; Jatakanon et al. 1998a; Lim 
et al. 1999; van Rensen et al. 1999) and oral steroids (Massaro et al. 1995). These 
results suggest that eNO may be a useful end-point in measuring the dose-
response relationship for the effect of inhaled corticosteroid therapy on airway 
inflammation. 
In this study, we aimed to evaluate the usefulness of serial eNO measurements in 
measuring the anti-inflammatory effects of inhaled beclomethasone, and to make 
comparisons with other end-points including lung function, sputum eosinophils 
and airway hyperresponsiveness to hypertonic saline. 
7.3. Methods 
Subjects 
Patients with mild to moderate asthma (ATS 1987) and who had been taking 
inhaled corticosteroid therapy for at least six months were recruited. 
Inclusion and exclusion criteria were the same as those given in Chapter Five. 
Study Design 
Inhaled corticosteroid therapy was discontinued after a run-in period of2-4 weeks 
during which inhaled corticosteroid dose was held constant. Thereafter patients 
were reviewed weekly until 'loss of control' developed OR for a maximum of six 

















from baseline in peak flow rates and symptoms (see Chapter Six) (Jones et al. 
2001 ). Those who did not develop loss of control were withdrawn from further 
participation. 
Following loss of control, patients received 20mg prednisone orally for two days 
in order to alleviate their deteriorating symptoms. This strategy was necessary for 
reasons of safety, although this may theoretically have influenced interpretation of 
subsequent inhaled corticosteroid effects, especially at one week. Simultaneously, 
at loss of control, patients were randomised to receive double-blind inhaled 
corticosteroid treatment for eight weeks, taking one puff daily from each of two 
identical metered dose inhalers (CFC delivery system) (Autohaler, 3M 
Pharmaceuticals) labelled "morning" and "evening". The treatments were: 
• Placebo ( 1 puff of placebo twice daily) 
• 50~-tgl day ( 1 puff of 50~-tg beclomethasone and 1 puff of placebo daily) 
• 100~-tg/day (1 puff of 100~-tg beclomethasone and one puff of placebo daily) 
• 200~-tg/day (1 puff of 100~-tg beclomethasone twice daily) 
• 500~-tg/day (1 puff of250~-tg beclomethasone twice daily). 
Following randomisation (visit 1), patients were reviewed weekly for the first four 
weeks (visits 2-5) and then at the end .of eight weeks treatment (visit 6). Those 
patients who experienced significant worsening of their asthma while taking the 
randomisation medication were withdrawn from that treatment group, given 20mg 
prednisone orally for a further two days, and entered into an open label treatment 
arm of 1000~-tg/day (2 puffs of250~-tg beclomethasone twice daily). These patients 
were also reviewed weekly for four weeks and again at the end of eight weeks 
treatment with 1000~-tg/day . 
Study procedures 
Diurnal peak expiratory flow measurements, bronchodilator use, and symptom 
scores were recorded in a daily record card. Measurements obtained at each study 
visit are shown in Table 7.1. Exhaled NO was measured prior to all other study 











measurement of single exhalations according to a standard protocol (Kharitonov 
et al. 1997a; ATS 1999), with the exception of flow rate (250 mls/sec) (the study 
was commenced prior to the publication of internationally agreed guidelines). 
Exhaled NO levels were read at the plateau corresponding to 70-80% of the C02 
curve. For a full description of study procedures refer to Chapter Four. 
Table 7.1. Study design and measurements obtained at each of the study 
visits. 
Visit number vo V1 V2 V3 V4 V5 V6 
Week 0 1 2 3 4 8 
~
eNO X X X X X X X 
Spirometry X X X X X X X 
Sputum X X X 
PD1s saline X X X 
i • • 
Withdrawal I LOC/Randomisation I I End of ofiCS treatment 
V = visit, ICS =inhaled corticosteroid, LOC= loss of control, PD1s saline= 
provocative dose of hypertonic saline required to induce a 15% fall in FEV1. 








Ethical considerations and safety 
Each patient's asthma control was monitored closely throughout the study. For 
ethical reasons, loss of control criteria included symptoms that were "disagreeable 
or distressing" irrespective of changes in peak expiratory flow rate. All patients 
were provided with an individualised self-management plan, an emergency card, 
and a supply of prednisone tablets. Patients had 24-hour access to one of the study 
investigators via the hospital paging system. Ethical approval was obtained from 
the Otago Ethics Committee and written informed consent was obtained from all 
study participants. 
Statistics 
Pearson correlations were calculated to assess the relationships between variables 
at randomisation and the end of the study. All data was analysed on an intention-
to-treat basis. Differences between groups were analysed by analysis of 
covariance (ANCOVA), using group and entry into the open 1000~-tg/day 
treatment subgroup as factors, and with baseline values as covariates. PD1s saline 
values were analysed as doubling dose change from baseline. Polynomial 
contrasts were fitted across the randomisation groups to look at the dose-response 
relationship. Estimated marginal means were calculated and compared, with 
Bonferroni adjustments for multiple comparisons. Post-hoc analyses were also 
performed excluding treatment withdrawals from the data. In all of the figures 













Eighty-seven patients entered the study. Three patients withdrew consent prior to 
inhaled corticosteroid withdrawal. Sixty-five patients (77%) developed loss of 
control and were randomised into one of the five treatment groups. Demographic 
data are given in Table 7.2. Data for study end-points measured at baseline before 
withdrawal of inhaled corticosteroid, visit 0, and at randomisation following 'loss 
of control', visit 1, are shown in Table 7.3. The only measurement demonstrating 
a statistically significant difference across the groups was sputum eosinophils at 
visit I (p = 0.029), where the 100!-tg/day group had a mean of 31.9% whereas the 
placebo group had only 6% eosinophils. However baseline levels in all the 
variables at randomisation were included as covariates in the further analyses 
therefore correcting for any differences between the groups. 
102 
-, 
~~ Table 7.2. Demographic data (at entry to the run-in phase) for the randomised 
study participants. 
Total Placebo 50~-tg/day 1 00~-tg/day 200~-tg/day 500~-tg/day 
,.-
Number of 
65 13 14 14 12 12 
patients (n) 
Male: 
22:43 4:9 6:8 7:7 2:10 3:9 
Female 
Age, yrs 42.4 42.5 43.3 44.7 ·41.2 39.6 
(range) (19-64) (19-61) (19-63) (21-59) (24-60) (19-64) 
Duration of 
27.0 30.3 30.6 22.5 31.2 20.2 
asthma, yrs ( 4-60) (4-60) (6-60) (4-48) (12-55) (4-40) 
i'r (range) 
Skin test 









:Non- 9:56 2:11 1:13 2:12 1:11 3:9 
smokers 
ICS dose, 658 731 550 700 671 642 
~-tg/day (100- (100- (200- (200- (200- (200-
(range) 1600) 1600) 1000) 1600) 1000) 1000) 
2.81 2.50 2.91 2.94 2.62 3.04 
FEV 1, litres (2.61, (2.07, (2.39, (2.42, (2.15, (2.60, 
3.00) 2.94) 3.45) 3.45) 3.09) 3.48) 
FEVI,% 
90.8 85.4 87.5 91.4 89.0 100.2 
(86.3, (72.1, (76.2, (81.4, (76.1, (92.2, 
predicted 
95.2) 98.8) 98.8) 101.5) 101.9) ' 108.2) 
FEV1/FVC, 
70.8 68.3 70.6 69.1 69.7 76.9 
(68.1, (59.5, (64.4, (62.2, (63.2, (72.2, 
% 
73.6) 77.1) 76.7) 76.02 76.3) 81.5) 
·c 
Unless stated results are expressed as mean (95% CI). 
ICS =inhaled corticosteroid, expressed as beclomethasone equivalent dose. 
FEV1 =forced expiratory volume in one second. 
" 
FVC =forced vital capacity. 
-;; 7 o-
Table 7.3. Comparison of randomisation groups at withdrawal of maintenance inhaled corticosteroid (VO) and at loss of 
control/randomisation (Vl). Comparisons are also made between those who completed treatment with randomised medication and those 
who withdrew from the randomised treatment group and subsequently received 1 ooo, .. t"g/day beclomethasone. 




















































































































Results are expressed as mean (95% CI). FEV1 =forced expiratory volume in one second. PD15 saline= provocative dose of hypertonic 










One patient randomised to receive 500f.!g/day was withdrawn at visit 1 due to the severity 
of their asthma, and was not considered further in the analysis. Twenty-five of the 
remaining 64 patients developed worsening of their asthma while receiving the 
randomised study medication, and were entered into the open-label arm of the study in 
which they were treated with IOOOf.!g ofbeclomethasone/day. The number(%) of patients 
withdrawn from the placebo, 50f.!g/day, lOOf.!g/day, 200f.!g/day, and 500f.!g/day groups 
was 6 (46%), 5 (38%), 8 (57%), 4 (31 %), and 2 (18%) respectively. There was no 
statistically significant difference in the rate of treatment withdrawals between these 
doses. Comparisons between those who withdrew from the randomised treatment arm 
and those who completed treatment are shown in Table 7.3. There were no significant 
differences between those who completed treatment and those who withdrew for eNO, 
sputum eosinophils or PD 15 saline at the time of randomisation. However, those who 
withdrew had reduced lung function at randomisation, as demonstrated by a FEV 1 % 
predicted of73.89% compared to 82.48% in those who remained on the randomised 
medications (p=0.005). Patients withdrawing also had a significantly higher dose of 
maintenance inhaled corticosteroid therapy at entry into the study. Those who withdrew 
had a mean (95% C. I.) of776 (635 to 917)f.!g ofBDP/day compared to 614 (536 to 
694)!-!g ofBDP/day in those who remained on randomised medication (2-tailed t-test 
p=0.042). 
Dose-Responses 
Changes from baseline in eNO and FEV 1 following one week and at the end of treatment 
are shown in Figures 7.1 and 7.2 respectively. Likewise changes in sputum eosinophils 
and PD15 saline from baseline to the end of treatment are shown in Figures 7.3 and 7.4 
respectively. Data shown are derived from all patients, but adjusted for baseline 
measurements and treatment withdrawals. 
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Figure 7 .1. Percentage change in eNO with increasing doses of inhaled 
beclomethasone. Mean changes after one week and at the end of the eight weeks 
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There was a significant difference in the change in eNO across treatment groups at one 
week (p=0.005) and at the end of treatment (p=0.015). The difference across the groups 













Figure 7.2. Percent change in FEV1 with increasing doses of inhaled beclomethasone. 
Mean changes occurring after one week and at the end of treatment are shown (error bars 
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There was a significant difference in the change in FEV 1 across treatment groups at one 
week (p=0.014) and at the end of treatment (p=0.036). The difference across the groups 
was linear at both one week and at the end of treatment (p=0.043 and p=0.006, 
respectively). 












Figure 7.3. Percentage change in sputum eosinophils at the end of treatment with 
increasing doses of inhaled beclomethasone. Mean changes occurring following eight 
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Figure 7.4. Mean doubling dose changes in PD1s saline at the end of treatment 
occurring with increasing doses of inhaled beclomethasone. Results shown are taken 
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Pair-wise comparisons of the changes in eNO, FEV1, sputum eosinophils and PD15 saline 
occurring with each of the treatment groups were also made. These are shown for values 
obtained following one week and at the end of treatment for both eNO and FEV1 are 
shown in Figures 7.5 and 7.6 respectively. Likewise results at the end of treatment for 
both sputum eosinophils and PD1s saline are shown in Figure 7. 7. In addition these 
graphs contain an insert showing the changes seen in the subset of patients receiving the 
open-label 1000!-tg/day treatment arm are also shown in the figures. These patients were 
included in the analysis ofthe randomisation groups (on an intention-to-treat basis), but 
on the graph are in addition shown as a separate group. The 1000~--tg/day subset have not 
been formally analysed due to selection bias: patients in this group were those who had 















Figure 7.5. Pair-wise comparisons of the percentage change in eNO after one week 
and at the end of the eight weeks treatment with inhaled beclomethasone. Mean ± 95% CI · 
is shown. 
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There were significant differences found between 100f.lg/day and both 200 and 
500f.lg/day at one week (*; p<0.05), and between 500f.lg/day and both placebo and 
lOOf.lg/day at the end of treatment (t; p=O.Ol and p=0.023 respectively). Data shown are 








Figure 7.6. Pair-wise comparisons of the percent change in FEV1 after one week and 
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There were only significant differences found between 100!-lg/day and placebo at one 
week(*; p=0.005) and 500!-lg/day and placebo at the end of treatment (t; p=0.040). Data 









A. Pair-wise comparisons of the percentage change in sputum eosinophils at the end 
of treatment. There was only a significant difference found between 500~-tg/day 
and 100~-tg/day (*; p=0.049). Mean± 95% CI is shown. 
B. Pair-wise comparisons of the doubling dose changes in PD15 saline at the end of 
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When those entering the 1000~-tg/day arm were excluded from the analysis the linear 
relationship seen across the groups for changes in eNO at the end of treatment was still 
seen (p=0.003). In those who remained on randomised medication until study completion 
the mean (±95% C.I.) change in eNO at the end of treatment with placebo, 50, 100, 200, 
and 500~-tg/day was 7.0 (-1.6, 15.63), -1.0 (-9.1, 7.1), -2.3 (-11.6, 7.0), -9.6 (-17.4, -1.77), 
and -8.6 (-16.4, -0.8), respectively. These patients was also demonstrated a significant 
difference in change in sputum eosinophils across the treatment groups (p=0.033), 
however this relationship was no longer linear (p=O. 75). Similar analyses using changes 
in FEV 1 and PD1s saline found no difference across treatments (p=0.327 and p=0.202, 
respectively). 
Correlations between inflammatory markers 
Correlations between eNO, sputum eosinophils, PD 15 saline and FEV1 % predicted at 
baseline and following treatment (expressed as absolute values and as changes from 
baseline) are shown in Table 7.4. Significant correlations were found between eNO and 
sputum eosinophils throughout the study. Changes in eNO correlated significantly with 
changes in sputum eosinophils. Changes in PD1s saline did not correlate with changes in 







Table 7.4. Correlations between markers of airway inflammation and lung function at 
randomisation (visit 1) and following treatment (visit 6). 
Correlation Visit 1 Visit 6 fj. Visit ( 6-1) 
eNO (ppb) and % r = 0.519 r= 0.548 r = 0.403 
eosinophils p < 0.001 p < 0.001 p = 0.002 
eNO (ppb) andPD1s r= -0.352 r = -0.270 r = -0.192 
saline (ml) p = 0.003 p = 0.051 p = 0.187 
eNO (ppb) and FEV 1 % r=-0.169 r = 0.021 r =-0.252 
predicted p = 0.125 p= 0.870 p = 0.045 
% eosinophils and PD1s r = -0.254 r = -0.185 r = 0.045 
saline (ml) p = 0.040 p = 0.204 p = 0.771 
% eosinophils and FEV 1 r = -0.262 r = 0.015 r = -0.585 
%predicted p = 0.023 p = 0.913 p < 0.001 
PD1s saline (ml) and r = 0.420 r= 0.533 r= -0.092 
FEV 1 % predicted p < 0.001 p < 0.001 p = 0.529 
Figures in bold represent statistically significant results. 
A Visit (6-1) =the change in the variables between visit 1 and 6. 
FEV 1 = the forced expiratory volume in one second and is expressed as a percentage of 
the predicted FEV1. PD15 saline= the provocative dose of hypertonic saline required to 
induce a 15% fall in FEV 1. % eosinophils = the percentage of eosinophils in induced 













7 .5. Discussion 
Dose-response relationships for eNO 
This study demonstrates that eNO measurements provide useful information regarding 
the dose-response relationship for the anti-inflammatory effects of inhaled 
corticosteroids. This has potential practical importance for the monitoring of anti-
inflammatory treatment in individual patients, as well as assessing the efficacy of 
different inhaled corticosteroids at different doses. 
There was a significant linear relationship between the change in eNO and the dose of 
inhaled corticosteroid used (over a range 0-500~-tg/day of beclomethasone) in patients 
with moderate bronchial asthma in whom inhaled corticosteroid had been withdrawn and 
"loss of control" occurred. This ensured that airway inflammation was sufficiently 
present for anti-inflammatory effects to be measured. The linear dose-response 
relationship was evident as early as one week after commencing therapy, and continued 
to eight weeks, indicating that eNO measurements respond rapidly to changes in airway 
inflammation and reflect the anti-inflammatory actions of inhaled corticosteroid therapy 
with time. Similar linear dose-response relationships were seen with FEV 1 at one and 
eight weeks and with sputum eosinophils at the end of eight weeks. Silkoff et al (200 1) 
has also recently demonstrated that in patients with elevated levels of eNO at baseline 
there is a strong relationship between inhaled corticosteroid dose and changes in eNO 
over the dose range 0-1600~-tg beclomethasone/day. However, further to the results of that 
investigation, the highly significant correlation between changes in eNO and changes in 
sputum eosinophils in the present study confirms that decreases in eNO correspond to 
reductions in airway inflammation. 
It has previously been shown that changes in eNO are seen in association with changes in 
other markers of airway inflammation following treatment with inhaled beclomethasone 
(Ichinose et al. 2000), budesonide (Lim et al. 1999) and fluticasone (van Rensen et al. 
1999). Furthermore, eNO appears to decrease in a dose-dependent manner following low 












It has been reported that the effect of inhaled corticosteroid therapy on eNO may plateau 
at a dose of 400~-tg/day (Jatakanon et al. 1999; Wilson and Lipworth 2000), with no 
f\lrther decreases in eNO seen using larger doses despite further reductions in other 
markers. Wilson and Lipworth (2000) studied twenty-six asthma patients before and after 
three weeks treatment with 400, 800 and 1600~-tg/day of budesonide. These treatment 
doses were given successively to all patients with no washout period between treatments. 
Changes occurring in eNO were then compared to changes found in airway 
hyperresponsiveness, serum levels of eosinophil cationic protein and lung function 
following the treatments. They found that above 400~-tg/day (the first step in their dose-
ranging study), no further reduction in eNO occurred despite further dose-related 
improvements in airway hyperresponsiveness to adenosine-5-monophosphate and serum 
eosinophil cationic protein. These authors concluded that the decrease in airway 
hyperresponsiveness seen with the higher doses demonstrated further reductions in 
airway inflammation undetected by eNO. However, this conclusion firstly assumes that 
airway hyperresponsiveness directly relates to airway inflammation, a point currently 
being debated (Brusasco et al. 1998; Haley and Drazen 1998). Secondly, it assumes that 
the reductions in airway hyperresponsiveness seen with the larger doses were not due to 
carry-over time-dependent effects. Airway hyperresponsiveness is known to decrease 
over a period of months in response to inhaled corticosteroid therapy (Kraan et al. 1988; 
Vathenen et al. 1991; van Essen-Zandvliet et al. 1992; Hofstra et al. 2000). During the 
Wilson and Lipworth study treatment regimens were given successively without a wash-
out period, therefore the results may potentially have been complicated by these time-
dependent changes. Recent data suggest that these time-dependent decreases may not be 
so noticeable using indirect bronchial challenges for assessing airway 
hyperresponsiveness (such as adenosine-5-monophosphate, hypertonic saline, and 
exercise) (Hofstra et al. 2000), however, the potential confounding influence of time in 
the Wilson and Lipworth study still exists. 
Importantly in the Wilson and Lipworth study maximal suppression of airway 









increased systemic effects as demonstrated by adrenal suppression. Thus illustrating the 
need to balance beneficial and adverse effects of inhaled corticosteroid in the clinical 
setting (Kamada et al. 1996; Lipworth and Wiilson 1998; O'Byme and Pederson 1998). 
A plateau in eNO has also been found in a smaller study by Jatakanon et al (1999). They 
assessed the effects of placebo, 100, 400 and 1600!-tg ofbeclomethasone/day on eNO, 
lung function, sputum eosinophils, and airway hyperresponsiveness to methacholine in 
patients with mild asthma. These authors reported a plateau in the eNO response at 
400!-tg/day, despite finding continuing reductions in sputum eosinophils with the higher 
dose (1600f.lg/day). However, this study is also limited by its methodology. It consisted 
of combining two studies together, one investigating placebo, 100 and 400!-tg/day, while 
the other investigated placebo and 1600!-tg/day, thus making a direct comparison between 
the treatments difficult. Notably, during the second study no significant difference was 
found in the change in eNO when comparing the effects of placebo and 1600!-tg/day. This 
is a reflection of the small number of patients involved (n=10) and the mild degree of 
asthma in the patients investigated. 
By contrast, in our current study the dose-response relationship between eNO and inhaled 
corticosteroid was linear and there was no evidence of a plateau throughout the range of 
doses studied (0-500!-tg/day). The current study was designed specifically to explore the 
dose-response relationship at relatively low doses of inhaled corticosteroid, and although 
the relationship was linear across the doses studied no extrapolation of these results to 
higher doses is possible. The contrast between our results and those of Jatakanon et al 
( 1999) may be due to differences in the degree of asthma inflammation at the time of the 
investigation. In our study treatment was withdrawn until "loss of control" occurred and 
those who did not exhibit loss of control were excluded. A similar study design has been 
used by other investigators when evaluating the dose-response for inhaled corticosteroid 
(Welch et al. 1997; Busse et al. 1999). The rationale for this approach is that the 
therapeutic effect of inhaled corticosteroid may be influenced by asthma severity: 
patients with milder asthma having little room for improvement. As a result, the degree of 










greater than that of the Jatakanon et al study. Our patients had a mean sputum eosinophil 
differential of 17% compared to 4% in the Jatakanon et al study. This therefore would 
have allowed for a greater improvement following inhaled corticosteroid treatment in our 
current study. 
Recently, Silk off et al (200 1) have demonstrated that eNO follows a dose-response 
relationship with higher doses of inhaled corticosteroid therapy in patients in whom 
baseline eNO is greatly elevated. In that study serial eNO levels were recorded from 
fifteen previously steroid-naive asthma patients after successive weekly treatments with 
placebo, 200, 800, and 1600~-tg beclomethasone/day. They found that eNO levels fell 
progressively over this dose range from 103.5 (95% CI: 78.5, 136.7)ppb with placebo to 
37.4 (95% CI: 29.1, 48.0)ppb following 1600~-tg/day (p=0.001). Furthermore, following 
dicotimization of the patients into two groups based on baseline eNO (into either mildly 
or greatly elevated eNO) these authors were able to show that those with higher baseline 
eNO had a significantly greater dose-response with increasing doses. In comparison, the 
dose-response relationship seen in those with mildly elevated eNO appeared to plateau 
following administration of 200~-tg/day. This again highlights that patients with higher 
levels of baseline inflammation will demonstrate dose-response relationships over a 
greater range of inhaled corticosteroid doses, whereas those with less inflammation will 
demonstrate a plateau in effect following low doses of corticosteroid therapy. 
Dose-response relationships- airway hyperresponsiveness 
The role of airway hyperresponsiveness as a measure of airway inflammation is still 
difficult to define. Non-specific airway responsiveness appears to reflect airway 
inflammation even in the absence of ongoing symptoms and abnormal lung function 
(Sont et al. 1996). This would suggest that changes in airway hyperresponsiveness might 
provide a useful measure by which the anti-inflammatory effects of inhaled corticosteroid 
could be evaluated. However, in our current study there were no significant changes in 
airway hyperresponsiveness to hypertonic saline following treatment with 
beclomethasone. This may be the result of the low doses of inhaled corticosteroid used 















although a change in airway hyperresponsiveness to hypertonic saline challenge should 
be visible within this time frame (duToit et al. 1997). 
Other authors have reported contrasting results using alternative methodologies for 
assessing airway hyperresponsiveness (Kraan et al. 1988; Dahl et al. 1993; Jatakanon et 
al. 1999; Taylor et al. 1999; Hofstra et al. 2000; Wilson and Lipworth 2000). Jatakanon et 
al (1999) found no improvement in airway hyperresponsiveness to methacholine 
following four weeks of treatment with 100 or 400~g budesonide/day despite significant 
improvements in sputum eosinophils. However, the same authors found a marked 
decrease in methacholine induced airway responsiveness following treatment with 
1600!-!g/day, despite only mild further reductions in sputum eosinophils. This illustrates 
the inconsistencies in the relationship between eosinophils and airway 
hyperresponsiveness. Part of the reason for this apparent discrepancy may lie in the 
different time effects of these two measurements. Previously it has been shown that 
changes in airway hyperresponsiveness to methacholine and histamine are time-
dependent, decreasing progressively over a period of at least eight weeks (Kraan et al. 
1988; Vathenen et al. 1991; Hofstra et al. 2000) with some suggestion that it may take 
many months for full effect (van Essen-Zandvliet et al. 1992). In contrast, eosinophil 
numbers have been shown to decrease rapidly following corticosteroid treatment, with 
decreases noted withi~ three hours of inhaled steroid administration (Oh et al. 1999). 
Airway hyperresponsiveness to methacholine and histamine generally appears to be less 
sensitive than indirect bronchial challenges in detecting changes occurring with 
corticosteroid treatment (O'Connor et al. 1992; Hofstra et al. 2000; ~ilson and Lipworth 
2000). By measuring airway hyperresponsiveness using adenosine-5-monophosphate 
Taylor et al (1999) have reported that this measurement is more sensitive than either 
sputum eosinophils or concentrations of the eosinophil degradation product, eosinophil 
cationic protein, in detecting changes in airway inflammation. This conclusion was based 
on the finding of a dose-dependent reduction in adenosine-5-monophosphate airway 
hyperresponsiveness following 100, 400, and 1600~g/day of circlesonide, whereas 












was seen with the higher dosing. In contrast to the author's conclusion, it could be argued 
that sputum eosinophils are more sensitive to the effects of inhaled corticosteroid than 
adenosine-5-monophosphate, and that at doses above 400~--tg/day there is little further 
effect on airway inflammation. If this was the case, then use of airway 
hyperresponsiveness to guide inhaled corticosteroid dose titration may lead to many 
patients being over treated, with the increased risk of systemic side effects (Wilson and 
Lipworth 2000). 
Dose-response relationships- lung function 
In the present study we also found that there was a dose-response relationship for changes 
in FEV 1 following treatment. As for eNO, this relationship was seen as early as one week 
into treatment. Previous studies have been conflicting in their findings of a dose-response 
relationship in lung function. Some have demonstrated a lack of dose-response, although 
these studies were often performed in mild asthma and thus patients were tested at the 
plateau of the dose-response relationship (Kamada et al. 1996; Lipworth 1996; Pederson 
and O'Byme 1997). By contrast, in other studies in which patients were treated following 
induced deterioration of their asthma, similar outcomes to our study have been observed 
(Dahletal.1993; Welchetal.1997;Busseetal.1999). 
The finding of a dose-response relationship for FEV 1 raises the question of whether eNO 
provides any further information than serial lung function in assessing the response to 
inhaled corticosteroid? Ultimately this question will only be answered in large 
longitudinal studies incorporating these measurements into clinical practice and 
comparing long-term outcomes. However, a suggestion that eNO provides different data 
to that of lung function is given in the close relationship seen between eNO and sputum 
eosinophils throughout the study, a relati~nship which was considerably weaker with 
both lung function and airway hyperresponsiveness. 
Correlations between eNO and eosinophils I airway responsiveness 
In our study changes in FEV 1 (% predicted) correlated well with changes in sputum 















FEV 1 (% predicted) could not be used directly as a marker of airway inflalnmation as it 
only weakly correlated with sputum eosinophils prior to treatment (r= -0.262, p=0.023) 
and there was no relationship with eosinophils following treatment (r=0.015, p=0.913). In 
contrast, highly significant correlations were found between eNO and sputum eosinophils 
at baseline (r=0.52, p<0.001), at the end of eight weeks treatment (r=0.55, p<0.001), and 
as changes in these parameters with treatment (r=0.40, p=0.002). These findings further 
validate the use of eNO as a means of measuring ongoing airway inflammation in 
asthma. 
The relationship between eNO and airway inflammation has been previously reported as 
being less reliable during the use of inhaled corticosteroid therapy (Berlyne et al. 2000; 
Lim et al. 2000). However, in contrast to our present study, these studies have been cross-
sectional rather than longitudinal and the study patients ,had lower levels of airway 
inflammation. The only previous longitudinal study to report on the correlation between 
changes in eNO and eosinophils with inhaled steroid therapy had found no correlation 
between the two (Pearson's correlation, r<0.56, p>0.15) (van Rensen et al. 1999). 
However, again, this study is limited by both small numbers ( n= 10 in the steroid treated 
group) and the mildness of asthma treated (mean eosinophil differential of 2.85%, 
compared with 17% in our current study), thus limiting the range over which changes in 
inflammation can be measured. Little et al (2000) have shown that an elevated level of 
eNO (> 1 Oppb) in patients treated with inhaled steroids has a positive predictive value of 
83% in distinguishing those patients in whom an improvement in lung function will occur 
following oral prednisone. This gives indirect evidence that eNO levels reflect reversible 
airway inflammation despite the concomitant use of inhaled corticosteroid therapy and is 
consistent with our findings. 
In our current study the relationship between eNO and PD1s saline was less well defined. 
When assessed as point-in-time measurements before treatment there was a weak but 
highly significant correlation between them (r= -0.352, p=0.003). Following inhaled 
steroid treatment this correlation was even weaker (r= -0.270, p=0.051). Previous reports 












hyperresponsiveness found in corticosteroid-naive asthma (Dupont et al. 1998~ Jatakanon 
et al. 1998~ Verleden et al. 1999~ van der Thoorn et al. 2000) and an absence of a 
correlation following inhaled corticosteroid therapy (Verleden et al. 1999~ Ichinose et al. 
2000). 
The absence of a relationship between eNO and airway hyperresponsiveness following 
inhaled corticosteroid therapy is further highlighted in the present study by our failure to 
find any relationship between changes in these measurements following inhaled steroid 
use. This apparent discrepancy may be partly explained by differing response times for 
eNO and airway hyperresponsiveness to inhaled corticosteroid therapy. Importantly, 
changes in PD1s saline did not correlate with changes in any of the other markers 
measured. In particular, the relationship between PD15 saline and sputum eosinophils 
remained minimal throughout the study, again suggesting that these two indices may be 
measuring differing aspects of the inflammatory process (Brusasco et al. 1998; Crimi et 
al. 1998~ Haley and Drazen 1998). This does not invalidate the use of hypertonic saline to 
induce airway hyperresponsiveness in assessing asthma control, but merely highlights the 
clinical difficulty in deciding which marker of asthma control should be measured in 
order to best assess long term outcomes. 
Study critidsms 
There are a number of potential criticisms of the current study. Firstly, the range of doses 
ofbeclomethasone to which patients were randomised did not include lOOO~g/day. This 
was because of earlier suggestions that the clinical benefits of inhaled corticosteroid may 
be limited at higher doses (Kamada et al. 1996~ O'Byrne and Pederson 1998) even in 
patients with severe asthma (Hummel and Lehtonen 1992). Because of this, our study 
was specifically designed to address the possibility that there is a threshold for the anti-
inflammatory effects of inhaled corticosteroid within the lower dose range. However, our 
results demonstrate that this is not the case. 
Secondly, the study model employed, i.e. withdrawal of inhaled corticosteroid prior to 














unexpectedly high number of patients whose asthma remained uncontrolled after being 
randomised. A total of 25/64 (39%) of patients remained uncontrolled and for ethical 
reasons these patients were re-allocated to receive 1000(lg/day. The patients who entered 
the 1000flg/day arm had both a lower FEV1 % predicted (73.9% versus 82.5% 
respectively, p=0.005) and a higher dose of maintenance inhaled corticosteroid at study 
entry (776(lg/day versus 614(lg/day beclomethasone respectively, p=0.042) when 
compared to those who remained on randomised medication, suggesting that these 
individuals had more severe asthma. The analyses of the dose-response effects were on 
an intention-to-treat basis, and took account of those patients who were changed to the 
higher dose. Because of selection bias no formai comparisons were made with the subset 
who received 1000~-tg/day. However, this group did provide useful information: eNO 
levels at week eight were higher following 1000(lg/day than was seen in the 500~-tg/day 
group. The 1000~-tg/day group had a mean eNO of 17.3ppb (95% C.I.: 11.08, 23.52) 
compared to 10.4ppb (95% C.I.: 4.41, 16.39) in those receiving 500(lg/day. This finding 
confirms that despite receiving higher doses of inhaled corticosteroid eNO levels may 
remain elevated in a subset of patients with more severe asthma (Stirling et al. 1998; 
Mattes et al. 1999), reflecting ongoing airway inflammation (Louis et al. 2000). 
Finally, despite finding a linear relationship between eNO and dose of inhaled 
corticosteroid, eNO measurements were not able to distinguish between adjacent inhaled 
corticosteroid doses consistently when assessed in pair-wise comparisons, although eNO 
was better in this regard than all other measured parameters. This appears to be a 
difficulty pertaining to almost all dose-response studies for inhaled corticosteroid, 
irrespective of the end-point used, and with even larger numbers of patients (Dahl et al. 
1993; Welch et al. 1997; Busse et al. 1999). 
Summary 
A dose-response relationship between eNO and inhaled corticosteroid therapy existed 
over a dose range of 0-500flg/day beclomethasone in patients treated following a recent 
deterioration in asthma control. This dose-response relationship was seen as early as one 














response relationships were seen with FEV 1 and sputum eosinophils at the end of 
treatment and with FEV1 at one week. In contrast to FEV1, eNO was strongly correlated 
to sputum eosinophil numbers at baseline and after treatment, as well as when assessed as 
change occurring with treatment. These findings suggest that eNO is a good marker of 
airway inflammation during inhaled corticosteroid therapy, being both easily measured 


















EXHALED NITRIC OXIDE AND RESPONSE TO 
CORTICOSTEROID ADMINISTRATION IN COPD 
8.1 Abstract 
Background: The appropriate use of corticosteroids in the management of stable COPD 
is still uncertain. This study was conducted to investigate whether eNO measurements 
could be helpful in identifying patients in whom benefit is gained from corticosteroid 
therapy. 
Method: Twenty-seven 'corticosteroid-free' patients with COPD were given a 10-14 day 
course of oral prednisone (30mg/day). Measurements of eNO, spirometry and 6-minute 
walk were performed before (visit 2) and after (visit 3) prednisone. The value of eNO in 
predicting a response to treatment defined as an improvement in 6-minute walk of 2SOm 
was calculated. 
Results: A significant decrease in eNO of -3.31ppb (-1.46 to -5.16) and an increase in 6-
minute walk of 34.4m (22.6 to 46.1) was seen following prednisone. No significant 
change occurred in lung function (M'EV1 0.041 (-0.02 to 0.09)). Exhaled NO at visit 2 
correlated marginally with the change in 6-minute walk (r=0.38, p=0.06) and FVC 
(r=0.53, p=0.01) following prednisone, but not with change in FEV1 (r=0.12, p=0.58). An 
eNO at visit 2 of s 1 Oppb had a negative predictive value of 82.2% and positive predictive 
value 43.7% for a significant improvement in 6-minute walk following prednisone. 
Conclusion. Low eNO at baseline predicts a poor functional improvement following 
corticosteroid in stable COPD. Measurements of eNO may be helpful in identifying 


















Chronic obstructive pulmonary disease (COPD) is characterised by abnormal expiratory 
airflow that does not change significantly over short to medium time intervals or with 
treatment (1987). Despite this, inhaled corticosteroids are often used in the treatment of 
COPD, although recent evidence has called their role in long-term management ofCOPD 
into question (van Schayck et al. 1996; Barnes 1998a; Anthonisen 1999; McEvoy and 
Niewoehner 2000). Further, current guidelines recommend inhaled corticosteroid therapy 
for those patients who show a clear objective response to a formal trial of either oral 
prednisone or high dose inhaled steroid. A positive response is defined as an 
improvement in FEV 1 of :::: 15% and ::::200ml, although this only occurs in a small 
minority of patients (BTS 1997a). 
One of the challenges in the treatment of COPD is identifying potential "responders" to 
corticosteroid therapy. Recent studies have shown that such patients are likely to be 
characterised by the presence of eosinophilic airway inflammation (Chanez et al. 1997; 
Pizzichini et al. 1998; Fujimoto et al. 1999; Brightling et al. 2000). Exhaled nitric oxide 
(eNO) is raised in asthma, a disease characterised by eosinophilic inflammation. Some 
studies have also demonstrated elevated levels of eNO and NO derivatives in the sputum 
of patients with COPD (Kanazawa et al. 1998; Corradi et al. 1999), especially in patients 
with unstable and partially reversible disease (Maziak et al. 1998; Agusti et al. 1999; Papi 
et al. 2000). These findings suggest that eNO measurements may be beneficial as a 
surrogate for assessing airway inflammation in patients with COPD, and therefore 
identify those patients who have the potential to benefit from anti-inflammatory 
treatment. In this study we aimed to evaluate eNO measurements in predicting changes in 
lung function and exercise capacity resulting from a 10-14 day course of oral 



















Patients aged 45-75 years with a clinical diagnosis of stable COPD were recruited (ATS 
1987; Fabbri et al. 1998a). Inclusion criteria for entry were FEV1/FVC <65%, FEV1 
<70% predicted and a smoking history of ;::30 pack years. Exclusion criteria included a 
history of asthma, onset of symptoms before age 35, a respiratory tract infection in the 
previous four weeks, and those currently participating in a COPD rehabilitation 
programme. Patients were not selected on the basis of reversibility to I)-agonist or their 
atopic status. 
Study design 
At study entry all current inhaled corticosteroid therapy was discontinued (Visit 1 ). 
Patients were assessed 2 weeks later (Visit 2) and commenced on a 10-14 day course of 
prednisone 30mg/day, followed by a further clinic visit at the end of the treatment period 
(Visit 3). At each clinic visit measurements of eNO, spirometry with reversibility to beta-
agonist, and 6-minute walk were performed. Bronchodilator therapy was avoided prior to 
each visit (I)-agonist for 4 hours, ipratropium for 6 hours). Those patients who were 
current smokers were asked to refrain from smoking on the morning of testing. 
Ethical approval was obtained from the Otago Ethics Committee and written informed 
consent was obtained from all study participants. 
Nitric oxide 
Measurements of eNO were obtained prior to all other study procedures using a 
chemiluminescence analyser (Logan LR 2000) according to a standardised technique for 
single breath on-line measurements (Kharitonov et al. 1997a; 1999), with the exception 
of flow rate which was 250 ml/sec. A previous study in patients with asthma (Jones et al. 
2001) had been conducted using a flow rate of 250ml/sec and this was the basis upon 
which the current study was designed. A total of three measurements was obtained at 



















the patient's clinical status. The plateau NO at end-expiration was read and the mean of 
the three measurements was recorded. 
Spirometry 
Spirometry was performed with the patient sitting, using a rolling seal spirometer. 
Reference values were obtained from the report of the working party of the European 
Community for Coal and Steel: "Standardisation of Lung Function Tests" (Quanjer et al. 
1993). Measurements were taken before and 15 minutes after two puffs of terbutaline 
administered via Turbuhaler (Bricanyl, 250~g/puft). 
6-Minute Walk 
Functional exercise performance was assessed by means of a standardised 6-minute walk 
(Steele 1996). Patients performed two 6-minute walk tests, with a rest period of at least 
15 minutes in between. Patients were allowed to use their usual inhaled bronchodilator as 
needed during the test. Standardised instructions and encouragement were given (Guyatt 
et al. 1984) and the furthest distance walked recorded. An improvement of greater than 
50 metres was considered clinically important (Redelmeier et al. 1997). Patients 
undertook 6-minute walk tests at each of the three study visits. The tests performed at 
visit 1 were deemed 'practice' walks, and only the distances measured during visits 2 and 
3 were analysed. 
Statistical analysis 
A clinically significant improvement in FEV 1 was defined as an increase of~ 15% and at 
least 200ml from the baseline value. Reversibility was assessed as both change in FEV 1 
from baseline and as an increase of ~15% of the predicted FEV1 (Brand et al. 1992). 
Correlations between eNO and FEV1, FVC and 6-minute walk tests were calculated at 
visit 2, and for the change between visits 2 and 3 using Spearman rank correlation 
coefficients. The predictive values for eNO were determined using 2x2 contingency 
tables, permitting calculation of sensitivities, specificities, positive predictive values 




















were used as these have previously been shown to be clinically useful in asthma (Little et 
al. 2000~ Jones et al. 2001 ). 
8.4 Results 
Thirty patients entered the study. Three patients developed an exacerbation of the"ir 
COPD between visits 1 and 2 (while off their maintenance inhaled steroid) and were 
withdrawn. Demographic data for the remaining 27 obtained at visit 2 are given in Table 
8.1. Three patients demonstrated FEV 1 reversibility to ~-agonist of :2:15% and :2:200ml of 
baseline at visit 2. However, none of these patients had reversibility to ~-agonist of :2:15% 
of predicted FEY 1 (Brand et al. 1992). A further two patients developed chest infections 
between visits 2 and 3 (while on prednisone) and were also withdrawn. A total of 25 
patients completed the study. 
Mean eNO, 6-minute walk distances, and spirometric measurements obtained before and 
after prednisone are shown in Table 8.2. A significant change in eNO of -3.31ppb (95% 
CI: -1.46 to -5.16ppb) was seen following treatment with prednisone. A plot of individual 
patients' eNO recordings at visit 2 and 3 are shown in Figure 8.1 along with the group 
means. The mean 6-minute walk distance increased by 34.4m (95% CI: 22.6 to 46.1m) 
between the two visits. A total of 8 patients had an increase in 6-minute walk distance of 
<!:50m. Both FEV1 and FVC demonstrated non-significant changes (0.041, 95% CI: -0.02 
to 0.09~ and 0.06 1, 95% CI: -0.06 to 0.18 1 respectively). Only two patients had an 




















Table 8.1. Demographic and baseline data at visit 2. 
n 27 




Current ICS use, n (%) 15 (56%) 
Current/ ex -smoker 13/14 
Smoking history, 52.6 
pack years a (range 30-80) 
FEV1% predicted 
41.8% 
(95% CI: 35.8-47.9) 
FEV1/FVC,% 
42.9% 
(95% CI: 39.2-46.6) 
FEV1 reversibility, 13.8% 
%absolute (95% CI: 9.7-17.9) 
FEV 1 reversibility, 4.9% 
% of predicted (95% CI: 3.7-6.1) 
FEV1 =forced expiratory vol~me in one second. 
FVC =forced vital capacity. 
FEV 1 reversibility is calculated following beta-agonist administration (two puffs of 
250!-lg/puff terbutaline via a Turbuhaler) and results expressed both as a percentage of 
baseline FEV 1 (% absolute) and as a percentage of predicted FEV 1. 
ICS =inhaled corticosteroid. 
a One pack year is equal to 20 cigarettes/day for one year. 
131 
'( Table 8.2. Study measurements obtained before (visit 2) and after (visit 3) treatment 
with 30mg prednisone daily for 10-14 days. n = 25. 
Visit 2 Visit 3 A Visit (3-2) 
,\ eNO (ppb) 
10.60 7.30 -3.31 
(7.95, 13.26) (5.36, 9.23) (-5.16, -1.46) 
t~ ..,-
6-minute walk (m) 
474.6 508.9 34.4 
(443.0, 506.1) (477.5, 540.3) (22.6, 46.1) 
FEV1 (i) 
1.25 1.28 0.04 
(1.02, 1.47) (1.06, 1.50) (-0.02, 0.09) 
;> 
FVC (1) 
2.79 2.85 0.06 
'I (2.41, 3.16) (2.48, 3.21) (-0.06, 0.18) 
,_, 
A Visit (3-2) =the difference in measurements between visit 2 and 3. 
Results are expressed as mean (95% CI). 
I> 
FEY 1 = forced expiratory volume in one second . 
• 



























Figure 8.1. Exhaled NO measurements before (visit 2) and after (visit 3) treatment 
with prednisone. 
Solid line and +representing those patients having an increase of greater than 50m in 6-
minute walk, and dashed line and • representing those who did not. The group means are 
also shown, error bars signifying the 95% C. I. (p=O.OOl for these comparisons) . 
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At visit 2 eleven patients (44%) had an eNO of greater than lOppb, and seven (28%) had 
a level higher than 15ppb. Exhaled NO inversely correlated with the 6-minute walk 
distance at visit 2 (r= -0.42, p=0.028). However the correlation between eNO at visit 2 
and the subsequent change in 6-minute walk following prednisone showed only marginal 
significance (r=0.38, p=0.06). There was no correlation between eNO and FEV1 
reversibility to j3-agonist at visit 2 (r= -0.03, p=0.88). Likewise, eNO at visit 2 did not 
correlate with the subsequent change in FEV 1 following treatment with prednisone 
(r=0.12, p=0.58), however eNO at visit 2 did correlate with post-steroid improvement in 
PVC (r=0.53, p=O.Ol). 
Patients were dichotomised into two groups based on the cut-off of 1 Oppb eNO measured 
at visit 2. The changes occurring within these two groups of patients are shown in Figure 
8.3. Those with an eNO of ~lOppb had a significantly larger decrease eNO (p=0.03) and 
increase in PVC (p=0.04) following prednisone treatment. These patients also had a 
larger increase in six minute walk distance following prednisone, although this difference 
was not statistically significant (p=0.07). 
An attempt was made to calculate the sensitivities, specificities, positive and negative 
predictive values of the ability of eNO measurements at visit 2 to predict an improvement 
in 6-minute walk. However due to the small study population these resulted in very large 
95% confidence intervals, limiting our ability to draw many conclusions from this data. 
These analyses are shown in a series of two-by-two contingency tables in Table 8.4. 
Bearing in mind the limitation of large confidence intervals, an eNO at visit 2 of <lOppb 
had a negative predictive value of 86% in predicting a failure to improve the 6-minute 
walk by c:50m. However, at that cut-point the positive predictive value was only 55%. On 
the whole, a cut-point for eNO of c:lOppb was associated with stronger predictive values 
than c: 15ppb. Analysis of the predictive value of eNO for predicting an improvement in 
FEV1 following prednisone was not possible because only two patients had an 


















Table 8.3. Comparison of patients based on eNO level at visit 2. Patients were 
dichotomised into two groups, those with an eNO of greater than 1 Oppb and those who 
had a level less than 10 ppb. 
eNO atV2 
<10ppb (n=14) ;;::lOppb (n=ll) 
Mean (95% CI) Mean (95% CI) p-value 
~eNOcv3-V2) (ppb) -1.4 (-0.1, -2.8) -5.7 (-2.5,-8.9) 0.03 
M'EV l(V3-V2) (ml) 29 (106, -48) 44 (113, -25) 0.79 
~%predicted 
1.4 (4.2, -1.5) 1.5 (3.7, -0.7) 0.95 
FEV l(V3-V2) (%) 
MVCcv3-V2) (ml) -42 (82, -165) 191 (371, 10) 0.04 
~6-minute walk (V3-
25 (39, 12) 46 (64, 28) 0.07 
V2) (m) 
~eNOcv3-V2) =change in eNO between visits 2 and 3. 
£1FEV1(V3-V2) =change in forced expiratory volume in one second (FEV1) between visits 
2 and 3. 
£1FVCcv3-V2) =change in forced vital capacity (FVC) between visits 2 and 3. 
~6-minute walk cv3-v2) = change in six minute walk distance between visits 2 and 3. 
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Table8.4. Two-by-two contingency tables assessing the ability of eNO at visit 2 
(V2) in predicting improvement in 6-minute walk (6-MW) following prednisone. The 
·I 
respective sensitivities, specificities, positive and negative predictive values (PPV and 
NPV, respectively) for the various cut points used are also given. 
\ 
a) Increase in 
(95% CI) 6-MW of:i!!SOm 
"' Yes No Total Sensitivity 75% (35-97) 
,, 
eNO Yes 6 5 11 Specificity 71% (44-90) 
:!:lOppb 
No 2 12 14 PPV 55% (23-83) 
·t atV2 
• • Total 8 17 25 NPV 86% (57-98) 
'>. 
b) Increase in 
(95% CI) 6-MW of:i!!SOm 
Yes No Total Sensitivity 38% (9-76) 
·t-{ eNO Yes 3 4 7 Specificity 76% (50-93) 
~ :!:l5ppb 
atV2 No 5 13 18 PPV 43% (10-82) 
!> Total 8 17 25 NPV 72% (47-90) 
I> 
c) Increase in 
(95% CI) 6-MW of:!:lO% 
Yes No Total Sensitivity 63% (24-91) 
eNO Yes 5 6 11 Specificity 65% (38-86) 
~ :!:lOppb 
atV2 No 3 11 14 PPV 46% (17-77) ;.. 
). Total 8 17 25 NPV 79% (49-95) 
d) Increase in 
(95% CI) .}- 6-MW of:!:lO% 
Yes No Total Sensitivity 38% (9-76) 
f eNO Yes 3 4 7 Specificity 76% (50-93) 
:!:l5ppb 
,,C atV2 No 5 13 18 PPV 43% (10-82) 




























This study was conducted in order to assess whether measurements of eNO could be used 
to identifY patients with COPD in whom improvement with corticosteroid therapy might 
occur. The results demonstrate that elevated levels of eNO (:<!::10ppb) are seen in a 
proportion of COPD patients and that these patients show a greater decrease in eNO and 
increases in FVC following prednisone treatment. Patients with eNO c: 1 Oppb also 
demonstrated twice as much improvement in 6-minute walk distance following 
prednisone compared to those with an eNO of <lOppb (46 metres versus 25), however 
the difference between the two groups was non-significant (p=0.07). 
In our study treatment with oral prednisone resulted in a significant decrease in the mean 
eNO level of -3.31ppb. It has been previously shown that eNO levels in COPD decrease 
with corticosteroid therapy following an acute exacerbation (Agusti et al. 1999) but no 
other study has assessed the effect of prednisone therapy on eNO in clinically stable 
COPD. Other studies have reported no difference in eNO levels in COPD patients on 
inhaled corticosteroid therapy when compared to those not on inhaled steroid therapy 
(Robbins et al. 1996; Delen et al. 2000). However, these investigations were cross-
sectional and did not allow for possible differences in baseline severity, or that eNO 
levels may differ between the groups while 'corticosteroid free'. In our study eleven 
patients (44%) had an eNO of :<!::10ppb and seven (28%) had a level of 2lSppb indicating 
that there is a subset of COPD patients in whom elevated levels of eNO are present. 
Furthermore the patients with elevated eNO had a significantly greater decrease in eNO 
following prednisone treatment (-5.7ppb compared to -1.4ppb, p=0.03). Despite this, the 
decrease in eNO that occurred with prednisone was small, and although there was also a 
significant improvement in 6-minute walk the relationship between the changes occurring 
in these markers was non-significant. 
We found no significant improvement in either FEV1 or PVC following prednisone. 




















walk. This highlights the limitation that measurements of lung function have in assessing 
response to treatment in COPD . 
Although calculation of sensitivities and specificities from our current study is limited by 
the small study number, the results suggest that eNO may be of benefit in distinguishing 
those patients in whom no functional benefit is seen following prednisone treatment. 
Patients who did not have an elevated eNO (~10ppb) while 'corticosteroid-free' were 
unlikely to obtain any benefit following treatment with prednisone. An eNO of less than 
10ppb had a negative predictive value of 86% (95%CI: 57-98%) in predicting an 
improvement in 6-minute walk distance of ~som. However we were unable to 
demonstrate that those with a high level of eNO would necessarily improve. The positive 
predictive value of eNO was only 55% (95%CI: 23-83%), much smaller than the results 
of a similar trial in asthma where an eNO of > 1 Oppb was associated with a positive 
predictive value of 83% for predicting an improvement in FEV 1 of> 15% (Little et al. 
2000). These findings are a reflection of the overall poor response to prednisone found in 
COPD. In this study only eight patients had an improvement in 6-minute walk of more 
than 50m and only two had an increase in FEV 1 of more than 200ml. 
Others have shown that short-term response to corticosteroid therapy is limited to COPD 
characterised by eosinophilic inflammation (Chanez et al. 1997; Pizzichini et al. 1998; 
Fujimoto et al. 1999), not neutrophilic inflammation (Keatings et al. 1997b ). It may be 
that eNO was associated with a low positive predictive value in our current study because 
it cannot be used to discriminate between these two types of inflammation, although this 
would appear to go against our findings in the asthma studies. Nitric oxide is released not 
only from eosinophils but also from a large number of other cell types found in airways, 
including neutrophils and macrophages (Gaston et al. 1994). For example, Kanazawa et 
al (1998) found that concentrations of sputum NO correlated with neutrophils and not 
eosinophils, whereas Rutgers et al (1999) found that eNO correlated with eosinophils and 
not neutrophils. Thus if short-term improvement is more likely in patients with sputum 
eosinophilia and yet eNO measurements cannot be used to discriminate between the types 

















patients in whom short-term clinical improvement will be obtained. Unfortunately no 
sputum samples for cell analysis were obtained during our current study . 
There are a number of potential limitations to the present study. Firstly, because a 
placebo-control arm was not included it is possible that eNO may have decreased 
spontaneously over time or that the decrease may have been a direct effect of prednisone 
on intrinsic NO production rather than on airway inflammation. Furthermore, five 
patients were withdrawn due to exacerbations and were not able to be included in the 
analysis. COPD characterised by frequent exacerbations is associated with greater. 
amounts of airway inflammation (Bhowmik et al. 2000). Therefore patients experiencing 
exacerbations may potentially have demonstrated the greatest response to corticosteroid 
therapy. Their withdrawal may have weakened our chances of obtaining a "'positive" 
result. Thirdly, no sputum samples were obtained so it remains unclear what role eNO 
has in identifying inflammation in COPD. Finally, the study included both current and 
ex-smokers. Previous studies have found that current smoking is associated with 
decreased levels of eNO when compared to ex-smokers (Maziak et al. 1998; Corradi et 
al. 1999; Delen et al. 2000). Unfortunately at the time of design for our current study 
these results were not available. The inclusion of smokers may have reduced our ability 
to detect a significant positive predictive value for eNO. 
COPD is a heterogeneous disease for which treatment with corticosteroid results in 
improvement in only a small proportion of patients. Several large multi-centre studies 
have confirmed this overall view (Burge 1999; Pauwels et al. 1999; Vestbo et al. 1999; 
Burge et al. 2000) and the challenge still remains to easily identify COPD patients who 
will obtain a beneficial response to steroids. The results of this current study show that 
eNO is elevated in a subset of COPD patients and suggests that these patients may have 
an increased response to corticosteroids in the short-term. However on the whole the 
response was small and it's clinical significance uncertain. Whether these patients have 
any long-term benefit from the use of inhaled steroids is still unknown. Further 
longitudinal studies assessing the utility of eNO in predicting responses to long-term 
therapy with inhaled corticosteroids are required. 
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CONCLUSIONS AND FUTURE RESEARCH 
9.1 Asthma 
In the studies presented in this thesis the role of eNO as a marker of airway inflammation 
in both controlled and uncontrolled asthma has been -considered. I have reported the 
variation occurring in eNO measurements during normal asthma control and have 
assessed the ability of serial eNO to predict and diagnose poorly controlled asthma. 
Finally, the dose-response relationship of eNO measurements to anti-inflammatory 
treatment with inhaled corticosteroid therapy was evaluated. From these studies it is 
concluded that eNO can provide accurate and clinically important information regarding 
the control of airway inflammation in asthma. These findings will have important 
implications for both the clinical assessment of asthma control in individual patients, and 
the comparison of differing doses of various anti-inflammatory treatments. 
Asthma patients were initially followed for a period of two to four weeks while 
remaining on a stable dose of maintenance inhaled corticosteroid therapy. Here eNO was 
found to be highly reproducible within a sitting (coefficient of variation 4.1% ). An 
important finding during this period was a lack of relationship between eNO measured at 
plateau and ambient NO levels. This aids the assessment of eNO in the clinical setting as 
patients are not required to inhale NO-free air in order to get reliable recordings. 
Additionally, in this sample eNO correlated positively with height but no other baseline 
patient demographic. This relationship with height has not been reported before, however 
it is biologically plausible given that concentration of eNO measured at the mouth is 
dependent on the velocity of air through the airways. The faster the velocity the higher 
the concentration of eNO. This possible relationship with height requires further 
investigation in order to help standardise eNO recordings. 
Serial measurements of eNO were shown to be useful in both predicting and diagnosing 
















that an absolute value of 15ppb, an increase of more than 1 Oppb or a increase of 60% 
over baseline, are useful thresholds for the detection of ongoing airway inflammation. 
These cut points also positively predicted the occurrence of breakthrough symptoms. This 
finding is clinically important as deteriorating asthma may be identified earlier than is 
currently possible. Thus treatment might be altered to avoid the occurrence of significant 
clinical symptoms based on eNO measurements. However these results need to be 
interpreted with a degree of caution, as complete cessation of inhaled corticosteroid 
therapy, as was used in our investigation, is not consistent with current clinical practice. 
Exhaled NO demonstrated a dose-response relationship over a dose range of inhaled 
corticosteroid therapy of 0-500f.tg beclomethasone/day. This relationship was linear and 
was present both at one week and following eight weeks treatment. Similar dose-response 
relationships were seen with both sputum eosinophils and lung function. These results 
suggest that eNO is a good marker of airway inflammation during inhaled corticosteroid 
therapy, as it is easily measured and responds rapidly when airway inflammation is 
reduced by steroid administration. This finding demonstrates that eNO may be useful for 
dose titration of inhaled corticosteroid therapy in individual patients and it also suggests 
that eNO may be used to compare the doses of differing anti-inflammatory treatments, 
thus enabling optimum dosing with these agents. This is a question that is currently being 
investigated in our research unit as a follow-up study from the research presented in this 
thesis. 
Throughout all of these studies eNO was shown to correlate well with markers of asthma 
control and airway inflammation. In particular the relationship was strongest between 
eNO and sputum eosinophils. This relationship was present when these measurements 
were compared as both point-in-time and change-over-time values in the setting of 
deteriorating and improving asthma control. The consistency of this relationship 
throughout all of the studies provides further supportive evidence for the use of eNO as a 
marker of eosinophilic airway inflammation, both in the absence and presence of inhaled 
corticosteroids. A relationship between eNO and the more traditional methods of 



















When measured as point-in-time there were no correlation between these markers and 
eNO. However the rise in eNO was significantly higher in the loss of control group 
(where loss of control had been based on traditional markers), and changes in these 
markers over time correlated with changes in eNO, confirming the usefulness of 
measuring eNO in assessing the clinical control of asthma over time. Perhaps one of the 
most surprising results from the studies was the lack of a consistent relationship between 
eNO and airway hyperresponsiveness to hypertonic saline. Although at loss of control 
there was a correlation between eNO and PD15 saline there was no consistent relationship 
elsewhere through the studies, suggesting that these measurements are assessing slightly 
different aspects of the asthma phenotype. For example there was no change in PD 15 
saline in any of the randomised treatment groups (over 0-500~-tg/day BDP), despite 
significant linear changes in eNO. Thus demonstrating that PD15 is less sensitive to the 
effects of inhaled steroid therapy than eNO. Further long-term longitudinal studies are 
needed to confirm that the clinical application of eNO measurement is worthwhile in 
optimising asthma management, and in particular its usefulness in the presence of inhaled 
corticosteroid therapy. 
Another aspect that needs to be considered in future research is the effect of lower 
exhalation rates on the clinical usefulness of eNO. During my studies eNO measurements 
were made during an exhalation flow rate of 250ml/sec. At the time of study 
commencement this was the accepted methodology, however since that time international 
guidelines have been developed suggesting the use of a lower flow rate of 50ml/sec. At 
lower flow rates there is a greater spread in eNO recordings between subjects and in 
particular the difference is greater between asthma and non-asthma patients. Thus it 
appears that the results reported in this thesis are conservative, and it is possible that at 
lower flow rates there is better differentiation in eNO recordings between controlled and 
uncontrolled airway inflammation. This may therefore improve the sensitivity of eNO 
and increase its clinical applicability. 
The usefulness of serial eNO measurements may be greatest in patients with atopic 















versus non-atopic asthma, and indeed only 9 of the 87 patients were non-atopic. However 
at 'loss of control' eNO values in the atopic group were double those of the non-atopic 
group, raising the possibility that eNO may be a more responsive marker in atopic 
asthma. This again needs to be the subject of further research. 
In summary, the optimum approach to monitoring asthma patients on inhaled 
corticosteroid has still not been defined. Measuring lung function does not appear to give 
an adequate representation of airway inflammation. Whether improved clinical outcomes 
are possible when monitoring specific markers of airway inflammation is still unknown. 
Recently it has been shown that minimising airway hyperresponsiveness improves both 
histological and clinical outcomes (Sont et al. 1999). Unfortunately, repeated 
measurements of airway hyperresponsiveness are unsuited for routine clinical practice 
and their widespread application seems unlikely. The same is true for induced sputum 
analyses. In contrast, eNO measurements are easy to perform, repeatable, and may be 
used to diagnose ongoing airway inflammation, predict the advent of breakthrough 
symptoms, and demonstrate a dose-response relationship to anti-inflammatory treatment. 
These findings offer the possibility that repeated measurements of eNO may be used to 
adjust dose of inhaled corticosteroid in patients with asthma and thus improve clinical 
outcomes. However this requires further prospective investigation. 
9.2 COPD 
The role of eNO in the assessment of COPD is less clear-cut. Exhaled NO was shown to 
decrease following a course of oral prednisone and this decrease was seen in association 
with improvements in functional ability. Furthermore, a low eNO at baseline predicted 
lack of significant functional improvement following prednisone, indicating that those 
patients with low eNO are unlikely to benefit from corticosteroid therapy. This may have 
some clinical application as it could help prevent the unnecessary usage of steroids in this 
group of patients. However, eNO was poor in predicting a positive response to steroids in 
COPD. This may be due to heterogeneity in the underlying inflammatory process. As no 
sputum samples were obtained during this study assessment of the type of inflammation 















COPD may have been due to the relatively short duration of treatment. The role of eNO 
in COPD deserves fuller exploration; in particular long-term clinical benefits and the 













Aalbers R., Kauffman H.F., Vrugt B., Koeter G.H. and Demonchy J.G.R. 1993 Allergen-
induced recruitment of inflammatory cells in lavage 3 and 24 hours after challenge in 
allergic asthmatic lungs. Chest 1 03( 4 ): 1178-1184. 
Agusti A.G., Villaverde J.M., Togores B. and Bosch M. 1999 Serial measurements of 
exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. 
European Respiratory Journal14(3): 523-8. 
Alving K., Lundberg J.O.N. and Nordvall S.L. 1995 Dose-dependent reduction of 
exhaled nitric oxide in asthmatic children by inhaled steroids. American Journal of 
Respiratory and Critical Care Medicine 151: A129. 
Alving K., Weitzberg E. and Lundberg J.M. 1993 Increased amount of nitric oxide in 
exhaled air of asthmatics. European Respiratory Journal6(9): 1368-1370. 
Anderson S.D. 1984 Is there a unifying hypothesis for exercise-induced asthma? Journal 
of Allergy and Clinical Immunology 73: 660-665. 
Anderson S.D. 1985 Bronchial challenge by ultrasonically nebulized aerosols. Clinical 
Review of Allergy 3: 427-439. 
Anderson S.D. 1996 Exercise-induced asthma and the use of hypertonic saline aerosol as 
a bronchial challenge. Review article. Respirology 3: 175-181. 
Anderson S.D., du Toit J.I., Rodwell L.T. and Jenkins C.R. 1994 Acute effect of sodium 
cromoglycate on airway narrowing induced by 4.5% saline aerosol- outcome before and 
· during treatment with aerosol corticosteroids in patients with asthma. Chest 105(3): 673-
680. 
Anderson S.D., Smith C.M., Rodwell T., du Toit J.I., Riedler J. and Robertson C.F. 1995 
The use of nonisotonic aerosols for evaluating bronchial hyperresponsiveness. In 
Provocation testing in clinical practice. Edited by Sheldon L. Spector. : Chapter 10. 
Anthonisen N.R. 1999 Steroids in COPD. The nearly eternal question. Chest 115: 3-4. 
Assreuy J., Cunha F.Q., Liew F.Y. and Moncada S. 1993 Feedback inhibition of nitric 
oxide synthase by nitric oxide. British Journal of Pharmacology 108: 833-837. 
A TS. 19 87 American Thoracic Society. Standards for the diagnosis and care of patients 
with chronic obstructive pulmonary disease (COPD) and asthma. American Review of 
Respiratory Disease 136: 225-244. 
ATS. 1999 Recommendations for standardized procedures for the on-line and off-line 















children-1999. Official statement of the American Thoracic Society. American Journal of 
Respiratory and Critical Care Medicine 160(6): 2104-117. 
Balzano G., Stefanelli F., Iorio C., De Felice A., Melillo E.M., Martucci M. and Melillo 
G. 1999 Eosinophilic inflammation in stable chronic obstructive pulmonary disease. 
Relationship with·neutrophils and airway function. American Journal of Respiratory and 
Critical Care Medicine 160( 5 Pt 1 ): 1486-92. 
Baraldi E., CarraS., Dario C., Azzolin N., Ongaro R., Marcer G. and Zacchello F. 1999 
Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children. 
American Journal of Respiratory and Critical Care Medicine 159: 262-266. 
Barnes N.C. 1998a Inhaled seroids in COPD. Lancet 351: 766-767. 
Barnes P.J. 1998b Efficacy of inhaled corticosteroids in asthma. Journal of Allergy and 
Clinical Immunology 102(4): 531-538. 
Barnes P.J. (1998c). Glucocorticosteroids. Asthma: Basic mechanisms and clinical 
management. P. J. Barnes, Academic Press Limited: 725-766. 
Barnes P.J. and Belvisi M.G. 1993 Nitric oxide and lung disease. Thorax 48: 1034-1043. 
Barnes P.J. and Kharitonov S.A. 1996 Exhaled nitric oxide: a new lung function test. 
Thorax 51: 233-237. 
Barnes P.J. and Liew F.Y. 1995 Nitric oxide and asthmatic inflammation. Immunology 
Today 16(3): 128-130. 
Barnes P.J., Pederson S. and Busse W.W. 1998 Efficacy and safety of inhaled 
corticosteroids: New developments. American Journal of Respiratory and Critical Care 
Medicine 157: S1-S53. 
Bentley A.M., Hamid Q., Robinson D.S., Schotman E., Meng Q., Assoufi B., Kay A.B. 
and Durham S.R. 1996 Prednisolone treatment in asthma. Reduction in the numbers of 
eosinophils, T cell, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and 
interferon-gamma cytokine gene expression within the bronchial mucosa. 'American 
Journal of Respiratory and Critical Care Medicine 153: 551-556. 
Berlyne G.S., Parameswaren K., Kamada D., Efthimiadis A. and Hargreave F.E. 2000 A 
comparison of exhaled nitric oxide and induced sputum as markers of airway 
inflammation. Journal of Allergy and Clinical Immunology 106: 638-644. 
Bhowmik A., Seemungal T.A., Sapsford R.J. and Wedzicha J.A. 2000 Relation of 
sputum inflammatory markers to symptoms and lung function changes in COPD 



















Bhowmik A., Seemungal T.A.R., Sapsford R.J., Devalia J.L. and Wedzicha J.A. 1998 
Comparison of spontaneous and induced sputum for investigation of airway inflammation 
in chronic obstructive pulmonary disease. Thorax 53: 953-956. 
Boulet L.-P., Turcotte H. and Brochu A. 1994 Persistence of airway obstruction and 
hyperresponsiveness in subjects with asthma remission. Chest 105: 1026-1031. 
Bousquet J., Chanez P., Lacoste J.Y., Bameon G., Ghavanian N., Enander I., et al. 1990 
Eosinophilic inflammation in asthma. New England Journal of Medicine 323': 1033-1039. 
Brand P.L.P., Quanjer P.H., Postma D.S., Kerstjens H.A.M., Koeter G.H., Dekhuijzen 
P.N.R., Sluiter H.J. and and the Dutch chronic non-specific lung disease study group. 
1992 Interpretation of bronchodilator response in patients with obstructive airways 
disease. Thorax 47: 429-436. 
Brightling C.E., Monteiro W., Ward R., Parker D., Morgan M.D., Wardlaw A.J. and 
Pavord I.D. 2000 Sputum eosinophilia and short-term response to prednisolone in chronic 
obstructive pulmonary disease: a randomised controlled trial. Lancet 356(9240): 1480-
1485. 
Brusasco V., Crimi E. and Pellegrino R. 1998 Airway hyperresponsiveness in asthma: not 
just a matter of airway inflammation. Thorax 53(11): 992-998. 
BTS. 1997a British Thoracic Society. Guidelines for the management of chronic 
obstructive pulmonary disease. Thorax 52 (suppl 5): S 1-28. 
BTS. 1997b British Thoracic Society. The British guidelines on asthma management. 
Thorax 52(Suppl 1): S1-S21. 
Burge P.S. 1999 EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Thorax 
54( 4): 287-288. 
Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A. and Maslen T.K. 
2000 Randomised, double blind, placebo controlled study of fluticasone propionate in 
patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE 
trial. BMJ 320: 1297-303 . 
Busse W.W., Brazinsky S., Jacobson K., .Striker W., Schmitt K., Vanden Burgt J., 
Donnell D., Hannon S. and Colice G.L. 1999 Efficacy response of inhaled 
beclomethasone dipropionate in asthma is proportional to dose and is improved by 
formulation with a new propellent. Journal of Allergy and Clinical Immunology 104: 
1215-1222. 
Butland R.J.A., Pang J., Gross E.R., Woodcock A.A. and D.M. G. 1982 Two-, 6-, and 











Cai Y., Carty K., Henry R.L. and Gibson P.G. 1998 Persistence of sputum eosinophilia in 
children with controlled asthma when compared with healthy children. European 
Respiratory Journal11(4): 848-853. 
Callahan C.M., Dittus R.S. and Katz B.P. 1991 Oral corticosteroid therapy for patients 
with stable chronic obstructive pulmonary disease. A meta-analysis. Annals of Internal 
Medicine 114: 216-223. 
Chambers D.C., Tunnicliffe W.S. and Ayres J.G. 1998 Acute inhalation of cigarette 
smoke increases lower respiratory tract nitric oxide concentrations. Thorax 53: 677-679. 
Chambers D.C., Tunnicliffe W.S., Fletcher T.J. and Ayres J.G. 1996 Measurement of 
lower respiratory tract nitric oxide: validity of using values at 75% of exhaled volume. 
Thorax 51 (Suppl. 3): A17. 
Chanez P., Vignola A.M., O'Shaugnessy T., Enander I., LiD., Jeffery P.K. and Bousquet 
J. 1997 Corticosteroid reversibility in COPD is related to features of asthma. American 
Journal of Respiratory and Critical Care Medicine 155: 1529-1534. 
Chan-Yeung M., Obata H., Dittrick M., Chan H. and Abboud R. 1999 Airway 
inflammation, exhaled nitric oxide, and severity of asthma in patients with western red 
cedar asthma. American Journal of Respiratory and Critical Care Medicine 159(5): 1434-
1438. 
Chetta A, Foresi A and Del Donno M. 1996 Bronchial responsiveness to distilled water 
and methacholine and its relationship to inflammation and remodelling of the airways in 
asthma. American Journal ofRespiratory and Critical Care Medicine 153: 910-17. 
Claman D.M., Boushey H.A., Liu J., Wong H. and Fahy J.V. 1994 Analysis of induced 
sputum to examine .the effects of prednisone on airway inflammation in asthmatic 
subjects. Journal of Allergy and Clinical Immunology 94: 861-869. 
Clini E., Bianchi L., Pagani M. and Ambrosino N. 1998 Endogenous nitric oxide in 
patients with stable COPD: correlates with severity of disease. Thorax 53(10): 881-883. 
Cockcroft D.W. (1997). Airway responsiveness. Asthma. P. J. Barnes, M. M. Grunstein, 
A R. Leffand A J. Woolcock. Philadelphia, Lippincott-Raven: 1253-1266. 
Cockcroft D.W., Ruffin R.E., Dolovich J. and Hargreave F.E. 1977 Allergen-induced 
increase in non-allergic bronchial reactivity. Clinical Allergy 7: 503-513. 
Corradi M., Majori M., Cacciani G.C., Consigli G.F., de' Munari E. and Pesci A. 1999 
Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary 









Corradi M., Pelizzoni A., Majori M., Cuomo A., de' Munari E. and Pesci A. 1998 
Influence of atmospheric nitric oxide concentration on the measurement of nitric oxide in 
exhaled air. Thorax 53(8): 673-676. 
Crater S.E., Peters E.J., Martin M.L., Andrew W.M. and Platts-Mills T.A.E. 1999 
Expired nitric oxide and airway obstruction in asthma patients with an acute 
exacerbation. American Journal of Respiratory and Critical Care Medicine 159: 806-811. 
Cremona G., Higenbottam T., Takao M., Hall L. and Bower E.A. 1995 Exhaled nitric 
oxide in isolated pig lungs. Journal of Applied Physiology 78(1): 59-63. 
Crimi E., Spanevello A., Neri M., Ind P.W., Rossi G.A. and Brusasco V. 1998 
Dissociation between airway inflammation and airway hyperresponsiveness in allergic 
asthma. American Journal of Respiratory and Critical Care Medicine 157(1): 4-9. 
Dahl R., Lundback B., Malo J.-L., Mazza J.A., Nieminen M.M., Saarelainen P. and 
Barnacle H. 1993 A dose-ranging study of fluticasone propionate in adult patients with 
moderate asthma. Chest 104: 1352-1358. 
Daviskas E., Anderson S.D., Gonda I., Eberl S., Meikle S., Seale J.P. and Bautovich G. 
1996 Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic 
and healthy subjects. European Respiratory Journal 9( 4 ): 725-732. 
de Gouw H., Grunberg K., Schot R., Kroes A.C.M., Dick E.C. and Sterk P.J. 1998a 
Relationship between exhaled nitric oxide and airway hyperresponsiveness following 
experimental rhinovirus infection in asthmatic subjects. European Respiratory Journal 
11(1): 126-132. 
de Gouw H.W.F.M., Hendriks J., Woltman A.M., Twiss I.M. and Sterk P.J. 1998b 
Exhaled nitric oxide (NO) is reduced shortly after bronchoconstriction to direct and 
indirect stimuli in asthma. American Journal of Respiratory and Critical Care Medicine 
158:315-319. 
Delen F.M., Sippel J.M., Osborne M.L., LawS., Thukkani N. and Holden W.E. 2000 
Increased exhaled nitric oxide in chronic bronchitis: comparison with asthma and COPD. 
Chest 117(3): 695-701. 
DiFranco A., Vagaggini B., Bacci E., Bartoli M.L., Cianchetti S., Carnevali S., et al. 
1998 Leukocyte counts in hypertonic saline-induced sputum in subjects with 
occupational asthma. Respiratory Medicine 92(3): 550-557. 
Di Stefano A., Capelli A., Lusuardi M., Balbo P., Vecchio C., Maestrelli P., et al. 1998 
Severity of airflow limitation is associated with severity of airway inflammation in 
















Dirnberger E., Lucan H., Eichler H., Kastner J., Pernerstorfer T. and Jilma B. 1998 
Effects of nitroglycerin and sodium nitroprusside on endexpiratory concentrations of 
nitric oxide in healthy humans. Life Sciences 62(8): PL103-108. 
Djukanovic R., Roche W.R., Wilson J.W., Beasley C.R.W., Twentyman O.P., Howarth 
P.H. and Holgate S.T. 1990 Mucosal inflammation in asthma. American Review of 
Respiratory Disease 142: 434-457. 
Djukanovic R., Wilson J.W., Britten K.M., Wilson S.J., Walls A.F., Roche W.R., 
Howarth P.H. and Holgate S.T. 1992 Effect of an inhaled corticosteroid on airway 
inflammation and symptoms in asthma. American Review of Respiratory Disease 145: 
669-674 . 
Dupont L.J., Rochette F., Demedts M.G. and Verleden G.M, 1998 Exhaled nitric oxide 
correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma . 
American Journal of Respiratory and Critical Care Medicine 157(3 Pt 1): 894-898. 
duToit J.I., Anderson S.D., Jenkins C.R., Woolcock A.J. and Rodwell L.T. 1997 Airway 
responsiveness in asthma: Bronchial challenge with histamine and 4.5% sodium chloride 
before and after budesonide. Allergy and Asthma Proceedings 18( 1): 7-14. 
Ellis A. G. 1908 The pathological anatomy of bronchial asthma. American Journal of 
Medical Science 136: 407-429. 
Enarson D., Vedal S., Schulzer M., DyBuncio A. and Chan-Yeung M. 1987 Asthma, 
asthma-like symptoms, chronic bronchitis and the degree of bronchial 
hyperresponsiveness in epidemiological surveys. American Review of Respiratory 
Disease 136: 613-617. 
Eschenbacher W.L. and Gravelyn T.R. 1988 Mediator release after local osmolar 
challenge to the airways. Mechanisms in asthma: pharmacology, physiology, and 
management: 355-363. 
Fabbri L., Caramori G., Beghe B., Papi A. and Ciaccia A. 1998a Chronic obstructive 
pulmonary disease international guidelines. Current Opinion in Pulmonary Medicine 
4(2): 76-84. 
Fabbri L.M., Caramori G., Beghe B., Papi A. and Ciaccia A. 1998b Physiologic 
consequences of long-term inflammation. American Journal of Respiratory and Critical 
Care Medicine 157: S195-S198. 
Fahy J.V., Liu J., Wong H. and Boushey H.A. 1993 Cellular and biochemical analysis of 
induced sputum from asthmatic and from healthy subjects. American Review of 














Fahy J.V., Liu J., Wong H. and Boushey H.A. 1994 Analysis of cellular and biochemical 
constituents of induced sputum after allergen challenge - a method for studying allergic 
airway inflammation. Journal of Allergy and Clinical Immunology 93(6): 1031-1039. 
Fahy J.V., Wong H., Liu J. and Boushey H.A. 1995 Comparison of samples collected by 
sputum induction and bronchoscopy from asthmatic and healthy subjects. American 
Journal of Respiratory and Critical Care Medicine 152: 53-58. 
Fontijin A., Sabadell A.J. and Ronco R.J. 1970 Homogenous chemiluminescenct 
measurement of nitric oxide with ozone: implications for continuous selective monitoring 
of gaseous air pollutants. Annals of Chemistry 42: 575-579. 
Foresi A., Bertorelli G., Pesci A., Chetta A. and Olivieri D. 1990 Inflammatory markers 
in bronchoalveolar lavage and in bronchial biopsy in asthma during remission. Chest 98: 
528-535. 
Fuglsang G., Vikre-Jorgensen J., Agertoft L. and Pedersen S. 1998 Effect of salmeterol 
treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children 
with mild asthma. Pediatric Pulmonology 25: 314-321. 
Fujimoto K., Kubo K., Yamamoto H., Yamaguchi S. and Matsuzawa Y. 1999 
Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in 
patients with pulmonary emphysema. Chest 115(3): 697-702. 
Gabbay E., Fisher A.J., Small T., Leonard A.J. and Corris P.A. 1998 Exhaled single-
breath nitric oxide measurements are reproducible, repeatable and reflect levels of nitric 
oxide found in the lower airways. European Respiratory Journal11(2): 467-472. 
Gaston B., Drazen J.M., Loscalzo J. and Stamler J.S. 1994 The biology of nitrogen 
oxides in the airways. American Journal of Respiratory and Critical Care Medicine 149: 
538-551. 
Georges G., Bartelson B.B., Martin R.J. and Silkoff P.E. 1999 Circadian variation in 
exhaled nitric oxide in nocturnal asthma. Journal of Asthma 36(5): 467-473. 
Gershman N.H., Wong H.H., Liu J.T., Mahlmeister M.J. and Fahy J.V. 1996 Comparison 
of two methods of collecting induced sputum in asthmatic subjects. European Respiratory 
Journal9: 2448-2453. 
Gibson P.G., Girgis-Gabardo A., Morris M.M., Mattoli S., Kay J.M., Dolovich J., 
Denburg J. and Hargreave F.E. 1989 Cellular characteristics of sputum from patients with 
asthma and chronic bronchitis. Thorax 44: 693-699 . 
Gibson P.G., Wlodarczyk J.W., Hensley M.J., Gleeson M., Henry R.L., Cripps A.W. and 
















symptoms and airway hyperresponsiveness in childhood. American Journal of 
Respiratory and Critical Care Medicine 158(1): 36-41. 
Gibson P.G., Wong B.J.O., Hepperle M.J.E., Kline P.A., Girgis-Gabardo A., Guyatt G., 
et al. 1992 A research method to induce and examine a mild exacerbation of asthma by 
withdrawal of inhaled corticosteroid. Clinical and Experimental Allergy 22: 525-532. 
Gollasch H. 1889 Zur kenntniss der asthmatischen sputums. Fortschritte der Medizin 
(Berlin) 7: 361-365 . 
Gravelyn T.R., Pan P.M. and Eschenbacher W.L. 1988 Mediator release in an isolated 
airway segment in subjects with asthma. American Review of Respiratory Disease 137: 
641-646. 
Grootendorst D.C., Sont J.K., Willems L.N.A., KluinNelemans J.C., VanKrieken J., 
VeselicCharvat M. and Sterk P.J. 1997 Comparison of inflammatory cell counts in 
asthma: Induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clinical and 
Experimental Allergy 27(7): 769-779. 
Gustaffson L.E., Leone A.M., Persson M.G., Wiklund N.P. and Moncada S. 1991 
Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. 
Biochemical and Biophysical Research Communications 181(2): 852-857. 
Gutierrez V., Prieto L., Torres V., Morales C. and Gonzalez E. 1998 Peak flow variability 
and sputum eosinophilia in allergic rhinitis. Annals of Allergy, Asthma and Immunology 
81: 143-150. 
Guyatt G.H., Pugsley S.O., Sullivan M.J., Thompson P.J., Berman L.B., Jones N.L., 
Fallen E.L. and Taylor D.W. 1984 Effect of encouragement on walking test performance. 
Thorax 39: 818-822. 
Haley K.J. and Drazen J.M. 1998 Inflammation and airway function in asthma. What 
you see is not necessarily what you get. Editorial. American Journal of Respiratory and 
Critical Care Medicine 157: 1-3. 
Hamid Q., Springall D.R., Riveros-Moreno V., Chanez P., Howarth P., Redington A, et 
al. 1993 Induction of nitric oxide synthase in asthma. Lancet 342: 1510-1513. 
Hansel T. T. 1994 The cardinal importance of sputum microscopy. Clinical and 
Experimental Allergy 24: 695-697. 
Hargreave F.E. 1998 Induced sputum and response to glucocorticoids. Journal of Allergy 














Hargreave F .E. and Leigh R. 1999 Induced sputum, eosinophilic bronchitis, and chronic 
obstructive pulmonary disease. American Journal of Respiratory and Critical Care 
Medicine 160(5 Pt2): S53-7. 
Henriksen A.H., Sue-ChuM., Lingaas Holmen T., Langhammer A. and Bjermer L. 1999 
Exhaled and nasal NO levels in allergic rhinitis: relation to sensitization, pollen season 
and bronchial hyperresponsiveness. European Respiratory Journal13: 301-306. 
Hetzel M.R. and Clark T.J. 1980 Comparison of normal and asthmatic circadian rhythms 
in peak expiratory flow rate. Thorax 35: 732-738. 
Ho L.P., Innes J.A. and Greening A.P. 1998 Exhaled nitric oxide is not elevated in the 
inflammatory airways diseases of cystic fibrosis and bronchiectasis. European 
Respiratory Joumal12: 1290-1294. 
Ho L.P., Wood F.T., Robson A., Innes J.A. and Greening A.P. 2000 The current single 
exhalation method of measuring exhaled nitric oxide is affected by airway calibre. 
European Respiratory Journal 15: 1009-1013. 
Hofstra W.B., Neijens H.J., Duiverman E.J., Kouwenberg J.M., Mulder P.G.H., Kuethe 
M.C. and Sterk P.J. 2000 Dose-response over time to inhaled fluticasone propionate 
treatment of exercise- and methacholine-induced bronchoconstriction in children with 
asthma. Pediatric Pulmonology 29: 415-423. 
Hogman M., Stromberg S., Schedin U., Frostell C., Hendenstiema G. and Gustafsson 
L.E. 1997 Nitric oxide from the human respiratory tract efficiently quantified by 
standardized single breath measurements. Acta Physiologica Scandinavica 159: 345-346. 
Holz 0., Jorres R.A., Koschyk S., Speckin P., Welker L. and Magnussen H. 1998a 
Changes in sputum composition during sputum induction in healthy and asthmatic 
subjects. Clinical and Experimental Allergy 28(3): 284-292. 
Holz 0., Richter K., Jorres R.A., Speckin P., Mucke M. and Magnussen H. 1998b 
Changes in sputum composition between two inductions performed on consecutive days. 
Thorax 53(2): 83-86. 
Houston J.C., de Navasquez S. and Trounce J.R. 1953 A clinical and pathological study 
of fatal cases of status asthmaticus. Thorax 8: 207-213. 
Hummel S. and Lehtonen L. 1992 Comparison of oral-steroid sparing by high-dose and 
low-dose inhaled steroid in maintenance treatment of severe asthma. Lancet 340: 1483-
1487. 
Ichinose M., Takahashi T., Sugiura H., Endoh N., Miura M., Mashito Y. and Shirato K. 
2000 Baseline airway hyperresponsiveness and its reversible component: role of airway 














in't Veen J.C.C.M., Smits H.H., HiemstraP.S., Zwinderman A.E., Sterk P.J. and Bel E.H. 
1999 Lung function and sputum characteristics of patients with severe asthma during an 
induced exacerbation by double-blind steroid withdrawal. American Journal of 
Respiratory and Critical Care Medicine 160: 93-99. 
in't Veen J.C.C.M., Smits H.H., Ravensberg A.J.J., Hiemstra P.S., Sterk P.J. and Bel E.H. 
1998 Impaired perception of dyspnea in patients with severe asthma. American Journal of 
Respiratory and Critical Care Medicine 158: 1134-1141. 
Iredale M.J., Wanklyn A.R., Phillips I.P., Krausz T. and Ind P.W. 1994 Non-invasive 
assessment of bronchial inflammation in asthma: no correlation between eosinophilia of 
induced sputum and bronchial responsiveness to inhaled hypertonic saline. Clinical and 
Experimental Allergy 24: 940-945. 
Iwamoto J., Pendergast D.R., Suzuki H. and Krasney J.A. 1994 Effect of graded exercise 
on nitric oxide in expired air in humans. Respiration Physiology 97(3): 333-345. 
Jatakanon A., Kharitonov S., Lim S. and Barnes P.J. 1999 Effect of differing doses of 
inhaled budesonide on markers of airway inflammation in patients with mild asthma. 
Thorax 54(2): 108-114. 
Jatakanon A., Lim S. and Barnes P.J. 2000 Changes in sputum eosinophils predict loss of 
asthma control. American Journal of Respiratory and Critical Care Medicine 161 (1 ): 64-
72. 
Jatakanon A., Lim S., Chung K.F. and Barnes P.J. 1998a An inhaled steroid improves 
markers of airway inflammation in patients with mild asthma. European Respiratory 
Journal12(5): 1084-1088. 
Jatakanon A., Lim S., Kharitonov S.A., Chung K.F. and Barnes P.J. 1998 Correlation 
between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in 
patients with mild asthma. Thorax 53(2): 91-95. 
Jeffery P.K., Godfrey R.W., Adelroth E., Nelson F., Rogers A. and Johansson S.-A. 1992 
Effects of treatment on airway inflammation and thickening of basement membrane 
reticular collagen in asthma. American Review ofRespiratory Disease 145: 890-899. 
Jones S.L., Kittelson J.M., Cowan J.O., Flannery E.M., Hancox R.J., McLachlan C.R. 
and Taylor D.R. 2001 The predictive value of exhaled nitric oxide measurements in 
assessing changes in asthma control. American Journal of Respiratory and Critical Care 
Medicine 164: 738-743. 
Juniper E.F., Frith P.A. and Hargreave F.E. 1981 Airway responsiveness to histamine and 














Kamada A.K., Szefler S.J., Martin R.J., Boushey H.A., Chinchilli V.M., Drazen J.M., et 
al. 1996 Issues in the use of inhaled glucocorticoids. American Journal of Respiratory 
and Critical Care Medicine 153: 1739-1748. 
Kanazawa H., Shoji S., Yoshikawa T., Hirata K. and Yoshikawa J. 1998 Increased 
production of endogenous nitric oxide in patients with bronchial asthma and chronic 
obstructive pulmonary disease. Clinical and Experimental Allergy 28(10): 1244-50. 
Keatings V.M. and Barnes P.J. 1997 Granulocyte activation markers in induced sputum: 
Comparison between chronic obstructive pulmonary disease, asthma, and normal 
subjects. American Journal of Respiratory and Critical Care Medicine 155(2): 449-453. 
Keatings V.M., Evans D.J., O'Connor B.J. and Barnes P.J. 1997a Cellular profiles in 
asthmatic airways: A comparison of induced sputum, bronchiai washings, and 
bronchoalveolar lavage fluid. Thorax 52(4): 372-374. 
Keatings V.M., Jatakanon A., Worsdell Y.M. and Barnes P.J. 1997b Effects of inhaled 
and oral glucocorticoids on inflammatory indices in asthma and COPD. American 
Journal of Respiratory and Critical Care Medicine 155(2): 542-8. 
Kharitonov S.A., Alving K. and Barnes P.J. 1997a Exhaled nitric oxide measurements: 
recommendations. ERS Task Force Report. European Respiratory Journal 10: 1683-
1693. 
Kharitonov S.A. and Barnes P.J. 1997 Nasal contribution to exhaled nitric oxide during 
exhalation against resistance or during breath holding. Thorax 52(6): 540-544. 
Kharitonov S.A. and Barnes P.J. 2001 Does exhaled nitric oxide reflect asthma control? 
Yes it does! American Journal of Respiratory and Critical Care Medicine 164: 727-728. 
Kharitonov S.A., Cailes J.B., Black C.M., duBois R.M. and Barnes P.J. 1997b Decreased 
nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary 
hypertension. Thorax 52: 1051-1055. 
Kharitonov S.A., Chung K.F., Evans D., O'Connor B.J. and Barnes P.J. 1996a Increased 
exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. 
American Journal of Respiratory and Critical Care Medicine 153(6): 1773-1780 . 
Kharitonov S.A., Donnelly L.E., Corradi M., Montuschi P. and Barnes P.J. 2000 Dose-
dependent onset and duration of action of 100/400 meg budesonide on exhaled nitric 
oxide and related changes in other potential markers of airway inflammation in asthma . 












Kharitonov S.A., Logan-Sinclair R.B., Busset C.M. and Shinebourne E.A. 1994a Peak 
expiratory nitric oxide differences in men and women: relation to the menstrual cycle. 
British Heart Journal 72: 243-245. 
Kharitonov S.A., O'Connor B.J., Evans D.J. and Barnes P.J. 1995a Allergen-induced late 
asthmatic reactions are associated with elevation of exhaled nitric oxide. American 
Journal of Respiratory and Critical Care Medicine 151(6): 1894-1899. 
Kharitonov S.A., Robbins R.A., Yates D., Keating V. and Barnes P.J. 1995b Acute and 
chronic effects of cigarette smoking on exhaled nitric oxide. American Journal of 
Respiratory and Critical Care Medicine 152(2): 609-612. 
Kharitonov S.A., Sapienza M.A., Barnes P.J. and Chung K.F. 1998 Prostaglandins E-2 
and F-2alpha reduce exhaled nitric oxide in normal and asthmatic subjects irrespective of 
airway caliber changes. American Journal of Respiratory and Critical Care Medicine 158: 
1374-1378. 
Kharitonov S.A., Yates D. and Barnes P.J. 1995c Increased nitric oxide in exhaled air of 
normal human subjects with upper respiratory tract infections. European Respiratory 
JournalS: 295-297. 
Kharitonov S.A., Yates D., Robbins R.A., Logansinclair R., Shinebourne E.A. and 
Barnes P.J. 1994b Increased nitric oxide in exhaled air of asthmatic patients. Lancet 
343(8890): 133-135. 
Kharitonov S.A., Yates D.H. and Barnes P.J. 1996b Inhaled glucocorticoids decrease 
nitric oxide in exhaled air of asthmatic patients. American Journal of Respiratory and 
Critical Care Medicine 153(1): 454-457. 
Kharitonov S.A., Yates D.H., Chung K.F. and Barnes P.J. 1996c Changes in the dose of 
inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. European 
Respiratory Journal 9(2): 196-201. 
KilJlberly B., Nejadnik B., Giraud G.D. and Holden W.E. 1996 Nasal contribution to 
exhaled nitric oxide at rest and during breathholding in humans. American Journal of 
Respiratory and Critical Care Medicine 153: 829-836. 
Kips J.C., Fahy J.V., Hargreave F.E., Ind P.W. and in't Veen J. 1998a Methods for 
sputum induction and analysis of induced sputum: a method for assessing airway 
inflammation in asthma. European Respiratory Journal 11: 9S-12S. 
Kips J.C., Peleman R.A. and Pauwels R.A. 1998b Methods of examining induced 
sputum: do differences matter? European Respiratory Journal11(3): 529-533. 
Knox A.J., Morrison J.F.J. and Muers M.F. 1988 Reproducibility of walking tests results 
















Kraan J., Koeter G.H., van der Mark T.W., Boorsma M., Kukler J., Sluiter H.J. and Vries 
K.D. 1988 Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. 
American Review of Respiratory Disease 137: 44-48. 
Kraan J., Koeter G.H., van der Mark T.W. and Sluiter H.J. 1985 Changes in bronchial 
hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with 
allergic asthma: a comparison between budesonide and terbutaline. Journal of Allergy 
and Clinical Immunology 76: 628-636. 
Lacasse Y., Wong E., Guyatt G.H., King D., Cook D.J. and Goldstein R.S. 1996 Meta-
analysis of respiratory rehabilitatioon in chronic obstructive pulmonary disease. Lancet 
348: 1115-1119. 
Laitinen L.A., Laitinen A. and Haahtela T. 1993 Airway mucosal inflammation even in 
patients with newly diagnosed asthma. American Review of Respiratory Disease 147: 
697-704. 
Lambert R.K. and Pare P.D. 1997 Lung parenchymal shear modulus, airway wall 
remodelling, and bronchial hyperresponsiveness. Journal of Applied Physiology 83: 140-
147. 
Leitch A. G., Morgan A., Ellis D.A., Bell G., Haslett C. and McHardy G.J.R. 1981 Effect 
of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic 
bronchitis. Thorax 36: 787-789. 
Lemiere C., Pizzichini M.M.M., Balkissoon R., Clelland L., Efthimiadis A., 
O'Shaughnessy D., Dolovich J. and Hargreave F .E. 1999 Diagnosing occupational 
asthma: use of induced sputum. European Respiratory Journal 13(3): 482-488. 
Lensmar C., Elmberger G., Sandgren P., Skold C.M. and Eklund A. 1998 Leukocyte 
counts and macrophage phenotypes in induced sputum and bronchoalveolar lavage fluid 
from normal subjects. European Respiratory Journal 12(3): 595-600. 
Leuppi J.D., Salome C.M., Jenkins C.R., Anderson S.D., Xuan W., Marks G.B., et al. 
200 1 Predictive markers of asthma exacerbation during stepwise dose reduction of 
inhaled corticosteroids. American Journal ofRespiratory and Critical Care Medicine 163: 
406-412. 
Lim S., Jatakanon A., John M., Gilbey T., O'Connor B.J., Chung K.F. and Barnes P.J. 
1999 Effect of inhaled budesonide on lung function and airway inflammation -
assessment by various inflammatory markers in mild asthma. American Journal of 
















Lim S., Jatakanon A., Meah S., Oates T., Chung K.F. and Barnes P.J. 2000 Relationship 
between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to 
moderately severe asthma. Thorax 55(3): 184-88. 
Lipworth B.J. 1996 Airway and systemic effects of inhaled corticosteroids in asthma: 
dose response relationship. Pulmonary Pharmacology 9: 19-27. 
Lipworth B.J. and Wiilson A.M. 1998 Dose response to inhaled corticosteroids: benefits 
and risks. Seminars in Respiratory and Critical Care Medicine 19(6): 625-646. 
Little S.A., Chalmers G.W., MacLeod K.J., McSharry C. and Thomson N.C. 2000 Non-
invasive markers of airway inflammation as predictors of oral steroid responsiveness in 
asthma. Thorax 55(3): 232-4. 
Louis R., Lau L.C.K., Bron A.O., Roldaan A.C., Radermecker M. and Djukanovic R. 
2000 The relationship between airways inflammation and asthma severity. American 
Journal ofRespiratory and Critical Care Medicine 161: 9-16. 
Lundberg J.O.N., Weitzberg E., Lundberg J.M. and Alving K. 1996 Nitric oxide in 
exhaled air. European Respiratory Journal 9: 2671-2680. 
Lundberg J.O.N., Weitzberg E., Nordvall S.L., Kuylenstiema R., Lundberg J.M. and 
Alving K. 1994 Primarily nasal origin of exhaled nitric oxide and absence in kartageners 
syndrome. European Respiratory Journal 7(8): 1501-1504. 
Maestrelli P., Saetta M., Distefano A., Calcagni P.G., Turato G., Ruggieri M.P., Roggeri 
A., Mapp C.E. and Fabbri L.M. 1995 Comparison of leukocyte counts in sputum, 
bronchial biopsies, and bronchoalveolar lavage. American Journal of Respiratory and 
Critical. Care Medicine 152(6): 1926-1931. 
Magnussen H. and Holz 0. 1999 Monitoring airway inflammation in asthma by induced 
sputum. European Respiratory Journall3(1): 5-7. 
Magyar P., Dervaderics M. and Toth A. 1984 Bronchial challenge with hypertonic KCl 
solution in the diagnosis ofbronchial asthma. Schweiz. Med. Wochenschr. 114: 910-913. 
Marczin N., Riedel B., Royston D. and Yacoub M. 1997 Intravenous nitrate vasodilators 
and exhaled nitric oxide. Lancet 349: 1742. 
Marrow-Brown H. 1958 Treatment of chronic asthma with prednisolone. Significance of 
eosinophils in the sputum. Lancet ii: 1245-1247. 
Martin U., Bryden K., Devoy M. and Howarth P. 1996 Increased levels of exhaled nitric 
oxide during nasal and oral breathing in subjects with seasonal rhinitis. Journal of Allergy 












Massaro A.F., Gaston B., Kita D., Fanta C., Stamler J.S. and Drazen J.M. 1995 Expired 
nitric oxide levels during treatment of acute asthma. American Journal of Respiratory and 
Critical Care Medicine 152: 800-803. 
Mattes J., Gravesande K.S., Reining U., Alving K., Ihorst G., Henschen M. and Kuehr J. 
1999 NO in exhaled air is correlated with markers of eosinophilic airway inflammation in 
corticosteroid-dependent childhood asthma. European Respiratory Journal 13(6): 1391-
1395. 
Maxwell D.L., Atkinson B.A., Barros M. and Lee T.H. 1990 Histamine release in 
isolated large airway segments of normal and asthmatic subjects in vivo. Thorax 45: 
309P . 
Maziak W., Loukides S., Culpitt S., Sullivan P., Kharitonov S.A. and Barnes P.J. 1998 
Exhaled nitric oxide in chronic obstructive pulmonary disease. American Journal of 
Respiratory and Critical Care Medicine 157(3 Pt 1): 998-1002. 
McEvoy C.E. and Niewoehner D.E. 2000 Corticosteroids in chronic obstructive 
pulmonary disease. Clinical benefits and risks. Clinics in chest medicine 21 ( 4 ): 739-752. 
Metzger W.J., Richerson H.B., Worden K., Monick H. and Hunninghake G.W. 1986 
Bronchoalveolar lavage of allergic asthmatic patients following allergen 
bronchoprovocation. Chest 89: 477-483. 
Moody A., Fergusson W., Wells A., Bartley J. and Kolbe J. 2000 Increased nitric oxide 
production in the respiratory tract in asymptomatic pacific islanders: an association with 
skin prick reactivity to house dust mite. Journal of Allergy and Clinical Immunology 
105(5): 895-9. 
Morris N.H., CarrollS., Nicolaides K.H., Steer P.J. and Warren J.B. 1995 Exhaled nitric 
oxide concentration and amniotic fluid nitrite concentration during pregnancy. European 
Journal of Clinical Investigation 25(2): 138-141. 
Morris N.H., Sooranna S.R., Steer P.J. and Warren J.B. 1996 The effect of the menstrual 
cycle on exhaled nitric oxide and urinary nitrate concentration. European Journal of 
Clinical Investigation 26(6): 481-484 . 
Morris N.H., Steer P.J. and Warren J.B. 1994 Exhaled nitric oxide concentration is not 
influenced by the menstrual cycle. Journal of Physiology-London 477P: P34-P34. 
Morrowbrown H., Storey G. and George W.H.S. 1972 A new steroid aerosol for the 
treatment of allergic asthma. British Medical Journal 8: 110. 
NHLBIIWHO. 1995 NHLBIIWHO Workshop Report. Global initiative for asthma. 
Global strategy for asthma management and prevention, National Institutes of Health, 













Nightingale J.A., Rogers D .F. and Barnes P .J. 1998 Effect of repeated sputum induction 
on cell counts in normal volunteers. Thorax 53: 86-90. 
Nishimura K., Koyama H., Ikeda A., Tsukino M., Hajiro T., Mishima M. and Izumi T. 
1999 The effect of high-dose inhaled beclomethasone dipropionate in patients with stable 
COPD. Chest 115(1): 31-37. 
Norman V. and Keith C.H. 1965 Nitrogen oxides in tobacco smoke. Nature 205: 915-
916. 
Noseda A., Carpiaux J., Prigogine T. and Schmerber J. 1989 Lung function, maximum 
and submaximum exercise testing in COPD patients: reproducibility over a long interval. 
Lung 167: 247-257. 
Obata H., Dittrick M., Chan H. and Chan-Yeung M. 1999 Sputum eosinophils and 
exhaled nitric oxide during late asthmatic reaction in patients with western red cedar 
asthma. European Respiratory Journal 13(3): 489-495. 
O'Byrne P.M. and Pederson S. 1998 Measuring efficacy and safety of different inhaled 
corticosteroid preparations. Journal of Allergy and Clinical Immunology 102(6): 879-
886. 
O'Connor B.J., Ridge S.M., Barnes P.J. and Fuller R.W. 1992 Greater effect of inhaled 
budesonide on adenosine 5-monophosphate induced bronchoconstriction in asthma. 
American Journal ofRespiratory and Critical Care Medicine 146: 560-564. 
Oh J.W., Lee H.B., Kim C.R., Yum M.K., Koh Y.J., Moon S.J., Kang J.O. and Park I.K. 
1999 Analysis of induced sputum to examine the effects of inhaled corticosteroid on 
airway inflammation in children with asthma. Annals of Allergy Asthma and 
Immunology 82(5): 491-496. 
O'Reilly J.F., Shaylor J.M. and Harrison B.D.W. 1980 Week-to-week reproducibility of 
the twelve-minute walking test and its use in assessing the effects of oral steroid 
treatment in chronic airways obstruction. Thorax 35: 718. 
Palmer R.M.J., Ferrige A. G. and Moncada S. 1987 Nitric oxide release accounts for the 
biological activity of endothelium-derived relaxing factor. Nature 327: 524-526. 
Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., Ciaccia A. and 
Fabbri L.M. 2000 Parial reversibility of airflow limitation and increased exhaled NO and 
sputum eosinophilia in chronic obstructive pulmonary disease. American Journal of 













Parameswaran K., Pizzichini E., Hussack P., Efthimiadis A. and Hargreave F.E. 1998 
Clinical judgment of airway inflammation versus sputum cell counts in asthma. Journal 
of Allergy and Clinical Immunology 101(1): S116. 
Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B. and 
Ohlsson S.V. 1999 Long-term treatment with inhaled budesonide in persons with mild 
chronic obstructive pulmonary disease who continue smoking. European Respiratory 
Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of 
Medicine 340: 1948-1953. 
Pavord J.D., Pizzichini M.M.M., Pizzichini E. and Hargreave F.E. 1997 The use of 
induced sputum to investigate airway inflammation. Thorax 52(6): 498-501. 
Peat J.K., Salome C.M., Berry G. and Woolcock A.J. 1992 Relation of dose-response 
slope to respiratory symptoms and lung function in a population study of adults living in 
Busselton, Western Australia. American Review of Respiratory Disease 146: 860-865. 
Pederson S. and O'Byrne P. 1997 A comparison of the efficacy and safety of inhaled 
corticosteroids in asthma. Allergy 52 (Suppl39): 1-34. 
Pedroletti C., Zetterquist W.C., Nordvall S.L. and Alving K. 2000 Evaluation of different 
exhalation flow rates in exhaled nitric oxide (ENO) measured in schoolchildren 
[abstract]. European Respiratory Journal 16(Suppl. 31): 22s. 
Peleman R.A., Rytila P.H., Kips J.C., Joos G.F. and Pauwels R.A. 1999 The cellular 
composition of induced sputum in chronic obstructive pulmonary disease. European 
Respiratory Journal 13( 4 ): 839-43. 
Persson M.G. and Gustafsson L.E. 1992 Ethanol can inhibit nitric oxide production. 
European Jo.umal ofPharmacology 224(1): 99-100. 
Persson M.G., Zetterstrom 0., Agrenius V., Ihre E. and Gustafsson L.E. 1994 Single-
breath nitric oxide measurements in asthmatic patients and smokers. Lancet 343(8890): 
146-147. 
Phillips C.R., Giraud G.D. and Holden W.E. 1996 Exhaled nitric oxide during exercise: 
site of release and modulation by ventilation and blood flow. Journal of Applied 
Physiology 80(6): 1865-1871. 
Piacentini G.L., Bodini A., Costella S., Vicentini L., Mazzi P., Sperandio S. and Boner 
A.L. 1999 Exhaled nitric oxide and sputum eosinophil markers of inflammation in 
asthmatic children. European Respiratory Joumal13(6): 1386-1390. 
Piacentini G.L., Bodini A., Vino L., Zanolla L., Costella S., Vicentini L. and Boner A.L. 
1998 Influence of environmental concentrations of NO on the exhaled NO test. American 













Pin I., Freitag A.P., Obyrne P.M., Girgisgabardo A., Watson R.M., Dolovich J., Denburg 
J.A. and Hargreave F .E. 1992a Changes in the cellular profile of induced sputum after 
allergen induced asthmatic responses. American Review of Respiratory Disease 145(6): 
1265-1269. 
Pin I., Gibson P.G., Kolendowicz R., Girgisgabardo A., Denburg J.A., Hargreave F.E. 
and Dolovich J. 1992b Use of induced sputum cell counts to investigate airway 
inflammation in asthma. Thorax 47(1): 25-29. 
Pizzichini E., Pizzichini M.M., Gibson P., Parameswaran K., Gleich G.J., Berman L., 
Dolovich J. and Hargreave F.E. 1998 Sputum eosinophilia predicts benefit from 
prednisone in smokers with chronic obstructive bronchitis. American Journal of 
Respiratory and Critical Care Medicine 158: 1511-1517. 
Pizzichini E., Pizzichini M.M.M., Efthimiadis A., Evans S., Morris M.M., Squillace D., 
Gleich G.J., Dolovich J. and Hargreave F.E. 1996a Indices of airway inflammation in 
induced sputum: Reproducibility and validity of cell and fluid-phase measurements. 
American Journal of Respiratory and Critical Care Medicine 154(2): 308-317. 
Pizzichini M.M.M., Pizzichini E., Cleeland L., Efthimiadis A., Mahony J., Dolovich J. 
and Hargreave F.E. 1997 Sputum in severe exacerbations of asthma. Kinetics of 
inflammatory indices after prednisone treatment. American Journal of Respiratory and 
Critical Care Medicine 155: 1501-1508. 
Pizzichini M.M.M., Pizzichini E., Clelland L., Efthimiadis A., Pavord I., Dolovich J. and 
Hargreave F .E. 1999 Prednisone-dependent asthma: Inflammatory indices in induced 
sputum. European Respiratory Journal 13(1): 15-21. 
Pizzichini M.M.M., Popov T.A., Efthimiadis A., Hussack P., Evans S., Pizzichini E., 
Dolovich J. and Hargreave F .E. 1996b Spontaneous and induced sputum to measure 
indices of airway inflammation in asthma. American Journal of Respiratory and Critical 
Care Medicine 154(4): 866-869. 
Popov T.A., Pizzichini M.M.M., Pizzichini E., Kolendowicz R., Punthakee Z., Dolovich 
J. and Hargreave F.E. 1995 Some technical factors influencing the induction of sputum 
for cell analysis. European Respiratory Journal 8( 4 ): 559-565. 
Pryor J.A. and Webber B.A. 1979 An evaluation of the forced expiration technique as an 
adjunct to postural drainage. Physiotherapy 65(10): 304-307. 
Quanjer P.H., Tammeling G.J., Cotes J.E., Pederson O.F., Peslin R. and Yernault J.C . 
1993 Lung volumes and forced ventilatory flows. Report Working Party standardization 
of lung function tests, European Community for Steel and Coal. Official statement of the 










Rabone S.J., Phoon W.O., Anderson S.D., Wan K.C., Seneviratne M., Gutierrez L. and 
Brannan J. 1996 Hypertonic saline challenge in an adult epidemiological survey. 
Occupational Medicine 46(3): 177-185. 
Rankin J.A., Marcy T. and Rochester C.L. 1992 Human airway macrophages. American 
Review of Respiratory Disease 145: 928-933. 
Redelmeier D.A., Bayoumi A.M., Goldstein R.S. and Guyatt G.H. 1997 Interprerting 
small differences in functional status: the six minute walk test in chronic lung disease 
patients. American Journal of Respiratory and Critical Care Medicine 155: 1278-1282. 
Riedler J., Gamper A., Eder W. and Oberfeld G. 1998 Prevalence of bronchial 
hyperresponsiveness to 4.5% saline and its relation to asthma symptoms in Austrian 
children. European Respiratory Joumalll: 355-360. 
Riedler J., Reade T., Dalton M., Holst D. and Robertson C. 1994a Hypertonic saline 
challenge in an epidemiologic survey of asthma in children. American Journal of 
Respiratory and Critical Care Mdicine 150: 1632-1639. 
Riedler J., Reade T. and Robertson C.F. 1994b Repeatibility of response to hypertonic 
saline aerosol in children with mild to severe asthma. Pediatric Pulmonology 18: 330-
336. 
Robbins R.A., Floreani A.A., VonEssen S.G., Sisson J.H., Hill G.E., Rubinstein I. and 
Townley R.G. 1996 Measurement of exhaled nitric oxide by three different techniques. 
American Journal of Respiratory and Critical Care Medicine 153(5): 1631-1635. 
Robbins R.A., Millatmal T., Lassi K., Rennard S. and Daughton D. 1997 Smoking 
cessation is associated with an increase in exhaled nitric oxide. Chest 112(2): 313-318. 
Rodwell L.T., Anderson S.D., Dutoit J. and Seale J.P. 1992a Nedocromil sodium inhibits 
the airway response to hyperosmolar challenge in patients with asthma. American 
Review ofRespiratory Disease 146(5): 1149-1155. 
Rodwell L.T., Anderson S.D. and Seale J.P. 1992b Inhaled steroids modify bronchial 
responsiveness to hyperosmolar saline. European Respiratory JournalS: 781-790. 
Rutgers S.R., Meijer R.J., Kerstjens H.A.M., van der Mark T.W., Koeter G.H. and 
Postma D.S. 1998 Nitric oxide measured with single-breath and tidal-breathing methods 
in asthma and COPD. European Respiratory Joumal12: 816-819. 
Rutgers S.R., Postma D.S., ten Hacken N.H., Kauffman H.F., van Der Mark T. W., Koeter 
G.H. and Timens W. 2000 Ongoing airway inflammation in patients with COPD who do 












Rutgers S.R., van der Mark T.W., Coers W., Moshage H., Timens W., Kauffman H.F., 
Koeter G.H. and Postma D.S. 1999 Markers of nitric oxide metabolism in sputum and 
exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 54(7): 
576-80. 
Ryan G., Latimer K.M., Dolovich J. and Hargreave F.E. 1982 Bronchial responsiveness 
to histamine: relationship to diurnal variation of peak flow rate, improvement after 
bronchodilator and airway calibre. Thorax 37: 423-29. 
Saetta M. 1999 Airway inflammation in chronic obstructive pulmonary disease. 
American Journal ofRespiratory and Critical Care Medicme 160: S17-S20. 
Saetta M., Di Stefano A., Maestrelli P., Turato G., Ruggieri M.P., Roggeri A., et al. 
1994a Airway eosinophilia in chronic bronchitis during exacerbation. American Journal 
of Respiratory and Critical Care Medicine 150: 1646-1652. 
Saetta M., Di Stefano A., Rosina C., Thiene G. and Fabbri L.M. 1991 Quantitative 
structural analysis of peripheral airways and arteries in sudden fatal asthma. American 
Review of Respiratory Disease 143: 138-143. 
Saetta M., Finkelstein R. and Cosio M.G. 1994b Morphological and cellular basis for 
airflow limitation in smokers. European Respiratory Journal 7: 1505-1515. 
Salome C.M., Peat J.K., Britton W.J. and Woolcock A.J. 1987 Bronchial 
hyperrresponsiveness in two populations of Australian schoolchildren. Relation to 
respiratory symptoms and diagnosed asthma. Clinical Allergy 17: 271-81. 
Sapienza M.A., Kharitonov S.A., Horvath 1., Chung K.F. and Barnes P.J. 1998 Effect of 
inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects. Thorax 53: 
172-175. 
Schilling J., Holzer P., Guggenbach M., Gyurech D., Marathia K. and Geroulanos S. 
1994 Reduced endogenous nitric oxide in the exhaled air of smokers and hypertensives. 
European Respiratory Journal 7(3): 467-471. 
Searle S.R. 1992 Variance Components. New York, Wiley. 
Sharma V.S., Taylor T.G. and Gardiner R. 1987 Reaction of nitric oxide with haem 
protein and model compounds of haemoglobin. Biochemistry 26: 3837-3843. 
Sheffer A.L. 1992 International consensus report on the diagnosis and management of 
asthma. International asthma management project. Clinical and Experimental Allergy 











Silkoff P.E., Martin D., Pak J. and Martin R.J. 2000 Exhaled nitric oxide and induced 
sputum analysis as markers of airway inflammation in subjects with COPD. Chest 177: 
281S. 
Silkoff P.E., McClean P., Spino M., Erlich L., Slutsky A.S. and Zamel N. 2001 Dose-
response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled 
beclomethasone dipropionate therapy in asthma patients. Chest 119: 1322-1328. 
SilkoffP.E., McClean P.A., Slutsky A.S., Furlott H. G., Hoffstein E., Wakita S., Chapman 
K.R., Szalai J.P. and Zamel N. 1997 Marked flow-dependence of exhaled nitric oxide 
using a new technique to exclude nasal nitric oxide. American Journal of Respiratory and 
Critical Care Medicine 155(1): 260-267. 
SilkoffP.E., Wakita S., Chatkin J., Ansarin K., Gutierrez C., Caramori M., et al. 1999 
Exhaled nitric oxide after beta(2)-agonist inhalation and spirometry in asthma. American 
Journal of Respiratory and Critical Care Medicine 159(3): 940-944. 
Silkoff P.E. and Zamel N. 1998 Exhaled nitric oxide measurements in asthma: 
Techniques and interpretation. Seminars in Respiratory and Critical Care Medicine 19(6): 
569-580. 
Sippel J.M., Holden W.E., Tilles S.A., O'Hollaren M., Cook J., Thukkani N., Priest J., 
Nelson B. and Osborne M.L. 2000 Exhaled nitric oxide levels correlate with measures of 
disease control in asthma. Journal of Allergy and Clinical Immunology 106: 645-650. 
Smith C.M. and Anderson S.D. 1989 Inhalation provocation tests using non-isotonic 
aerosols. Review. Journal of Allergy and Clinical Immunology 84: 781-790. 
Smith C.M. and Anderson S.D. 1990 Inhalation challenge using hypertonic saline in 
asthmatic subjects: a comparison with responses to hyperpnoea, methacholine and water. 
European Respiratory Journal3: 144-151. 
Sont J.K., Han J., van Krieken J.M., Evertse C.E., Hooijer R., Willems L.N.A. and Sterk 
P.J. 1996 Relationship between the inflammatory infiltrate in bronchial biopsy specimens 
and clinical severity of asthma in patients treated with inhaled steroids. Thorax 51: 496-
502. 
Sont J.K., Willems L.N.A., Bel E.H., van Krieken J.H.J.M., Vandenbroucke J.P. and 
Sterk P.J. 1999 Clinical control and histopathologic outcomes of asthma when using 
airway hyperresponsiveness as an additional guide to long-term treatment. American 
Journal of Respiratory and Critical Care Medicine 159: 1043-1051. 
Spanevello A., Beghe B., Bianchi A., Migliori G.B., Ambrosetti M., Neri M. and Ind 
P.W. 1998 Comparison oftwo methods ofprocessing induced sputum: Selected versus 










Springall D.R., Meng Q.-H., Redington A., Howarth P.H., Evans T.J. and Polak J.M. 
1995 Inducible nitric oxide synthase in asthmatic airway epithelum is reduced by 
corticosteroid therapy. American Journal of Respiratory and Critical Care Medicine 151: 
A833. 
Stanescu D., Sanna C., Veriter S., Kostianev S., Calcagni P.G., Fabbri L.M. and 
Maestrelli P. 1996 Airways obstruction, chronic expectoration, and rapid decline of 
FEVI in smokers are associated with increased levels of sputum neutrophils. Thorax 51: 
267-271. 
Steele B. 1996 Timed walking tests of exercise capacity in chronic cardiopulmonary 
illness. Journal ofCardiopulmonary Rehabilitation 16: 25-33. 
Sterk P.J., de Gouw H., Ricciardolo F .L.M. and Rabe K.F. 1999 Exhaled nitric oxide in 
COPD: glancing through a smoke screen. Thorax 54(7): 565-567. 
Sterk P.J., Fabbri L.M., Quanjer P.H., Cockcroft D.W., O'Byrne P.M., Anderson S.D., 
Juniper E.F. and Malo J.L. 1993 Airway responsiveness. Standardized challenge testing 
with pharmacological, physical and sensitizing stimuli in adults. European Respiratory 
Journal6 (Suppl. 16): 53-83. 
Stirling R.G., Kharitonov S.A., Campbell D., Robinson D.S., Durham S.R., Chung K.F. 
and Barnes P.J. 1998 Increase in exhaled nitric oxide levels in patients with difficult 
asthma and correlation with symptoms and disease severity despite treatment with oral 
and inhaled corticosteroids. Thorax 53(12): 1030-1034. 
Swets J.A. and Picket R.M. 1982 Evaluation of Diagnostic Systems: Methods from 
Signal Detection Theory. New York, Academic Press. 
Taylor D.A., Jensen M.W., Kanabar V., Engelstatter R., Steinijans V.W., Barnes P.J. and 
O'Connor B.J. 1999 A dose-dependent effect of the novel inhaled corticosteroid 
ciclesonide on airway responsiveness to adenosine-5-monophosphate in asthmatic 
patients. American Journal of Respiratory and Critical Care Medicine 160: 237-243. 
ten Hacken N.H.T., van der Vaart H., van der Mark T.W., Koeter G.H. and Postma D.S. 
1998 Exhaled nitric oxide is higher both at day and night in subjects with nocturnal 
asthma. American Journal of Respiratory and Critical Care Medicine 158(3): 902-907. 
Toogood J.H., Lefcoe N.M., Haines D.S.M., Jennings B., Errington N., Baksh L. and 
Chuang L. 1977 A graded dose assessment of the efficacy of beclomethasone 
dipropionate aerosol for severe chronic asthma. Journal of Allergy and Clinical 
Immunology 59( 4): 298-308. 
Trigg C.J., Manolistas N.D., Wang J., Calderon M.A., McAulay A., Jordan S.E., et al. 




















corticosteroids in asthma. American Journal of Respiratory and Critical Care Medicine 
150: 17-22. 
Trolin G., Anden T. and Hedenstierna G. 1994 Nitric oxide (NO) in expired air at rest 
and during exercise. Acta Physiologica Scandinavica 151: 159-163. 
Troosters T., Gosselink R. and Decramer M. 2000 Short- and long-term effects of 
outpatient rehabilitation in patients with chronicobstructive pulmonary disease: a 
randmised trial. American Journal of Medicine 109: 207-212. 
Tunnicliffe W.S., Fletcher T.J., Chambers D.C. and Ayres J.G. 1996 Influence of 
breathhold on peak and plateau concentrations of nitric oxide in the exhaled air of adults. 
Thorax 51 (Suppl. 3): A17. 
van der Thoorn L.M., Prins J.-B., Overbeek S.E., Hoogsteden H.C. and de Jongste J.C. 
2000 Adolescents in clinical remission of atopic asthma have elevated exhaled nitric 
oxide levels and bronchial hyperresponsiveness. American Journal of Respiratory and 
Critical Care Medicine 162: 953-957. 
van Essen-Zandvliet E.E., Hughes M.D., Waalkens H.J., Duiverman E.J., Pocock S.J., 
Kerrebijn K.F. and CNSLD D. 1992 Effects of 22 months' treatment with inhaled 
corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and 
symptoms in children with asthma. American Review of Respiratory Disease 146: 547-
554. 
van Grunsven P.M., van Schayck C.P., Molema J., Akkermans R.P. and van Weel C. 
1999 Effect of inhaled corticosteroids on bronchial responsiveness in patients with 
"corticosteroid naive" mild asthma: a meta-analysis. Thorax 54: 316-322. 
van Rensen E.L.J., StraathofK.C.M., Veselic-Charvat M.A., Zwinderman A.H., Bel E.H. 
and Sterk P.J. 1999 Effect of inhaled steroids on airway hyperresponsiveness, sputum 
eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 54(5): 403-
408. 
van Schayck C.P., van Grunsven P.M. and Dekhuijzen P.N.R. 1996 Do patients with 
COPD benefit from treatment with inhaled corticosteroids? European Respiratory Journal 
9: 1969-1972. 
Vathenen A.S., Knox A.J., Wisniewski A. and Tattersfield A.E. 1991 Time course of 
change in bronchial reactivity with an inhaled corticosteroid in asthma. American Review 
of Respiratory Disease 143: 1317-1321. 
Verberne A.A.P.H., Frost C., Roorda R.J., van der Laag H., Kerrebijn K.F. and and The 
Dutch Paediatric Asthma Study Group. 1997 One year treatment with salmeterol 
compared with beclomethasone in children with asthma. American Journal ofRespiratory 





















Verleden G.M., Dupont L.J., Verpeut A.C. and Demedts M.G. 1999 The effect of 
cigarette smoking on exhaled nitric oxide in mild steroid-naive asthmatics. Chest 116(1): 
59-64. 
Vestbo J., Sorensen T., Lange P., Brix A., Torre P. and Viskum K. 1999 Long-term effect 
of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a 
randomised controlled trial. Lancet 535: 1819-1823. 
Welch M.J., Levy S., Smith J.A., Feiss G. and Farrar J.R. 1997 Dose-ranging study of the 
clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately 
severe asthma. Chest 112: 598-606 . 
Wilson A.M. and Lipworth B.J. 2000 Dose-response evaluation of the therapeutic index 
for inh.aled budesonide in patients with mild-to-moderate asthma. American Journal of 
Medicine 108: 269-275. 
Woolcock A.J., Peat J.K., Salome C.M., Yan K., Anderson S.D., Schoeffel R.E., 
McCowage G. and Killalea T. 1987 Prevalence of bronchial hyperresponsiveness and 
asthma in a rural adult population. Thorax 42: 361-368. 
Yates D.H., Kharitonov S.A. and Barnes P.J. 1997 Effect of short- and long-acting 
inhaled beta 2-agonists on exhaled nitric oxide in asthmatic patients. European 
Respiratory Journal 1 0(7): 1483-1488. 
Yates D.H., Kharitonov S.A., Robbins R.A., Thomas P.S. and Barnes P.J. 1995 Effect of 
a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. 
American Journal of Respiratory and Critical Care Medicine 152: 892-896 . 
Yates D.H., Kharitonov S.A., Robbins R.A., Thomas P.S. and Barnes P.J. 1996a The 
effect of alcohol ingestion on exhaled nitric oxide. European Respiratory Journal 9(6): 
1130-1133. 
Yates D.H., Kharitonov S.A., Thomas P.S. and Barnes P.J. 1996b Endogenous nitric 
oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. 
American Journal of Respiratory and Critical Care Medicine 154(1): 247-250 . 
Zapol W.M., Rimar S., Gillis N., Marietta M. and Bosken C.H. 1994 Nitric oxide and the 
lung. NHLBI Workshop Summary. American Journal of Respiratory and Critical Care 


























This thesis is based on work performed while I was Respiratory Research Fell ow in the 
Department of Respiratory Medicine, Dunedin School of Medicine, University of Otago. 
It represents two years of full time data collection and further two-and-a-half years of 
part-time writing up. 
Current publications in peer-reviewed journals include: 
Jones S.L., Kittelson J.M., Cowan J.O., Flannery E.M., Hancox R.J., McLachlan C.R. 
and Taylor D.R. 2001 The predictive value of exhaled nitric oxide measurements in 
assessing changes in asthma control. American Journal of Respiratory and Critical Care 
Medicine 164: 73 8-7 43. (a copy of this paper and the editorial accompanying it follows) 
Jones S.L., Herbison P., Cowan J.O., Flannery E.M., Hancox R.J., McLachlan C.R., 
Taylor D.R. 2002 Exhaled NO and assessment of anti-inflammatory effects of inhaled 
steroid: dose-response relationship. European Respiratory Journal20: 601-608. (a copy of 
this paper follows) 
Conference proceedings in which data has been presented are: 
Jones S.L., Kittelson J.M, Cowan J.O., McLachlan C.R., Flannery E.M., Hancox R.J., 
and Taylor D.R. 2000 Exhaled nitric oxide in stable asthma- week to week variation and 
correlation with other inflammatory markers. European Respiratory Journal 16 
(supplement 31): 534s. 
Jones S.L., Kittelson J.M, Cowan J.O., McLachlan C.R., Flannery E.M., Hancox R.J., 
and Taylor D.R. 2000 Exhaled nitric oxide as a predictor of deteriorating asthma. 















The Predictive Value of Exhaled Nitric Oxide 
Measurements in Assessing Changes in 
Asthma Control 
STUART L. JONES, JOHN KITTELSON, JAN 0. COWAN, ERIN M. FLANNERY, ROBERT J. HANCOX, 
CHRISTENE R. MCLACHLAN, and D. ROBIN TAYLOR 
Department of Medical and Surgical Sciences and Department of Preventive and Social Medicine, Dunedin School of Medicine, University of 
Otago, Dunedin, New Zealand 
Exhaled nitric oxide (eNO) levels are increased in untreated or un-
stable asthma and measurements can be made easily. Our aim was 
to assess the usefulness of eNO for diagnosing and predicting loss 
of control (LOC) in asthma following steroid withdrawal. Compar-
isons were made against sputum eosinophils and airway hyperre-
sponsiveness (AHR) to hypertonic saline (4.5%). Seventy-eight pa-
tients with mild/moderate asthma had their inhaled steroid therapy 
withdralll!n until LOC occurred or for a maximum of 6 wk. Sixty 
(77.9%) developed LOC. There were highly significant correlations 
between the changes in eNO and symptoms (p < 0.0001), FEV1 (p < 
0.002), sputum eosinophils (p < 0.0002), and saline PD15 (p < 
0.0002), and there were significant differences between LOC and 
no LOC groups. Both single measurements and changes of eNO 
(10 ppb, 15 ppb, or an increase of> 60% over baseline) had posi-
tive predictive values that ranged from 80 to 90% for predicting 
and diagnosing LOC. These values were similar to those obtained 
using sputum eosinophils and saline PD 1s measurements. We con-
clude that eNO measurements are as useful as induced sputum 
analysis and AHR in assessing airway inflammation, with the ad-
vantage that they are easy to perform. 
Keywords: asthma; exacerbation; nitric oxide; eosinophils; bronchial 
provocation tests 
Nitric oxide is a key messenger for cell to cell signaling. and 
has an important role in the biochemistry of intlammation (!. 
:::). Exhaled nitric oxide ( e:--10) has been confirmed as a marker 
nf airway intlammalion and is present in higher concentra-
tions in steroid-naive asthma compared with normal control 
subjects (3 ). Higher levels of eNO are seen during asthma ex-
acerbations (~).and decreases occur following treatment with 
both inhaled (5) and systemic corticosteroids ( 6 ). Furthermore 
eNO appears to be sensitive to changes in antiinflammatory 
treatment. even in the absence of changes in lung function (7). 
These findings suggest that eNO may be a useful indicator in 
the longitudinal assessment of asthma control. 
Both induced sputum cell counts Pl) and responsiveness to 
h~pt:rtonic salint: challenge (HSCl IY) have also been investi-
gated as markers of airway inllammation in asthma. Sputum 
.:osinophil numbers increase during asthma exacerbations ( 10). 
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Conversely. a decrease in the percentage of sputum .:osinophils 
occurs following prednisone treatment ( ll ), and after commenc-
ing inhaled corticosteroid (ICS) (12). Du Toit and coworkers 
have demonstrated a progressive reduction in responsiveness 
to HSC following initiation of ICS treatment ( L\ ). However. 
the scope for using these techni4ues to monitor asthma con-
trol in clinical practice is limitt:d by the resources re4uired for 
repeatt:d measurements. In contrast the measurement ,,f eNO is 
4uick and easy to perform. thus lending itself to repeated mea-
surements over time. Although single measurements of eNO 
have been used to assess airway inflammation in asthma ( 14-17). 
the usefulness of eNO in the longitudinal assessment of asthma 
control has not been extensively investigated. To be clinically 
useful eNO would need to correlate with known markers of 
asthma control as well as airway inllammation. and be respon-
sive to changes in these parameters over time. If this were the 
case. then eNO measurements could be used to confirm poorly 
controlled asthma and to predict imminent deterioration. There 
might also he a role for eNO in optimizing antiinllammatory 
therapy such as has been done using measurements of airway 
hyperresponsiveness (AHR) ( lR). 
The aim of our study was to evaluate the predictive and di-
agnostic value of eNO in unstable asthma and to .:orrelate this 
;ith sputum eosinophils and AHR to hypertonic saline. Csing 
a model of steroid withdrawal described by Gibson and co-
workers ( 19). we aimed to induce a deterioration in asthma 
control in the majority uf patients thus enabling us to assess 




Patients with mild to moderate asthma. confirmed at our research 
screening clinic using A TS criteria (20). and who had heen taking ICS 
tht!rapy for at lt!ast 6 rna were r~cruitcJ. The Jme uf lCS was un-
changed for at kast 6 wk. Patients "ere excluded 1 h~causc the study 
involved withdrawal of ICS treatment) if thev had a historv of ~cute 
asthma requiring hospital admission. asthma ~haracterized hy sudden 
attacks. or used oral prednisont! Juring tht! previous 3 mo. 
Study Design 
ICS treatment was stopped following a 2- to 4-wk run-in during which 
tht: maintenance dose remained unchanged. Patients were then re-
viewed weekly until loss of control (LOC) developed or for a maxi-
mum of 6 wk. When LOC occurred. patit!nts were seen within 2.:1 h. 
The 'lSi! at which !CS therapy \\as 'topped was designJteJ visit I. the 
final visit of the study was designated visit F. and the visit immt!diately 
prior to the final visit was designated visit P (penultimate). 
Criteria for LOC were as follows: 
I. A fall in the mean ( ovt!r last 7 d) morning peak expiratory flow rate 
( PEFR) of greater than 1 O'l'o from bast!line. or a fall in either morn-
ing or evening PEFR on two consecutive days to 80% of baseline 
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' Mean daily bronchodilator use of greater than three puffs more 
than during run-in. or 
3. :"i<.lctumal ~ wak~n ing with asthma ;ymptclmS em three nights or 
more per week greater than during the run-in. or 
-l. Asthma symptoms that were disagr~.:ahlc or distressing. 
Study Procedures 
Diurnal PEFR. hronchc.lJilaLOr us.:. and >ymptom >cor<:s were ;~­
curded in a Jailv record card. Measurements c>btained Jt each study 
v1sit are shown in Tabk I. ~NO was measured prior to all other study 
procedures using a calibrated chemiluminescence analyzer with on-
line measun:mcnt of single exhalations according to a standard proto-
col (21. 22). with the exception of flow rate (250 mVs). eNO levels 
w~re read at the plateau corresponding to 7!h~O% of the C01 curve. 
Spirom~try was measured using a rolling seal spirometer. 
AHR to hypertonic saline (-1.5%) was measured using a modified 
standardized protocol (23. 24 ). Spirometry was performed I min aft~r 
saline n~bulization. and patients were ~ncouraged to produce sputum 
hetw~en inhalations. The challenge was discontinued wh~n a 20% fall 
in FEY1 occurred clr a cumulative inhalation time of 20 min was 
rc<Kh~d. Th~ PD1., was calculated as the cumulative dose of saline 
causing a 15% fall in FEY,. · 
[fa 20% fall in FEV1 occurred salhutamol was administered and 
sputum induction continued until an adequate sputum sample was ob-
tained. The whole specimen (sputum plus saliva) was analyzed using a 
standardised method (25). Cell viability was assessed by the trypan 
hlue exclusion test. and a cell count was pcrfc>rmcd by hcmocvtome-
tcr. Cytospin slides wer~ stained with Mav-Grunwald-Giemsa stain 
and " total of 400 nons4uamous cdls were countt:d on two occasions. 
Where the difference he tween the two counts was greater than I tl% for 
any .:ell type then the count was repeated twic:e more <Jnd the mean 
for all four was recorded. 
Ethical Considerations and Safety 
Each patient's asthma control was monitored closely throughout the 
study. All patients were provided with an individualized self-manage-
ment plan. an emergency card. and a supply of prednisone tablets. Pa-
tients had 2+-h access to one of the study inve'lig<Jtms via the hospital 
paging system. For ~thical reasons. LOC c:ritena mcludcd svmptclms 
that were Jisagreeahle or distressing irrespective: ,,f PEfR chan~cs. 
Ethical approval was obtained from 1 he Otago Eth1cs Committee and 
mformed consent was obtamed fn>m dll study participants. 
Statistical Analysis 
Sources of variabilitv in cNO measurements during run-in were esti-
mated using variance components methods (26 ).~ Associations be-
tween eNO and other measurements were analyzed using the rank 
corr-elation coefficient because it does not depend nn the measure-
ment scale. Regression methods were used to compare airway in flam-
TABLE 1. MEASUREMENTS OF EXHALED NITRIC OXIDE, 
SPIROMETRY, HYPERTONIC SALINE CHALLENGE, AND SPUTUM 
ANALYSIS AT VARIOUS STUDY VISITS• 
Visit Number 










Definition of abbreviations: eNO -= exhaled nitric oxide; F = final; HSC = hypertoniC 
~aline challenge; tCS ..,. inhaled corticosteroid; LOC -=- loss of control; p -= penultimate; 
R ,-= run-in; V -=- vis1t. 
.. The number of visits between V1 and VF was variable. 
t Inhaled steroid was discontinued dt VI. 
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mation parameters in patients who lost control with those who did 
not. and to adjust the comparisons for ha~eline diffe:·~nces. The prog-
n<1Sl1C Jnd diagnostic unlity of eNO w:Ls evaluated '-lnd compared with 
other measures using methoJs for constructing receiver-operator 
characteristic (ROC) curves (27). Exhaled nitric oxide and PD15 mea-
surements were analyzed using logarithmic transformations to re-
move the skew in these data: other measur~ments were analyzed 
without transformation. The results of these analvses did not change 
following t.he transformations. . -
RESULTS 
Run-in Data 
Seventy-eight patients entered the study. Demographic data 
are given in Table 2. The mean eNO during run-in was 9.38 ppb 
(95% reference range 2.72-32.35). The coefficients of variation 
for eNO were measured over four visits during the run-in phase 
of the study. The within-patient within-sitting coeflicient of vari-
ation was 4.1% and the within-patient between-sitting varia-
tinn was W.5%. eNO was not related to ambient NO (range 
U-234 ppb. p = 0.23) and so no corrections were made for am-
bient NO measurements. 
Loss of Control 
Sixty patients (77.9%) developed loss of c:ontrul according to 
predetermined study criteria. The median time to LOC was 17 d 
(<l5% C1: 14. 2H). Twenty-two patients developed LOC within 
1 wk of corticosteroid withdrawal. The frequencies with which 
LOC criteria were met were fall in PEFR . .ftl: increased bron-
chodilator use. 15: increased nocturnal wakin!!. Ill: distressing 
symptoms. 39. Nine patients had LOC on the basis of distress: 
ing symptoms alone. two on the basis of increased reliever use 
alone. Thirty-two patients fulfilled two or more criteria at the 
time of LOC. Sputum induction was performed m all patients 
at visits I and F. Adequate sputum samples were ohtained in 
71 of 77 patients at visit I (92'~{,). and m 54 /9!1"<,) and 15 
!H8%) of the LOC and no LOC groups at visit F. re'ipt:.:tively. 
The LOC group experienct:d a 2.lli-fold increase in eNO 
hetween visits I and F. which was significantly greater than the 
1.-1-4-fold increase for the no LOC group ( p ~ 0.004) (Table 3 ). 
There were also significant differences between LOC and no 
LOC groups for the fall in mean morning PEFR ( 13% versus 
1%. p < O.O()(Jl) the decrease in FEV 1 (mean fall of 11.9% 
predicted compared to 2.6% predicted. p = ().()()!). the in-
crease in sputum eosinophils (4.73-fold increase compared with 
2.tl5-fold. p .= U.ll-1-4 ). and the decrease in saline PD 1, (0.8 dou-
bling doses compared with 0.03 douhling doses. p = 0.001). 
TABLE 2. DEMOGRAPHIC DATA FOR STUDY POPULATION MEANS• 
Number of patients. n 
Male:female 
Age, yr 
Duration of asthma, yr 
Skin test positive, n 
Ex-smokers:nonsmokers 















(range 1 00-1600) 
2.88 12.10, 3.06) 
92.0 (81.9, 96.1) 
71.0 (68 3, 73.7) 
• Unless stated otheiWise, figures in parentheses are 95% confidence intervals. Ex-
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TABLE 3. COMPARISONS BETWEEN LOC AND NO LOC GROUPS* 
LOC NoLOC 
in~ 60) (n ~ 17) p Value 
FEV,,% pred 
Visit 1 89.6 102.1 0.015 
(84.7, 94 5) (944. 109.8) 
·,.,..iSil F 77 7 :o1 !J 0.0001 
(72.5, 82.9) (92.2. 109 9) 
Change -11.9(-15.2, -8 7) -: 1 (-3.3, U) 0.0003 
(VF-V1) 
eNO, ppb 
Visit 1 9.67 8.34 0.39 
(8.18, 11.43) (6. 36, 1 0.94) 
Visit F 20.85 11.98 0.008 
(17.15, 25.34) (8.48, 16.91) 
Change 2.16 1.44 0.004 
(VFiV1) (1.88, 2.48) (1.13, 1.82) 
Sputum eosinophils, % 
Vis1t 1 4.6 (1.8, 7.3) 3.9 (0.2. 7.7) 0.83 
Visit F 18.9 6.8 0.050 
(12.6, 25.1) (1.6, 12.1) 
Change 14.3 3.3 0.067 
!VF-V1) (8.0, 20.6) (-U, 8.0) 
PD 15 saline, ml 
Visit 1 10.9 13.8 0.37 
(8.40, 14.23) (9. 30, 20.35) 
Visit F 6.2 14 0 0.006 
(4.53, 8.47) (9.12, 21.56) 
Change (d.d.) -0.80 0.03 0.010 
(-1.18, -0.42) (-0.33, 0.28) 
Defimtion 0f atJbreviOCJons: d.d. = doubling aose change 1n PO,~ tram visit 1 to visit F; 
eNO """ exhaled mtic oxide; LOC -= loss of control; PO. 5 - dose of saline causing a 15% 
fall in FEV1• 
*Comparison between groups for eNO, FEV1 % pred, percentage eosinophils, and 
saline PO, 5 values measured at visit 1 and visit F. Arithmetic means (and 95% Cl) are 
reported for FEV1 % pred and percentage eos1nophils. Geometric means (and 95% Cl) 
are reported for eNO and PO, 5• 
Correlations between Study End Points 
There were highly significant correlations between the changes 
in eNO that occurred between visits I and F and the changes in 
-;ymptoms. lung function. sputum cosinophils. and AHR to HSC 
that occurred over the same period (Table 4). In general. the 
correlations between single measurements of eNO and these 
same parameters were lo~er than those seen 'l'.ith changes over 
time and were not consistently significant (Table 4). 
Predictive and Diagnostic Values 
The ability of eNO measurements to predict upcoming LOC 
was assessed in three ways: first. using the baseline eNO mea-
surement (visit l ). second. using the measurement of eNO at 
the visit immediately prior to LOC (the penultimate visit. visit 
P), and third, using the change in eNO that occurred between 
visit 1 and visit P. Analysis of receiver-operator curves (ROCs) 
demonstrated parity between these different approaches. The 
curves were similar whether absolute or proportional changes 
in cNO were used. The st:nsitivities. specificities. and positive 
and negative predictive values at relevant cut points also showed 
that nn cme prognostic indicator was clearly superior (Table 
5). Specific cNO cut points evaluated included 10 ppt. 15 ppb. 
and a oO% increase over the baseline mean (the upper limit of 
the 95% reference range for weekly variation in e:"'O over the 
run-in period). 
The prognostic utility of eNO was also compared with other 
indices of airway intlammation. specifically single measurements 
of responsiveness to hypertonic saline ( PD 15 less than 12 ml) 
and sputum eosinophils (greater than 4%) obtained at visit 1 
(Figure I. top panel. and Table 5). Compared with eNO. no mea-
surement was clearly superior. Similarly. the prognostic value of 
changes in FEY 1% predicted. daily PEFR variation. symptom 
scores. and bronchodilator use between visit I and visit P was 
evaluated. None of these clinical parameters was found to be 
superior to eNO in predicting LOC (Figure I. bottom panel). 
The ability of eNO to diagnose LOC was also assessed us-
ing eNO measurements at visit F (Table 6). Both the single 
measurements of eNO at visit F and the chan!!c h.:tween visit 
I and visit F were evaluated. As for the asse~smenl of prog-
nosTic utility. there was no clearly superior eNO measurement. 
and the performance of eNO was comparable to that based on 
sputum eosinophil counts and saline PD 15 measurements. 
DISCUSSION 
This is the largest longitudinal study to date in which the util-
ity of eNO measurement in asthma management has been as-
sessed. Our results document the usefulness of c!'IO for pre-
dicting and diagnosing poorly controlled asthma compared 
with other currently used markers of airway inflammation and 
clinical parameters. Regardless of the way in which eNO mea-
surements were analyzed (absolute values. absolute changes. 
or proportional changes from baseline) the results were simi-
lar. cNO was associated with a positive predictive value (PPV) 
of between 1\0 and 90% for predicting and diagnosing LOC 
On the whole. changes in eNO over time had higher PPV. sen-
sitivities. and specificities both for predicting and diagnosing 
LOC than did single measurements. For example. an increase in 
eNO between visit I and visit P of more than 60% over base-
line had a PPV for predicting LOC of 83% (sensitivity 50%. 
specificity 65% ). A similar increase between visit I and visit F 
had a PPV for diagnosing LOC of 87% (sensitivity 68%. spec-
ificity 65% ). In comparison. for a single measurement of 
greater than 15 ppb obtained at visit I. when patients were still 
TABLE 4. RANK CORRELATIONS BElWEEN EXHALED NITRIC OXIDE (eNO) AND OTHER MEASURES OF 
ASTHMA CONTROL AND AIRWAY INFLAMMATION MEASURED AT VISIT F AND BETWEEN THE CHANGES 
IN eNO (VISIT 1 TO VISIT F) AND THE CHANGES IN EACH OF THE OTHER PARAMETERS 
Visit F Changes between Visits 1 and F 
Rank Rank 
Correlation 95%CI p Value Correlation 95%CI p Value 
FEV1,% pred -0.20 -0.41, 0.02 0.079 -0.35 -0.53, -0.14 0.0017 
Morning peak flow 0.14 -0.09, 0.35 0.23 -0.43 -0.60, -0.23 0.0001 
Bronchodilator use 0.19 -0.04, 0.39 0.1 0.23 0.00, 0.43 0.05 
Symptom score 0.33 0.11,0.51 0.0039 0.45 0.25, 0.61 0.0001 
Sputum eosinophils 0.62 0.44, 0]4 < 0.0001 0.44 0.23, 0.62 0.0002 
PD15 saline -0.41 -0.6, -0.18 0.0008 -0.45 -0.63, -0.23 0.0002 
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TABLE 5. PREDICTING LOSS OF CONTROL* 
Sensitivity Specificity 
eNO at visit 1 
> 10 ppb 0.50 0.53 
·0.37. 0.63) \0.28. 0.7!) 
:-15 ppb 0.25 0.88 
(0.15, 0.38) (0.64, 0.99) 
eNO at visit P 
> 10 ppb 0.65 0.41 
(0.52, 0.77) (0.18, 0.67) 
.., 15 ppb 0.50 0.65 
(0.37, 0.63) (0.38, 0.86) 
Change in eNO from 
visit 1 to visit P 
.l > 10 ppb 0.27 0.76 
(0.16, 0.40) (0.50, 0.93) 
.l > 60% 0.50 0.65 
(0. 37, 0.63) (0.38, 0.86) 
Percentage eosinophils 
at visit 1 
·4% 0.21 0.80 
(0.12, 0.34) (0.52, 0.96) 
Saline PD 15 at visit 1 
o 12 ml 0.53 0.50 
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Definition of aobrev,anons: eNO -= exhaled nitric oxide; PO 1 ~ -- dose of saline causing 
a 15% tall in FEV .. 
• The preoictive values of single measurements ot eNO, percentage eosinophils, and 
saline PO,~ measured Jt viSit 1 and tfor eNO) at the visit 1mmediatel!' prior to loss of 
control (LOC) (visit P) in distinguishing those who went on to develop LOC from those 
who did not. The predictive values for the changes in eNO between visit 1 and visit P 
are also given. Sputum induction and hypertonic saline challenge were not carried out 
at visit P. Figures in parentheses are 95% confidence intervals. 
taking inhaled steroids, the PPY was 88% (sensitivity 25%, 
specificity 8il'Yo) for predicting LOC within 1 wk. 
Overall. using the cut points selected. these outcomes retlect 
poor sensitivity but good specificity for e~O measurements. 
:--Jevertheless, they compare favourably with the usefulness of 
the other. more elaborate techniques of sputum induction and 
hypertonic saline challenge used in this study to assess deteri-
orating asthma. For example, we found that a doubling dose 
increase in saline PD 15 was marginally bener than the other mea-
surements for diagnosing LOC with a PPV of95% (sensitivity 
41%, specificity 94%). This compared with a PPY of 84% for 
a 4% change in eosinophils (sensitivity 51%, specificity 64%) 
and with a PPV of 91% for an increase in eNO from baseline 
to LOC of 10 ppb (sensitivity 48%, specificity 82%). However. 
as a procedure. measuring eNO has the advantage of being 
quick and easy to perform, making it a suitable test for use in 
the clinical rather than the research setting. This becomes all 
the more important given our tinding that changes in eNO 
have higher sensitivity and specificity for changes in clinical 
status than do single measurements. implying the need for re-
peated tests. Interestingly, eNO proved to be comparable to 
other more conventional measurements such as FEY1, peak 
flows, symptom score. or daily reliever use in predicting up-
coming LOC (see Figure I) despite the fact that some of these 
other parameters were used in the ddinition of LOC. 
Our results conlirm earlier lindings that eNO levels are ele-
vated in unstable asthma (4, 6), and point to it as being a useful 
marker of airway inflammation. Previous studies have yielded in-
consistent data regarding the correlation between eNO and spu-
tum eosinophils because of the confounding effect of inhaled ste-
roid use ( 15, 16, 28). This was not the case in the present study in 
which data were obtained from patients in whom maintenance 
inhaled steroid therapy had been temporarily withdrawn. Highly 
741 
-;ignificant correlations between eNO and sputum eosinophils 
1 rank correlation 0.62. p < O.!XX)I) and saline PD 15 (rank correla-
tion -0.41. p < 0.0008) at a single point in time (visit F) were ob-
tained. although the correlations for symptoms and lung function 
were nonsignificant (see Table 4). More importantly. when mea-
sured longitudinally the changes in eNO correlated signiticantly 
not only with changes in the other markers of Jirway inflamma-
tion but also with measurements of airway caliber Jnd symptoms 
!see Table 4). These findings provide additioml support for the 
use of eNO measurements as a tool in the assessment of airw:~y 
inllammation and long-term asthma controL 
Our study was designed to assess the usefulness of eNO in 
a clinical context. For this reason, loss of control criteria were 
prospectively based on a combination of peak flow and symp-
tom changes as used in clinical practice. Evidence that these 
criteria were relevant and appropriate is provided by the sig-
nificantly greater changes in FEV 1• sputum eosinophils, and 
saline PD 1, seen in the LOC group. Thus the subsequent com-
parisons between LOC and no LOC groups were valid. Dur-
ing our studv eNO was measured using an exhalation !low rate 
<){250 mils, -;,_,hich is significantlY mor~ than current guidelines 
suggest (22). Our study was co.mmenced before these guide-
lines were published. eNO has been shown to be tlow depen-
dent (29). and at lower !low rates the differences between 
healthv and'asthmatic individuals are increased (30). Thus it is 
possible that at a lower expiratory !low rate (e.g .. 50 mVs) dif-
ferences between patients who did and did not experience 
LOC might have been greater. If this were the case. then the 
sensitivities and specificities for eNO as a diagnostic test may 
be better than we have reported. , 
A number of investigators have sought to evaluate the role 
of eNO in assessing long-term asthma controL In the present 
study we chose to withdraw ICS in an attempt to induce a de-
terioration in asthma control and mimic an exacerbation. This 
implies that our findings may not strictly apply to patients re-
ceiving maintenance ICS. However. the usefulness of eNO in 
the presence of ICS is supported by Stirling and coworkers 
who found higher levels of eNO in patients with greater asthma 
severity irrespective of steroid use ( 17). Further. Kharitonov 
and coworkers have demonstrated that a simple reduction in 
the dose of ICS increases eNO (7) even in the ahsence of sig-
nificant change in peak flow variability or spirometry. Using a 
study design similar to our own, hut with incomplete with-
drawal of ICS, Jatakanon and colleagues (31) reduced the dose 
of inhaled budesonide to 200 !J.g/day (less than one-fourth of 
the usual maintenance dose) in 15 patients with asthma. 
Patients were followed for a maximum of 8 wk. Just under 
half developed an exacerbation. There was a parallel increase in 
e~O and sputum eosinophils, which correlated over time with 
changes in FEY1 and !3-agonist use. The authors suggested that 
changes in sputum eosinophil numbers were superior to eNO in 
predicting loss of asthma controL However, because of the small 
study numbers a quantitative assessment of the predictive values 
of the changes in eNO and sputum eosinophils was not possible. 
In another longitudinal study, Baraldi and coworkers (32) mea-
sured eNO in children with asthma before, during. and after the 
pollen season. A rise in eNO was seen during the pollen season 
consistent with the presumed increase in airway inflammation 
that occurred with allergen exposure. 'This occurred despite the 
fact that over one-third of the children were taking inhaled ste-
roids and in the absence of changes in FEY1. These authors also 
concluded that eNO might be useful in the longitudinal assess-
ment of asthma. 
Asthma is a complex disease whose symptoms are dependent 
on the severity of airway intlammation, airway remodeling, and 













































intervention ought to be aimed at controlling symptoms alone. 
optimizing lung function, or minimizing airway intlammation, 
and hyperresponsiveness (33-35). A recent study has provided 
evidence that when antiinflammatory therapy is tailored to 
TABLE 6. DIAGNOSING LOSS OF CONTROL* 
eNO at vistt F 
.> 10 ppb 
> 15 ppb 
Change in eNO 
from visit 1 to visit F 
.:. C> 10 ppb 
.:. > 60% 
Sputum eosinophils at 
vrsit F-. 4% 
Change in sputum 
eosinophils 
from visit 1 to visit F 
.l>4% 
Saline PD, at visit F 
< 12ml 
ChJnge tn saline P0 15 
trom visit 1 to visit F 








0.83 0.29 0.81 0.33 
(0.71, 0.93) (0.10, 0.56) (0.69, 0.90) (0.12, 0.62) 
0.60 0.65 0.86 0.31 
(0.47, 0.72) (0.38, 0.86) (0.71, 0.95) (0.17, 0.49) 
0.48 0.82 0.91 0.31 
(0.35, 0.62) (0.57, 0.96) (0.75, 0.98) (0.18, 0.47) 
0.68 0.65 0.87 0.37 
(0.55, 0.80) (0.38, 0.86) (0.74, 0.95) (0.20, 0.56) 
0.59 O.oO 0.84 0.29 
(0.45, 0.72) (0.32, 0.84) (0.69, 0.94) (0.14, 0.48) 
0.51 0.64 0.84 0.26 
(0.37, 0.65) (0.35, 0.87) (0.67, 0.95) (0.12, 0.43) 
0.43 0.82 0.87 0.35 
(0.29, 0.61) (0.57, 0.96) (0.66, 0.97) (0.21' 0.52) 
0.41 0.94 0.95 0.36 
(0.27, 0.57) (0.70, 1.00) (0.75, 1.00) (0.22, 0.52) 
OefinttJon of abbreviations: eNO ...:. exhaled nitric oxide; P0 15 .o dose of saline causing 
" 15% tall in FEV,_ 
• ! hf' predictive values of single measurements of eNO, percentagt> eos•nophils, .md 
saline PD, 5 measured at visit F for diagnosing loss of controL The table also includes the 
predictive values for changes that occurred between visit 1 and visit F tor each of these 
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Figure 7. (.4) Receiver-oper-
ator curves for eNO (propor-
tional change between visit 
1 and visit P), percentage 
eosinophils at visit 1, and sa-
line PD 15 at visit 1 for pre-
dicting upcoming loss of 
control. (8) Receiver-opera-
tor curves for the changes in 
eNO, FEVT- peak expiratory 
flow rate (PEFR), bronchodi-
lator use, and symptom 
score between visit 1 and 
visit P for predicting upcom-
,ng loss of control. 
improve AHR clinical outcomes are also improved ( 18). Our 
results suggest that a similar approach may be valid for eNO. Our 
data indicate that at an exhalation flow rate of 250 mils. an abso-
lute value for eNO of 15 ppb or greater. or an increase of more 
than 10 ppb or 60% over baseline. is a useful threshold for the de-
tection of ongoing airway int1ammation. and that it also posi-
tively predicts the advent of breakthrough symptoms. L:nfortu-
nately the absence of these changes does not preclude the 
possibility of deteriorating asthma. Further studies are needed to 
contirrn that the clinical application of eNO measurement is 
worthwhile in optimizing asthma management. 
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Does Exhaled Nitric Oxide Reflect Asthma Control? 
Yes, It Does! 
There has been an explosion of research into exhaled nitric ox-
ide ( eNO) since levels were found to be increased in patients 
with asthma. But what is th!! clinical value of eNO measure-
ments in asthma? We are edging closer to the answer after the 
timely study by Jones and colleagues published in this issue ( 1 ). 
The key findings of this article are that eNO measurements 
have a positive predictive value of between 80 and 90% for 
predicting and diagnosing loss of control in asthma. and are as 
useful as induced sputum eosinophils and airway hyperre-
sponsiveness to hypertonic saline, but with the enormous ad-
vantage that they are easy to perform. In addition. it has been 
shown that the changes in eNO were strongly related to asthma 
symptoms and FEV 1• and that the levels of eNO were signifi-
cantly different in patients with and without loss of control. 
This is the largest longitudinal study ( 11 wk) to date in which 
the utility of repeated (once a week for 7 wk) eNO. symptoms, 
and spirometry measurements has been explored in 78 pa-
tients with predominantly atopic asthma. Patients maintained 
a good lung function (FEV1 92% predicted) on inhaled corti-
costeroids of 630 fl.g/d (range 100--loOO fl.g beclomethasone 
equivalent) during a 4-wk run-in period before their steroid treat-
ment was stopped. Although a placebo-controlled study would 
be a better choice, the current design was simple and sufficient 
to pick up 7H% of the patients with deterioration of their 
asthma within 6 wk after the cessation of steroid treatment. 
The median time to loss of control was 17 d. and the most fre-
quent criteria of the loss were fall in peak expiratory t1ow and 
symptoms . 
This study is a natural continuation of previous studies. 
which convincingly demonstrated that eNO is a useful marker 
of airway in!larri""~ation (2). It seems. however. that eNO re-
llects asthma control better than asthma severity (3). Thus, it 
is elevated in mild asthma. but it is almost normal in stable 
moderate asthma adequately treated with corticosteroids ( 4). 
However, eNO levels are often further elevated in patients 
with severe (5) and uncontrolled asthma (6). 
An advantage of eNO as a ··Joss-of-control marker" (7) is that 
an increase in eNO and asthma symptoms may be seen before 
any significant deterioration in airway hyperresponsiveness. spu-
tum eosinophils. or lung function during asthma exacerbation in-
duced by steroid reduction (8. 9). Recently. it has been confirmed 
that eNO is closely related to several markers of asthma control. 
such as asthma symptoms. dyspnea score. daily use of rescue 
medication, and reversibility of airllow obstruction (6). 
The results were less conclusive when single baseline eNO 
measurements instead of serial assessments were used. Al-
though the high number of sputum eosinophils of patients 
who eventually develop exacerbations was a good predictor of 
asthma deterioration. the changes in eospinophils following 
steroid reduction were slow and insignificant (9). Similarly, a 
single baseline assessment of either exhaled NO (9. Ill) or spu-
tum eosinophils (IOJ had a low power to predict asthma dete-
rioration during the reduction of steroid treatment. 
Unfortunately. one of the main advantages of serial eNO 
measurements has not been fully exploited in the latter study. 
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h mo :.titer the dose of corticosteroids was halved I 10). How-
'~ver. it is well known that changes in c:NO ~an be sec:n within 
3--5 d following either introduction (II) or discontinuation of 
steroids (3). and a different study design with more frequent 
measurements would have been more informative. 
Jones and coworkers have realized the importance of assess-
ment of the changes in ;;\10 when measured lnngirudinally. 
Thus. eNO was measured ewry week for 6 wk after steroid 
treatment was stopped. in contrast to sputum eosinophils and 
airway hyperresponsiveness. which were measured twice only, 
at baseline and at the final visit. Importantly, the authors have 
calculated the differences and correlations between the changes 
in eNO that occurred between the first visit at which inhaled 
corticosteroids treatment was stopped, and the final visit at 
which loss of control developed. but no longer than 6 wk. In 
addition. the ability of eNO to predict upcoming loss of con-
trol was assessed in three ways: first. using the baseline eNO: 
second. using eNO measurement immediately before loss of 
~ontrol (the penultimate: visi!): and third. usit;g tbe <.:hange in 
eNO that m:curred between baseline and the penultimate visit. 
The finding that changes in eNO measured nver time have 
higher predictive values. sensitivities. and specificities both for 
predicting and diagnosing loss of <.:ontrol th:m did single mea-
surements dearly indicates the need for repeated tests. When 
measured longitudinally the changes in eNO <.:orrelated signiti-
cantly not only with changes in sputum eosinophils and hyperre-
sponsiveness. but also with lung function and asthma symptoms. 
The utility of eNO measurements in relation to sputum 
J.nalysis or airway hyperresponsiveness is important. \<lethod-
ologically, standardized eNO measurements (12) have obvi-
ous advantages over sputum induction and airway hyperrespon-
siveness or any other bronchial provocation tests due to their 
simplicity. reproducibility, and entirely noninvasive nature. It 
is vital that this technique can be used repeatedly in patients 
with severe disease and to assess disease in <.:hildren. making it 
a suitable test for use in the clinical as well as the resea~ch 
practice. The scope for using sputum analysis to monihlr asthma 
control in clinical practice is limited not onlv hv the resources 
re4uired. but also by the well-Jocumented- pr.ointlammatDry 
action of hypertonic saline. 
In conclusion. the available evidence suggests that e:--.10. es-
pecially when repeated. as longitudinal "~easurements. re-
tlects control of asthma. Because the techni4ue is noninvasive. 
it is possible to make repeated measurements without Jisturb-
ing the system. in contrast to the invasive or semiinvasive pro-
cedures currently used. Individual eNO values. like individual 
peak expiratory flows. should be established and monitored. 
and when the levels are above or below a certain reference 
level. steroid lreatment should be either reduced or increased. 
We clearly need further clinical research on eNO to be able to 
tailor strategies for effective treatment and early intervention 
in asthma. As eNO analyzers become more wtdely available 
and miniaturized. it is likely that this measurement will be-
come wutine in monitoring asthma control, particularly in pa-
tients with unstahle and difficult tl1 control :1sthma. 
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Inhaled corticosteroids (ICS) are the most effective 
treatment for airway inflammation in asthma [1]. 
Their use results in an improvement in symptoms and 
lung function, as well as in reductions in inflammatory 
cells in bronchial biopsies [2] and induced sputum [3]. 
As a result, airway hyperresponsiveness (AHR) is also 
reduced [4, 5]. Current guidelines recommend the use 
of ICS therapy in all but the mildest asthma [6]. The 
guidelines are based on the assumption that treating 
airway inflammation leads to improvement in asthma 
control. However, several studies have demonstrated 
incongruities in the relationship between both symp-
toms and lung function and airway inflammation 
[7-9]. This raises questions as to whether the primary 
goal when using ICS is to achieve symptom control, 
optimise lung function, minimise airway inflammation 
or reduce AHR. 
In the past, dose-response relationships for ICS have 
been described using symptoms and lung function as 
the main outcome variables. Although a dose-response 
relationship exists for these end points, it may plateau 
at a relatively low dose. Thus, there may be some 
difficulty in differentiating between the effects of 
adjacent doses [1, 10]. Other studies have shown that 
dose-response relationships vary when other end points 
are used [11]. For example, much higher doses of ICS 
are required to control airway hyperresponsiveness 
than symptoms [11, 12]. There are fewer data to clarify 
these relationships for airway inflammation, even 
though control of airway inflammation is the primary 
reason for administering these drugs. Such informa-
tion might be clinically helpful in assessing the relative 
efficacy of different ICS doses and as a guide to opti-
mising long-term therapy . 
Exhaled nitric oxide (eNO) is a repeatable, easily 
measured marker of airway inflammation [13, 14]. High 
levels are seen in both steroid-nai·ve asthma [15] and 
during acute exacerbations [16, 17]. Furthermore, levels 
decrease following treatment with both inhaled [3, 18, 
19] and oral steroids [20]. These results suggest that 
eNO may be a useful end point in measuring the dose-
response relationship for the effect of ICS therapy on 
airway inflammation. 
Recently the current authors have confirmed the 
usefulness of eNO measurements in predicting deterio-
ration in asthma control when ICS are withdrawn 
[17]. In this follow-up study the aim was to evaluate the 
usefulness of serial eNO measurements in measuring 
the anti-inflammatory effects of different doses of inhaled 
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with other end points including lung function, sputum 
eosinophils and AHR to hypertonic saline. 
Methods 
Subjects 
Patients with mild-to-moderate asthma [21] on main-
tenance ICS therapy were recruited. Patients were 
excluded (because the study involved withdrawal of 
ICS treatment) if they had a history of acute asthma 
requiring hospital admission, asthma characterised by 
sudden attacks, or had used oral prednisone during 
the previous 3 months. 
Study design 
Following run-in, ICS therapy was discontinued. 
Patients were reviewed weekly until "loss of control" 
developed, or for a maximum of 6 weeks. Those who 
did not develop loss of control were then withdrawn. 
Loss of control was defined by predetermined criteria 
[ 1 7] consisting of: 1) a fall in the mean (over the last 
7 days) morning peak expiratory flow rate (PEFR) 
of > 1 O'Y., from baseline, or a fall in either morning 
or evening PEFR on two consecutive days to ::;;; sm;;, 
of baseline; or 2) mean daily bronchodilator use of 
>3 puffs longer than during run-in; or 3) nocturnal 
wakening with asthma symptoms on ;;:::. 3 nights· 
week- 1 greater than during the run-in; or 4) asthma 
symptoms which were disagreeable or distressing. 
Following loss of control, patients received 20 mg 
prednisone orally for 2 days in order to alleviate their 
deteriorating symptoms. Although this may theoreti-
cally have influenced interpretation of subsequent 
ICS effects at 1 week, this strategy was necessary for 
reasons of safety. Patients were randomised to receive 
double-blind ICS treatment for 8 weeks, taking one 
puff from two identical metered-dose inhalers (Auto-
haler; 3M Pharmacueticals, St Paul, MN, USA) labelled 
"morning" and "evening". The treatments were: placebo 
(placebo twice daily (b.i.d)); 50 f..lg·day· 1 (50 f..lg BDP 
in the _morning, placebo at night); 1~0 )..lg·day· 1 (100 f..l~ 
BOP 111 the mornmg, placebo at mght); 200 f..lg·day· 
(100 ~Lg BOP b.i.d); 500 f..lg·day· 1 (250 f..lg BOP b.i.d) . 
Those patients who experienced significant worsen-
ing of their asthma while taking the randomised medi-
cation were withdrawn from that treatment group, 
given 20 mg prednisone orally for a further 2 days, 
and entered into an open label treatment arm of 
1,000 ~Lg·day· 1 (2 puffs of 250 f..lg BDP b.i.d). 
Following randomisation (visit 1 ), patients were 
reviewed weekly for the first 4 weeks (visits 2-5) and 
then at the end of treatment (8 weeks, visit 6). Those 
patients whose ICS dose needed to be increased to 
1,000 f..lg· day· 1 were also reviewed weekly for 4 weeks 
and again at the end of 8 week's treatment. 
Study procedures 
Diurnal PEFR, bronchodilator use and symp-
tom scores were recorded on a daily record card. 
Measurements of eNO and spirometry were made at 
each study visit and a hypertonic saline challenge with 
sputum induction was performed at the beginning and 
end of treatment. 
Exhaled nitric oxide. eNO was measured prior to all 
other study procedures using a calibrated chem-
iluminescence analyser with on-line measurement of 
single exhalations according to a standard protocol 
[13, 14], with the exception of flow rate (250 mL·s- 1) 
(the study was commenced prior to the publication 
of consensus guidelines). eNO levels were read at 
the plateau corresponding to 70-80% of the carbon 
dioxide curve. These readings were made at a later 
date by a person blinded to the patient's clinical 
status. 
Hypertonic saline challenge. AHR to hypertonic saline 
(4.5%) was measured using a modified standardised 
protocol [22, 23]. Spirometry was performed 1 min 
after each saline nebulisation. The challenge was 
discontinued when a 20% fall in forced expiratory 
volume in one second (FEVI) occurred or a cumulative 
inhalation time of 20 min was reached. The PD 15 was 
calculated as the cumulative provocation dose of saline 
causing a 15% fall in FEVI. 
Sputum induction. During the hypertonic saline chal-
lenge patients were encouraged to produce sputum 
between nebulisations. If a 20% fall in FEVI occurred 
before an adequate sputum sample was obtained, inhaled 
salbutamol was administered and sputum induction was 
continued for a maximum cumulative time of 20 min. 
Once an adequate sputum sample was obtained the 
whole specimen (sputum plus saliva) was analysed using 
a standardised method [24]. Cell viability was assessed 
by the trypan blue exclusion test, and a cell count was 
performed by haemocytometer. Cytospin slides were 
stained with May-Grunwald-Giemsa stain and a total 
of 400 nonsquamous cells were counted on two occa-
sions. Where the difference between the two counts was 
>10% for any cell type then the count was repeated 
twice and the mean for all four was recorded. 
Ethical considerations and safety 
Each patient's asthma control was monitored closely 
throughout the study. For ethical reasons, loss of 
control criteria included symptoms that were "dis-
agreeable or distressing" irrespective of PEFR changes. 
All patients were provided with an individualised 
self-management plan, an emergency card, and a 
supply of prednisone tablets. Patients had 24-h access 
to one of the study investigators via the hospital paging 
system. In addition, recognising that ICS withdrawal 
had the potential to result in poor asthma control, 
each patient was telephoned by a study investigator on 
days 1 and 3 following randomisation. Ethical appro-
val was obtained from the Otago Ethics Committee 
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Statistical analysis 
The primary outcome of the study was to assess 
whether a dose-response relationship exists between 
inhaled corticosteroid dose in the range 0-500 jlg·day- 1 
and changes in eNO. Comparisons were made with 
sputum eosinophils, FEY! and PD!5 saline. Data were 
analysed on an intention-to-treat basis using analysis 
of covariance, adjusting for values at randomisation 
and for patients who for reasons of safety were later 
switched during the active treatment phase to receive 
1000 IlK day-'. Polynomial contrasts were fitted across 
the randomisation groups to establish the nature of the 
dose-response relationships. PD!5 saline values were 
analysed as doubling-dose change from baseline. Esti-
mated marginal means were calculated, and post-hoc 
analysis of pairwise between-dose comparisons were 
made, with Bonferroni adjustments for multiple com-
parisons. Pearson's correlations were calculated to 
assess the relationship between eNO, sputum eosino-
phils, FEY! and PD!s saline at randomisation and at 
the end of the study. 
At the time the study was designed there was no 
information on which to make power calculations. 
Based on anecdotal evidence it was calculated that 15 
patients per group would offer >80°/t, power to detect 
a difference of >0.8 so between groups. Although this 
afforded sufficient power to detect a linear trend 
across the groups, this was not determined a priori. 
Results 
Randomisation 
Eighty-seven patients entered the study. Three 
patients withdrew consent prior to ICS withdrawal. 
Sixty-five patients (77°/o) developed loss of control and 
were randomised into one of the five treatment 
groups. Demographic data are given in table 1. Data 
for study end points measured at baseline (before 
withdrawal of ICS, visit 0) and at randomisation (visit 
1) are shown in table 2. 
Treatment withdrawals 
One patient randomised to receive 500 jlg·day-1 was 
withdrawn at visit 1 due to the severity of their 
asthma, and was not considered further in the 
analysis. Twenty-five of the remaining 64 patients 
developed worsening of their asthma after randomi-
sation and were entered into the open-label 
1,000 jlg·day-1 arm of the study. The number of 
patients withdrawn from each of the treatment groups 
was six, five, eight, four, and two in the placebo, 50, 
100, 200, and 500 jlg·day- 1 BDP groups, respectively. 
Comparisons between those who withdrew from the 
randomised treatment arm and those who completed 
treatment are shown in table 2. There were no 
significant diffen;nces between these two groups for 
eNO, sputum eosinophils or PD1s saline at the time of 
randomisation. Those who withdrew had a lower 
FEY! %predicted than those who did not withdraw 
(73.9 versus 82.5%, respectively, p=0.005). Those who 
withdrew also had a higher dose of maintenance ICS 
at study entry (mean (95% confidence interval (CI) 
776 (635-917) jlg·day·' and 614 (536-694) jlg·day- 1 
respectively, p=0.042). 
Dose-responses 
Changes in eNO and FEY! (at 1 week and at the 
end of treatment) and in sputum eosinophils, and 
Table 1.-Demographic data for the randomised study participants 
Total Treatment group 
Placebo 50 !lg·day-1 I 00 !lg·day·1 200 !lg·day·1 500 !lg·day-' 
Number of pat_ients n 65 13 14 14 12 12 
Number switched 25 6 5 8 4 2 
to 1000 !lg·day- 1 
Male: female 22:43 4:9 6:8 7:7 2:10 3:9 
Age yrs (range) 42.4 42.5 43.3 44.7 41.2 39.6 
(19-M) (19-61) (19-63) (21-59) (24-60) (19-64) 
Duration of asthma 27.0 30.3 30.6 22.5 31.2 20.2 
yrs (range) (4--60) (4-60) (6-60) (4-48) (12-55) (4-40) 
Skin test positive n ('Y,,) 60 (92.3) 12 (92.3) 14 (100) 12 (85.7) 12 (100) I 0 (83.3) 
Exsmokers:nonsmokers 9:56 2: II 1:13 2:12 I: II 3:9 
ICS dose 11g-day' 1 658 73I 550 700 67I 642 
(BDP equivalent) (IOO-I600) (100-1600) (200-IOOO) (200-1600) (200-1000) (200-1000) 
FEY! L 2.81 2.50 2.91 2.94 2.62 3.04 
(2.61-3.00) (2.07-2.94) (2.39-3.45) (2.42-3.45) (2.I5-3.09) (2.60-3.48) 
FEY!% pred 90.8 83.7 91.0 91.9 85.2 102.5 
(86.3-95.2) (71.3-96.1) (82.1-99.8) (82.2-1 0 1.5) (71.6-98.8) (93.9-111.0) 
FEY1/FYC '% 70.8 68.3 70.6 69.1 69.7 76.9 
(68.1-73.6) (59.5-77.1) (64.4-76.7) (62.2-76.0) (63 .2-76.3) (72.2-81. 5) 
Data are presented as mean (95'Yo confidence intervals) unless otherwise stated. ICS: inhaled corticosteroids; BDP: 
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Table 2.- Data for study end-points measured at baseline (visit (V) 0) and at randomisation (V1) 
Subjects eNO ppb FEY! '%pred Sputum eosinophils '% PD!5 saline mL 
n 
vo VI vo VI vo VI ----yo VI 
Treatment group 
Placebo 13 9.6 20.9 85.4 82.0 4.8 6.0 17.0 12.5 
(6.4-12.7) (12.2-29.6) (72.1-98.8) (67 .8-96.3) (0-12.6) (2.1-9.9) (8.2-25.8) (3.5-21 .5) 
50 J.!g·day·' 14 11.6 22.1 87.5 77.7 3.6 10.0 15.0 11.0 
(6.8-16.3) (14.0-30.2) (76.2-98.8) (66.1-S9.3) (0-7.9) (0.7-19.3) (8.6--21 .4) (3.6-18.4) 
100 J.!g·day·' 14 I 3.8 32.1 91.4 75.1 8.5 31.9 15.9 13.3 
(7.3-20.3) (18.8-45.4) (81.4-101.5) (65.7-S4.5) (0-18.2) (15.3-48.6) (7.0-24.7) (5.4-21.2) 
200 J.!g·day·' 12 11.3 29.9 89.0 73.9 1.4 I 6.4 20.1 8.4 
(7.9-14.7) (13.3-46.6) (76.1-101.9) (59.7-S8.1) (0.5-2.2) (3.8-29.0) (11.4-28.9) (1.9-14.8) 
500 J.!g·day·' 12 11.4 25.2 100.2 87.9 1.9 22.8 15.7 13.2 
(4.4-18.3) (12.6-37.8) (92.2-108.2) (75.2-100.5) (0.1-3.8) (3.6-42.1) (8.0-23.5) (3.5-22.8) 
Completed 40 24.6 82.5 17.8 12 .. 1 
(18.5-30.8) (76.4-S8.6) (10.4--25.3) (8.0-16.1) 
Withdrew 25 28.2 73.9 17.3 11.8 
(19 .6-36.8) (64.9-S2.9) (7.5-27.2) (5.8-16.8) 
Data are presented as mean (95'Yo confidence interval). eNO: exhaled nitric oxide; FEY!: forced expiratory volume in one 
second; PD!5 saline: the cumulation provocative dose of saline causing a I 5% fall in FEY!. 
PDI5 saline (at the end of treatment) are shown in 
figs. 1 and 2, respectively. 
There was a significant linear relationship between 
ICS dose and each of the following: changes in eNO at 
1 week and end of treatment (p=0.022 and p=0.015, 
respectively); changes in FEY! at 1 week and end of 
treatment (p=0.043 and p=0.006, respectively); and 
changes in sputum eosinophils at the end of treat-
ment (p=0.037). There was no significant relationship 
between ICS dose and the change in PD1s saline. All 
of these comparisons were adjusted for baseline 
measurements and changes in numbers due to with-
drawals. When those entering the 1,000 !lg· day·' arm 
were excluded from the analysis the significance of the 
linear relationship seen across the groups for changes 
in eNO persisted (p=0.003), however, the linear relation-
ship seen with FEY! and sputum eosinophils became 
nonsignificant. 
In assessing the between-dose effects ofiCS therapy, 
pairwise comparisons for each of the treatment groups 
were performed. There were significant differences in 
eNO between 100 !lg·day"1 and both 200 and 500 !lg·day·' 
at l week (p<0.05 for each), and between 500 !lg·day·' 
and both placebo and 100 ~tg· day·' and at the end of 
treatment (p=O.Ol and p=0.023, respectively). For FEY!, 
there was a significant difference between 500 !lg·day·' 
and placebo at the end of treatment (p=0.04) but not 
for any of the other between-dose comparisons. Like-
wise, the only significant difference in sputum eosino-
phils with treatment occurred between 100 !lg·day·' 
and 500 11g· day- 1 (p=0.049). No other significant differ-
ences were found using pairwise comparisons. There 
were no significant differences in PD15 saline between 
treatments. 
Correlations between inflammatory markers 
Correlations between eNO, sputum eosinophils, 
PD1s saline and FEY! % pred at baseline and 
following treatment (expressed as absolute values 
and as changes from baseline) are shown in table 3 . 
Significant correlations were found between eNO 
and sputum eosinophils throughout the study. Also, 
changes in eNO correlated significantly with changes 
in sputum eosinophils. Changes in PD 15 saline did not 
correlate with changes in any of the other markers. 
Discussion 
In this study it has been demonstrated that eNO 
measurements provide useful information regarding 
the dose-response relationship for the anti-inflammatory 
effects of ICS. This has potential practical impor-
tance not only to facilitate the monitoring of anti-
inflammatory treatment in individual patients, but 
also in assessing the efficacy of different inhaled corti-
costeroids at different doses. A significant linear 
relationship between the change in eNO and the dose 
of ICS used (over a range 0-500 11g· day·' of BDP) was 
found in patients with moderate bronchial asthma in 
whom ICS had been withdrawn and loss of control 
occurred. This ensured that airway inflammation was 
sufficient for anti-inflammatory effects to be measured. 
The linear dose-response relationship was significant 
as early as 1 week after commencing therapy, and con-
tinued to 8 weeks, indicating that eNO measurements 
are not only rapidly responsive to changes in airway 
inflammation but that they also reflect the ongoing 
anti-inflammatory action of ICS therapy with time. A 
similar linear dose-response relationship was also 
found with FEY! at 1- and 8-week's treatment. In a 
recently reported investigation SILKOFF et a/. [25] 
have also demonstrated a stepwise decrease in eNO 
over a dose range of 0-800 !lg·BDP·day·' in patients 
with elevated levels of eNO. The results of the present 
study go further. The highly significant correlation 
between changes in eNO and changes in sputum eosi-
nophils, together with a linear dose-response rela-
tionship between ICS dose and changes in sputum 
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Placebo ~g-day·1 ~g-day-1 J.lg·day-1 J.lg·day-1 
Treatment group 
Fig. l.- Percentage change in a) exhaled nitric oxide (eNO) and b) 
forced expiratory volume in one second (FEV1) after I week ( ) 
and at the end of the 8 weeks (_j) of inhaled corticosteroid tre~­
ment. Data are presented as mean±95'Y., confidence intervals. Data 
were derived from all patients, but adjusted for differences in 
baseline measurements and the numbers of patients remaining in 
the group at each time point. a) There was a significant difference 
across treatments at I week (p=0.005) and at the end of treatment 
(p=O.O 15). These differences were linear (p=0.022 and p=0.003. 
respectively). b) There was a significant difference across treatment 
groups at I week (p=O.Ol4) and at the end of treatment (p=0.036). 
These differences were linear (p=0.043 and p=0.006. respectively). 
dose-related decreases occurring in eNO correspond 
to a reduction in airway inflammation and provide 
validation of the primary outcome of the study. 
It has been shown previously that changes occur-
ring in eNO are seen in association with changes in 
other markers of airway inflammation following treat-
ment with inhaled budesonide [26] and fluticasone [3]. 
However, the present study is the largest to date in 
which dose-dependency for these anti-inflammatory 
effects has been investigated. WILSON and LIPWORTH 
[27] have reported that at doses of >400 ~g budeso-
nide daily (the first step in their dose-ranging study for 
budesonide), no further reduction in eNO occurred 
despite further dose-related improvements in FEVI 
and sputum eosinophil cationic protein. In a smaller 
study, JATAKANON et al. [28] reported that despite 
continuing reductions in sputum eosinophils at doses 
up to 1,600 !lg budesonide· day· 1, changes in eNO 
reached a plateau at 400 ~-tg-day- 1 • In contrast, in the 
a) 40 
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':i§i -2.0 ::::> 
~ -2.5~ 
Placebo 
~g·day-1 ~g-day d -1 -1 J.lg·day-1 ~g- ay 
Treatment group 
Fig. 2.- a) Percentage change in sputum eosinophils at the end of 
treatment. There was a significant linear relationship across the 
treatment groups (p=0.037). b) Doubling dose changes in cumula-
tive provocative dose of saline causing a 15'% fall in forced 
expiratory volume in one second (PDts saline) at the end of 
treatment. No significant differences were seen across the treat-
ment groups (p=0.837). Data are presented as means±95'Y,, 
confidence intervals. Data are derived from all patients, but 
adjusted for baseline measurements and the numbers of patients 
remaining in the group at each time point. 
present study the dose-response relationship between 
eNO and ICS was linear and there was no evid-
ence of a plateau over the range of doses studied 
(0-500 Jlg· day· 1 ), with similar outcomes observed for 
both sputum eosinophils and FEVI. However, the 
current study is not able to offer comment on whether 
or not a plateau to the dose-response relationship occurs 
with doses >500 ~-tg·day· 1 • 
The apparent conflict between these results and 
those of previous studies may be due to differences in 
asthma severity at the time of the investigation. In the 
current study, treatment was withdrawn until loss of 
control occurred and those who did not exhibit loss of 
control were excluded. A similar study design has been 
used by other investigators when evaluating the dose-
response for ICS [29, 30]. The rationale for this 
approach is that the therapeutic ratio for ICS may be 
influenced by asthma severity: patients with milder 
asthma may have little room for improvement. This 
may have influenced the results of previous studies 
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Table 3. -Correlations between various markers of airway 
inflammation and lung function 
Correlation Visit 1 Visit 6 ~Visit (6-1) 
--
eNO versus r-0.519 r=0.548 r=0.403 
'Y., eosinophils p<O.OOI# p<O.OOI# p=0.002# 
eNO versus r=-0.352 r=-0.270 r--0.192 
PD!5 saline p=0.003# p=0.051 p=O.l87 
eNO versus r=-0.169 r=0.021 r=-0.252 
FEY!% pred p=0.125 p=0.870 p=0.045# 
% eosinophils versus r=-0.254 r=-0.185 r=0.045 
PD!5 saline p=0.040# p=0.204 p=0.771 
% eosinophils versus r=-0.262 r=O.Ol5 r=-0.585 
FEY!% pred p=0.023# p=0.913 p<O.OOI# 
PD 15 saline versus r-0.420 r=0.533 r=-0.092 
FEY!% pred p<O.OOI# p<O.OOI# p=0.529 
eNO: exhaled nitric oxide; PD1s saline: cumulative provo-
cative dose of saline causing a 15% fall in forced expiratory 
volume in one second (FEVI). 
of SJLKOFF et a!. [25] who noted that patients with 
higher baseline eNO demonstrated dose-response reduc-
tions over a higher dose range (0-800 j.l.g· BDP·day· 1) 
than those with lower levels of eNO at baseline 
(0-200 J.l.g-BDP·daf 1). 
There are a number of potential criticisms of the 
current study. Firstly, the range of doses of BDP to 
which patients were randomised did not include 
1,000 j.l.g· day·'. This was because of earlier suggestions 
that not only were eNO measurements very sensitive 
to changes in res dose, but that the clinical benefits of 
res were limited at higher doses [31], even in patients 
with severe asthma [32]. Therefore, the current authors 
wished to address the possibility that there is a 
threshold for the anti-inflammatory effects of res 
within the lower dose range. Secondly, the study 
model which was employed i.e. withdrawal of res 
prior to beginning the randomised phase of the study 
[3 3], resulted in a significant number of patients whose 
asthma remained uncontrolled after randomisation. 
For ethical reasons these patients were re-allocated 
to receive 1,000 j.l.g·day· 1• The analysis was on an 
intention-to-treat basis, and therefore included statis-
tical adjustments for those patients who were changed 
to the higher dose. When analysed post-hoc as a separate 
treatment group, the patients receiving 1,000 j.l.g·day· 1 
did provide useful information: in this group eNO 
levels at week 8 were higher (mean eNO, 17.3 parts per 
billion (ppb) (95°/., cr, 11.1-23.5)) than patients 
receiving 500 j.l.g·day· 1 (mean eNO, 10.4 ppb (95% 
cr, 4.4-16.4)). Because of selection bias the difference 
between the groups was not formally analysed. How-
ever, this suggests that despite higher doses of res, 
eNO levels remain elevated in a subset of patients with 
more severe asthma [34], reflecting ongoing airway 
inflammation in this subgroup, and confirming the 
need for higher doses of ICS. Finally, despite finding 
a linear relationship between eNO and the dose of 
res, eNO measurements were not able to distinguish 
between adjacent ICS doses consistently when assessed 
in pairwise comparisons, although eNO was better in 
this regard than all other measured parameters. This 
appears to be a feature of almost all dose-response 
studies for res, irrespective of the end point used, and 
with even larger numbers of patients [29, 30, 35]. 
Nonspecific airway responsiveness appears to reflect 
airway inflammation even in the absence of ongoing 
symptoms and abnormal lung function [7]. Changes in 
AHR might therefore provide a useful measure by 
which the anti-inflammatory effects of ICS could be 
evaluated. However in the current study, there were 
no significant changes in AHR to hypertonic saline. 
This may reflect the low doses of ICS used or the 
relatively short duration of treatment. Other authors 
have reported contrasting results using alternative 
methodologies [27, 28, 35-37]. In general AHR to 
the direct bronchoconstrictors methacholine and 
histamine appears to be less sensitive than indirect bron-
choconstrictors in detecting changes occurring with 
corticosteroid treatment [27, 38]. Unfortunately, the 
interpretation of many studies is made difficult because 
they have included patients with mild asthma and 
have used high doses of res [4]. 
The optimum approach to establishing patients on 
an appropriate dose of ICS has still not been defined. 
There are two questions of relevance. Firstly, does 
increasing the dose of ICS above a certain threshold 
result in greater efficacy? In the majority of patients 
only small increments in lung function are achieved 
when the dose of ICS is increased progressively [29, 
30, 35]. This calls into question either the effectiveness 
of higher doses of ICS, or more likely, the validity of 
simple lung function measurements in this setting. 
Secondly, is it necessary to suppress airway inflamma-
tion completely in order to obtain optimum control, 
and how is this best assessed? Minimising airway 
responsiveness to adenosine monophosphate or metha-
choline (as a surrogate for airway inflammation [7]) 
appears to be dose-related [27, 36, 37]. When anti-
inflammatory therapy is tailored to reduce AHR, 
clinical outcomes are improved [39]. Unfortunately, 
repeated measurements of AHR are unsuited for routine 
clinical practice and it is unlikely that their widespread 
application will become commonplace. In contrast, eNO 
measurements are repeatable and easy to perform. 
The current authors have recently shown that 
exhaled nitric oxide measurements may be used to 
predict deteriorating asthma control, and that they 
reflect changes in underlying airway inflammation 
[17]. These findings, together with the results of the 
present study, offer the possibility that repeated mea-
surements of exhaled nitric oxide may be useful in 
guiding dose adjustments of inhaled corticosteroids in 
patients with persistent asthma. This requires further 
prospective investigation. 
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